Preparation method for and use of dihydrothienopyrimidine derivative
Patent Information
- Application Number
- MYPI2025005031
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-25
- Filing Date
- 2024-02-28
- Publication Date
- 2024-08-28
AI Technical Summary
Existing PDE4 inhibitors are difficult to effectively inhibit inflammation and fibrosis, have low requirements on pharmacokinetics and toxicological properties, and cannot effectively treat idiopathic pulmonary fibrosis and other PDE4B-mediated diseases.
Developed a new class of dihydrothiopyrimidine derivative compounds, prepared by multiple synthetic methods, with selective PDE4B inhibitory activity, excellent pharmacokinetic properties and low toxicological properties for the treatment of PDE4B-mediated diseases .
These compounds display strong PDE4B inhibitory effects, good bioavailability and metabolic properties, providing an effective treatment option for idiopathic pulmonary fibrosis and other PDE4B-mediated diseases.
Abstract
Description
Preparation method and use of dihydrothienopyrimidine derivatives Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to compounds serving as PDE4B inhibitors, particularly substituted dihydrothienoazaaryl derivatives and prodrugs thereof, and methods for preparing and using the same. Background Art
[0002] Phosphodiesterases (PDEs) hydrolyze intracellular second messengers (cAMP, cyclic adenosine monophosphate, or cGMP, cyclic guanosine monophosphate), degrading them and thereby terminating the biochemical effects transmitted by these second messengers. cAMP and cGMP play a crucial role in regulating cellular activity, with their concentrations primarily determined by the balance between their synthesis by nucleotide cyclases and their hydrolysis by phosphodiesterases (PDEs). PDEs are widely distributed in the human body, and their physiological roles span multiple research areas. Human PDE4 isoenzymes are classified into four subtypes: PDE4A, 4B, 4C, and 4D. PDE4 is involved in the hydrolysis of cAMP in various inflammatory cells. Therefore, inhibition of PDE4 can suppress immune and inflammatory cells.
[0003] In addition, according to literature reports, PDE4 plays a role in controlling the calcium-induced calcium release process, and preferential inhibition of PDE4B can maintain the therapeutic efficacy of pulmonary fibrosis.
[0004] Therefore, selective inhibitors of PDE4B are expected to become effective drugs for the treatment of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease through dual inhibitory effects on inflammation and fibrosis.
[0005] Summary of the Invention
[0006] The present invention aims to provide a novel PDE4B inhibitor compound, a method for preparing the compound, and its use in treating diseases mediated by PDE4B. The novel compound is biochemically effective and physiologically active, has good pharmacokinetic properties and low toxicological properties.
[0007] The first aspect of the present invention provides a compound represented by the following formula (I), a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound:
[0008] wherein X is selected from S, SO or SO2;
[0009] Y is NR Y ;
[0010] R Y is hydrogen or deuterium;
[0011] Ring Q is: C 3-8 Cycloalkyl, C 4-8 Cycloalkenyl, 3-10 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 aryl;
[0012] Each R Q Selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH, -L Y -SH, -L Y -C(O)OH、-L Y -NH-C(O)H、-L Y -C(O)NH2、-L Y -NHC(O)OH, -L Y -C(O)H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-3 Alkyl, -L Y -OC(O)R d 、-L Y -OC(O)OR d ; Preferably, each R Q Selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH, -L Y -SH, -L Y -C(O)OH、-L Y -NH-C(O)H、-L Y -C(O)NH2、-L Y -NHC(O)OH, -L Y -C(O)H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C4-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-3 Alkyl, -L Y -OC(O)R d More preferably, each R Q Selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH, -L Y -SH, -L Y -C(O)OH、-L Y -NH-C(O)H、-L Y -C(O)NH2、-L Y -NHC(O)OH, -L Y -C(O)H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-3 alkyl;
[0013] L Y is optionally substituted: C 1-4 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-4 Alkyleneoxy, wherein optionally substituted refers to one or more selected from halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, halogenated C 1-3 substituted by an alkyl substituent;
[0014] L is a bond, or optionally substituted: C 1-4 Alkylene, C 2-4 Alkenylene, C 2-4 Alkynylidene, C 1-4 Alkyleneoxy, wherein optionally substituted refers to one or more selected from deuterium, halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, halogenated C 1-6substituted by an alkyl substituent;
[0015] Ring W is C 4-16 Cycloalkyl, C 4-16 Cycloalkenyl, saturated or partially unsaturated 4-18 membered heterocyclic group, 5-16 membered heteroaryl, C 6-18 aryl;
[0016] Each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, acetamido, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m 、-NR b R c 、-C(O)OR d , optionally substituted: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, wherein optionally substituted refers to one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -C(O)OR d 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 Preferably, each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m , optionally substituted: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, wherein optionally substituted refers to one or more selected from halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 substituted by a cycloalkyl substituent;
[0017] R b and R c are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Hydroxyalkyl, halogenated C 1-6 alkyl;
[0018] R d Selected from H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, C 1-6 Alkylamino; preferably, R d Selected from H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, halogenated C 1-6 alkyl;
[0019] Z is C 4-16 Cycloalkyl, C 4-16 Cycloalkenyl, saturated or partially unsaturated 4-18 membered heterocyclic group, 5-16 membered heteroaryl, C 6-12 aryl;
[0020] R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, saturated or partially unsaturated 4-6 membered heterocyclic group, -OR Z1 、-NR Z2 R Z3 ; R Z1 Selected from C 1- 6-alkyl, halogenated C 1-6 Alkyl; R Z2 、R Z3 are independently selected from H, C1-6 Alkyl; preferably, R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy; more preferably, R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 alkoxy;
[0021] n is 0, 1, 2, 3, 4 or 5;
[0022] q is 0, 1, 2, 3, 4, or 5;
[0023] m is 0, 1, 2, 3, 4 or 5;
[0024] The conditions are:
[0025] (1) When L is a bond, Not for
[0026] (2) When L is a bond, for When R w Unsubstituted phenyl and
[0027] (3) When X is SO and L is a bond, Not for any of; or
[0028] (3') When X is SO and L is a bond, Not for Any of;
[0029] (4) When X is S or SO2, and L is a bond, ring Q and ring W are not substituted phenyl at the same time; or when X is S, and L is a bond, ring Q is phenyl, and ring W is not and
[0030] (5) When X is S or SO2 and L is a bond, ring Q is not
[0031] The heteroatoms in the heterocyclic group and heteroaryl group are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2 or 3.
[0032] In a preferred embodiment of the present invention, R Y for deuterium;
[0033] In a preferred embodiment of the present invention, R Y is hydrogen;
[0034] In a preferred embodiment of the present invention, Y is NH;
[0035] In a preferred embodiment of the present invention, X is S;
[0036] In a preferred embodiment of the present invention, X is SO;
[0037] In a preferred embodiment of the present invention, X is SO2;
[0038] In a preferred embodiment of the present invention, ring Q is: C 4-6 Cycloalkyl, C 4-6 Cycloalkenyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, phenyl;
[0039] In a preferred embodiment of the present invention, ring Q is: C 4-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl;
[0040] In a preferred embodiment of the present invention, ring Q is: cyclobutane, cyclohexenyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, phenyl, tetrahydropyranyl;
[0041] In a preferred embodiment of the present invention, each R Q are independently: halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamide, ethylsulfonamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH, -L Y -C(O)OH、-L Y -C(O)H, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-6 Cycloalkyl, C3-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-3 Alkyl, -L Y -OC(O)R d 、-L Y -OC(O)OR d ;
[0042] In a preferred embodiment of the present invention, each R Q are independently: halogen, oxo, acetyl, -L Y -OH, -L Y -C(O)OH、C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -L Y -OC(O)R d 、-L Y -OC(O)OR d ;
[0043] In a preferred embodiment of the present invention, each R Q are independently: halogen, oxo, acetyl, -L Y -OH, -L Y -C(O)OH、C 1-3 Alkyl, C 3-6 Cycloalkyl, -L Y -OC(O)R d 、-L Y -OC(O)OR d ;
[0044] In a preferred embodiment of the present invention, each R Q are independently: hydroxymethyl, carboxymethyl, acetyl, Hydroxyisopropyl, Cl, oxo, cyclopropyl,
[0045] In a preferred embodiment of the present invention, L Y is optionally substituted: C 1-4 Alkylene, wherein optionally substituted refers to one or more selected from halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, halogenated C 1-3 substituted by an alkyl substituent;
[0046] In a preferred embodiment of the present invention, L Y is optionally substituted: C1-2 alkylene, wherein optionally substituted refers to one or more selected from halogen, -OH, -SH, -NH2, C1-3 Alkyl, halogenated C 1-3 substituted by an alkyl substituent;
[0047] In a preferred embodiment of the present invention, L Y Optionally substituted: methylene, ethylene, wherein optional substitution means substitution by one or more substituents selected from halogen, -OH, -SH, methyl, ethyl;
[0048] In a preferred embodiment of the present invention, for
[0049] In a preferred embodiment of the present invention, for
[0050] In a preferred embodiment of the present invention, for
[0051] In a preferred embodiment of the present invention, L is a bond, or optionally substituted: C 1-3 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, wherein optionally substituted refers to one or more selected from deuterium, halogen, oxo, -CN, -OH, -SH, -NH2, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-8 Cycloalkyl, halogenated C 1-3 substituted by an alkyl substituent;
[0052] In a preferred embodiment of the present invention, L is a bond, or optionally substituted: C 2-4 Alkenylene, C 2-4 Alkyne, wherein optionally substituted refers to one or more selected from deuterium, -CN, -OH, -SH, -NH2, C 1-3 substituted by an alkyl substituent;
[0053] In a preferred embodiment of the present invention, L is a bond, or optionally substituted: vinyl, propenyl, ethynyl, propynyl, wherein optionally substituted refers to one or more selected from deuterium, -CN, -OH, -SH, -NH2, C 1-3 substituted by an alkyl substituent;
[0054] In a preferred embodiment of the present invention, L is a bond;
[0055] In a preferred embodiment of the present invention, L is ethynyl;
[0056] In a preferred embodiment of the present invention, L is optionally substituted: propynyl, wherein optionally substituted refers to being replaced by one or more radicals selected from deuterium, -CN, -OH, -SH, -NH2, C 1-3 substituted by an alkyl substituent;
[0057] In a preferred embodiment of the present invention, ring W is C 4-12 Cycloalkyl, C 4-12 Cycloalkenyl, saturated or partially unsaturated 4-12 membered heterocyclic group, 5-16 membered heteroaryl, C 6-12 aryl;
[0058] In a preferred embodiment of the present invention, ring W is C 4-10 Monocyclic cycloalkyl, C 5-12 Bicyclic cycloalkyl, C 9-12 tricyclic cycloalkyl, C 4-10 Monocyclic cycloalkenyl, C 7-12 Bicyclic cycloalkenyl, C 9-12 tricyclic cycloalkenyl, saturated or partially unsaturated 4-12 membered monocyclic heterocyclyl, saturated or partially unsaturated 7-12 membered bicyclic heterocyclyl, saturated or partially unsaturated 9-12 membered tricyclic heterocyclyl, 5-8 membered monocyclic heteroaryl, 9-16 membered bicyclic heteroaryl, 9-16 membered tricyclic heteroaryl, phenyl, naphthyl;
[0059] In a preferred embodiment of the present invention, ring W is C 4-5 Monocyclic cycloalkyl, C 5-10 Bicyclic cycloalkyl, C 4-8 Monocyclic cycloalkenyl, C 7-10 Bicyclic cycloalkenyl, saturated or partially unsaturated 4-8 membered monocyclic heterocyclyl, saturated or partially unsaturated 7-12 membered bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 9-16 membered bicyclic heteroaryl, phenyl, naphthyl;
[0060] In a preferred embodiment of the present invention, ring W is
[0061] In a preferred embodiment of the present invention, ring W is
[0062] In a preferred embodiment of the present invention, ring W is
[0063] In a preferred embodiment of the present invention, ring W is
[0064] In a preferred embodiment of the present invention, ring W is
[0065] In a preferred embodiment of the present invention, ring W is
[0066] In a preferred embodiment of the present invention, ring W is
[0067] In a preferred embodiment of the present invention, ring W is
[0068] In a preferred embodiment of the present invention, ring W is
[0069] In a preferred embodiment of the present invention, ring W is
[0070] In a preferred embodiment of the present invention, for
[0071] In a preferred embodiment of the present invention, for
[0072] In a preferred embodiment of the present invention, for
[0073] In a preferred embodiment of the present invention, each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, acetamido, -CN, -OH, -SH, -NO2, -CONH2, -Z-(R Z ) m 、-NR b R c 、-C(O)OR d , optionally substituted: C 1-6 Alkyl, C 1-6 Alkoxy, wherein optionally substituted refers to one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 substituted by a cycloalkyl substituent;
[0074] R b and R c are independently selected from H, C 1-3 Alkyl, C 1-3 Hydroxyalkyl, halogenated C 1-3 alkyl;
[0075] R d Selected from H, C 1-3 Alkyl, C 1-3 Hydroxyalkyl, halogenated C 1-3 alkyl;
[0076] In a preferred embodiment of the present invention, each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m , optionally substituted: C 1-6 Alkyl, C 1- 6 alkoxy, wherein optionally substituted refers to one or more selected from halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2- 6 alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 substituted by a cycloalkyl substituent;
[0077] Z is C 4-10 Cycloalkyl, C 4-10 Cycloalkenyl, saturated or partially unsaturated 4-12 membered heterocyclic group, 5-12 membered heteroaryl, C 6-12 aryl;
[0078] R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy, saturated or partially unsaturated 4-6 membered heterocyclic group, -OR Z1 、-NR Z2 R Z3 ;
[0079] R Z1 Selected from C 1-3 Alkyl, halogenated C 1-3 alkyl;
[0080] R Z2 、R Z3 are independently selected from H, C 1-3 alkyl;
[0081] In a preferred embodiment of the present invention, each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m , optionally substituted: C 1-6 Alkyl, C1-6 alkoxy, wherein optionally substituted means substituted by one or more selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 substituted by a cycloalkyl substituent;
[0082] Z is a saturated or partially unsaturated 4-12 membered heterocyclic group, a 5-12 membered heteroaryl group, a C 6-12 metaaryl;
[0083] R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy, saturated or partially unsaturated 4-6 membered heterocyclic group, -OR Z1 、-NR Z2 R Z3 ;
[0084] R Z1 Selected from C 1-3 Alkyl, halogenated C 1-3 alkyl;
[0085] R Z2 、R Z3 are independently selected from H, C 1-3 alkyl;
[0086] In a preferred embodiment of the present invention, each R w are independently selected from halogen, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamino, ethylsulfonylamino, -CN, -OH, -SH, -NH2, -Z-(R Z ) m , or optionally substituted: C 1-4 Alkyl, C 1-4 Alkoxy, wherein optionally substituted refers to one or more selected from halogen, -CN, -OH, -SH, -NO2, -NH2, -CONH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-3 Alkyl, halogenated C 1-3 Substituted by an alkoxy group or a halogenated phenyl group;
[0087] Z is a 5-6 membered heteroaryl group or a phenyl group;
[0088] R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy, saturated or partially unsaturated 4-6 membered heterocyclic group, -OR Z1 、-NR Z2 R Z3 ;
[0089] R Z1 Selected from C 1-3Alkyl, halogenated C 1-3 alkyl;
[0090] R Z2 、R Z3 are independently selected from H, C 1-3 alkyl;
[0091] In a preferred embodiment of the present invention, each R w are independently selected from halogen, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamino, ethylsulfonylamino, -CN, -OH, -SH, -NH2, -Z-(R Z ) m , optionally substituted: C 1-4 Alkyl, C 1-4 Alkoxy, wherein optionally substituted refers to one or more selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-3 Alkyl, halogenated C 1-3 Substituted by an alkoxy group or a halogenated phenyl group;
[0092] Z is pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, or phenyl;
[0093] R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy, saturated or partially unsaturated 4-6 membered heterocyclic group, -OR Z1 、-NR Z2 R Z3 ;
[0094] R Z1 Selected from C 1-3 Alkyl, halogenated C 1-3 alkyl;
[0095] R Z2 、R Z3 are independently selected from H, C 1-3 alkyl;
[0096] In a preferred embodiment of the present invention, each R ware independently selected from methanesulfonyl, ethylsulfonyl, F, Cl, -CN, -OH, -SH, -NH2, -Z-(R Z ) m , or optionally substituted: methyl, ethyl, isopropyl, methoxy, ethoxy, methylthio, ethylthio, wherein optionally substituted refers to one or more selected from halogen, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkyl, C 1-3 substituted by a haloalkoxy substituent;
[0097] In a preferred embodiment of the present invention, -Z-(R Z ) m Selected from
[0098] In a preferred embodiment of the present invention, each R w Each of the following groups is independently selected from methylsulfonyl, methylsulfonamido, -F, -Cl, -CN, -OH, -SH, -NH2, -CF3, and -CH3;
[0099] In a preferred embodiment of the present invention, each R w Independently selected from
[0100] In a preferred embodiment of the present invention, each R w Independently selected from
[0101] In a preferred embodiment of the present invention, m is 1, 2 or 3;
[0102] In a preferred embodiment of the present invention, m is 1 or 2;
[0103] In a preferred embodiment of the present invention, n is 0, 1, 2 or 3;
[0104] In a preferred embodiment of the present invention, n is 0, 1 or 2;
[0105] In a preferred embodiment of the present invention, n is 1 or 2;
[0106] In a preferred embodiment of the present invention, q is 0, 1, 2 or 3;
[0107] In a preferred embodiment of the present invention, q is 0, 1 or 2;
[0108] In a preferred embodiment of the present invention, q is 1 or 2;
[0109] The present invention further provides compounds represented by the following formulas (IA), (IB), and (IC), stereoisomers, tautomers, or mixtures thereof, or pharmaceutically acceptable salts of the compounds:
[0110] Among them, X, q, R Q , Ring Q, n, R W , Ring W is as described for the compound of formula (I);
[0111] The present invention further provides compounds represented by the following formulas (II-A) to (II-E), stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compounds:
[0112] Where X, n, R W , Ring W, R Q , q is as described for the compound of formula (I);
[0113] The present invention further provides compounds represented by the following formulas (III-A) to (III-H), stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compounds:
[0114] Among them, n, R W , Ring W, R Q , q is as described for the compounds of formula (I), (II-A) to (II-E);
[0115] S* is a chiral sulfur atom;
[0116] In a preferred embodiment of the present invention, S* is a chiral sulfur atom having R / S-enantiomers;
[0117] In a preferred embodiment of the present invention, S* is a chiral sulfur atom having an R-enantiomer;
[0118] In a preferred embodiment of the present invention, S* is a chiral sulfur atom having an S-enantiomer;
[0119] The present invention further provides compounds represented by the following formulas (IV-A) to (IV-E), stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compounds:
[0120] Among them, n, R W, Ring W is as described for the compounds of formula (I), (II-A) to (II-E), (III-A) to (III-H);
[0121] In a preferred embodiment of the present invention, in the above formula (IV-A) or formula (IV-E), for
[0122] In a preferred embodiment of the present invention, in the above formula (IV-A) or formula (IV-E), for More preferably, Rw is Z-(R Z ) m ;
[0123] In a preferred embodiment of the present invention, in the above formula (IV-A) or formula (IV-E), for
[0124] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0125] Preferably, the compound provided by the present invention or its stereoisomer, tautomer or mixture thereof, or a pharmaceutically acceptable salt of the compound, wherein the compound has the following structure:
[0126] The present invention also aims to provide a method for preparing the compound represented by the above general formula, the stereoisomers, tautomers or mixtures thereof, or the pharmaceutically acceptable salts of the compound.
[0127] The compound of the general formula can be prepared by a variety of methods, including but not limited to the following methods:
[0128] Option 1:
[0129] Wherein, M is boron or metal containing ligand
[0130] Z represents a leaving group such as halogen, sulfonate, alkylthio, alkylthioyl, or alkylsulfinyl.
[0131] Option 2:
[0132] Here, Z is a leaving group such as halogen, sulfonate, alkylthio, alkylthioyl, or alkylsulfinyl.
[0133] The present invention also provides a pharmaceutical composition comprising the compound of the present invention, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound.
[0134] The present invention also provides a pharmaceutical composition comprising the compound of the present invention, stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compound and pharmaceutically acceptable excipients.
[0135] The present invention also aims to provide the use of the compound of the present invention, the stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compound in the preparation of drugs for treating or preventing diseases mediated by PDE4B.
[0136] In some embodiments, the PDE4B-mediated disease is a fibrosis-related disease or an immune-inflammatory-related disease.
[0137] In some embodiments, the PDE4B-mediated disease comprises respiratory disease, gastrointestinal disease, inflammatory disease, allergic disease, autoimmune disease, or cancer.
[0138] Preferably, the respiratory disease is selected from respiratory or lung diseases accompanied by increased mucus production, respiratory inflammation and / or obstructive diseases; further preferably, the respiratory disease is selected from idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial pneumonia, chronic obstructive pulmonary disease (COPD), α-antitrypsin deficiency, chronic sinusitis, asthma or chronic bronchitis;
[0139] Preferably, the gastrointestinal disease is selected from stage ileitis, ulcerative colitis or Crohn's disease;
[0140] Preferably, the inflammatory disease is selected from dry eye syndrome or glaucoma;
[0141] Preferably, the autoimmune disease is selected from diffuse connective tissue diseases such as systemic lupus erythematosus, atopic dermatitis, seborrheic dermatitis, psoriasis, urticaria, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis or Sjögren's disease.
[0142] Further preferably, in some embodiments, the PDE4B-mediated disease is chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, asthma or interstitial lung disease.
[0143] The present invention also aims to provide a method for preventing and / or treating diseases mediated by PDE4B, which comprises administering to a patient a therapeutically effective dose of the compound of the present invention, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound or the pharmaceutical composition of the present invention.
[0144] The compounds of the present invention, stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compounds can be administered in combination with other inhibitors for treating or preventing diseases mediated by PDE4B, such as fibrosis or immunoinflammation.
[0145] When the compound of the present invention, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salt is administered in combination with another inhibitor for treating, for example, fibrosis or immunoinflammatory disease, the compound of the present invention or its pharmaceutically acceptable salt may provide enhanced effects in treating diseases mediated by PDE4B, such as anti-fibrotic effects or anti-immunoinflammatory effects.
[0146] definition
[0147] Unless otherwise specified, the term "alkyl" refers to a monovalent saturated aliphatic hydrocarbon group, a straight or branched chain group containing 1 to 20 carbon atoms, preferably containing 1 to 10 carbon atoms (i.e., C 1-10 Alkyl), further preferably containing 1 to 8 carbon atoms (C 1-8 Alkyl), more preferably containing 1-6 carbon atoms (ie C 1-6 Alkyl), such as "C 1-6 "Alkyl" means that the group is an alkyl group and the number of carbon atoms in the carbon chain is between 1 and 6 (specifically 1, 2, 3, 4, 5 or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, and the like.
[0148] Unless otherwise specified, the term "alkenyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond. The alkenyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C 2-10 alkenyl), further preferably containing 2 to 8 carbon atoms (C 2-8 alkenyl), more preferably containing 2 to 6 carbon atoms (ie, C 2-6 alkenyl), 2-5 carbon atoms (ie C 2-5 alkenyl), 2-4 carbon atoms (ie C 2-4 alkenyl), 2-3 carbon atoms (ie C2-3 alkenyl), 2 carbon atoms (i.e., C2 alkenyl), for example, "C 2-6 The term "alkenyl" refers to an alkenyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl and 1,3-butadienyl.
[0149] Unless otherwise specified, the term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. The alkynyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C 2-10 Alkynyl), further preferably containing 2 to 8 carbon atoms (C 2-8 Alkynyl), more preferably containing 2-6 carbon atoms (ie, C 2-6 Alkynyl), 2-5 carbon atoms (ie C 2-5 Alkynyl), 2-4 carbon atoms (ie C 2-4 Alkynyl), 2-3 carbon atoms (ie C 2-3 alkynyl), 2 carbon atoms (i.e., C2 alkynyl), for example, "C 2-6 "Alkynyl" means that the group is an alkynyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl and 1-butynyl.
[0150] Unless otherwise specified, the term "cycloalkyl" refers to a hydrocarbon group selected from saturated cyclic hydrocarbon groups, including monocyclic and polycyclic (eg, bicyclic and tricyclic) groups, including fused cycloalkyl groups, bridged cycloalkyl groups, or spirocycloalkyl groups.
[0151] For example, cycloalkyl can comprise 3 to 16 (such as 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5 or 3 to 4) carbon atoms.Even further for example, cycloalkyl can be selected from the monocyclic group comprising 3 to 12 (such as 3 to 10, further such as 3 to 8, 3 to 6) carbon atoms.The example of monocyclic cycloalkyl comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl.Particularly, the example of saturated monocyclic cycloalkyl (for example, C3-8 cycloalkyl) includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.In preferred embodiments, cycloalkyl is the monocycle (abbreviated as C3-6 cycloalkyl) comprising 3 to 6 carbon atoms, and it includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of bicyclic cycloalkyls include those having 5 to 12, further such as 7 to 12 or 5 to 10 ring atoms arranged as a fused bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] or [6,6] ring systems, or arranged as a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.2]nonane. Other examples of bicyclic cycloalkyls include rings arranged as bicyclic rings selected from [5,6] and [6,6] ring systems. The rings may be saturated or have at least one double bond (i.e., partially unsaturated), but are not fully conjugated and are not aromatic as aromatic is defined herein.
[0152] The term "spirocycloalkyl" refers to a cyclic structure containing carbon atoms and formed by at least two rings sharing one atom. For example, the term "7- to 12-membered spirocycloalkyl" refers to a cyclic structure containing 7 to 12 carbon atoms and formed by at least two rings sharing one atom.
[0153] The term "fused cycloalkyl" refers to a fused ring containing carbon atoms and formed by two or more rings that share two adjacent atoms. For example, the term "5- to 10-membered fused cycloalkyl" refers to a fused ring containing 5 to 10 ring carbon atoms and formed by two or more rings that share two adjacent atoms.
[0154] Examples include, but are not limited to, bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[4.1.0]heptyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, decalin, and benzo 3 to 8 membered cycloalkyl, benzo C4-6 cycloalkenyl, 2,3-dihydro-1H-indenyl, 1H-indenyl, 1,2,3,4-tetrazolyl, 1,4-dihydronaphthyl, etc. Preferred embodiments are 8 to 9 membered fused rings, which refer to cyclic structures containing 8 to 9 ring atoms in the above examples.
[0155] The term "bridged cycloalkyl" refers to a cyclic structure containing carbon atoms and formed by two rings sharing two non-adjacent atoms. The term "7- to 12-membered bridged cycloalkyl" refers to a cyclic structure containing 7 to 12 carbon atoms and formed by two rings sharing two non-adjacent atoms.
[0156] The term "cycloalkenyl" refers to a non-aromatic cyclic alkyl group of 4 to 16, for example 4-12, carbon atoms, which has a monocyclic or polycyclic ring and has at least one double bond and preferably 1 to 2 double bonds. In one embodiment, the cycloalkenyl group is a cyclopentenyl group (1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl) or a cyclohexenyl group (1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl), preferably a cyclohexenyl group.
[0157] Unless otherwise specified, the term "oxaalkyl" refers to an alkyl residue in which one or more carbon atoms (and their associated hydrogen atoms) are replaced by oxygen, such as "alkoxy" and "alkoxyalkyl". Examples include methoxy, ethoxy, propoxy, methoxypropyl, and the like. The term oxaalkyl is understood in the art [see Nomenclature and Indexing of Chemical Substances for Chemical Extraction, published by the American Chemical Society, 196, but not limited to 127(a)], i.e., it refers to compounds in which an oxygen atom is bonded to its adjacent atom by a single bond (forming an ether bond); it does not refer to the double-bonded oxygen found in a carbonyl group.
[0158] "Alkoxy" refers to an -O-alkyl group, wherein the alkyl group is as defined above, i.e., containing 1-20 carbon atoms, preferably 1-10 carbon atoms, more preferably 1-8 carbon atoms, and more preferably 1-6 carbon atoms (specifically 1, 2, 3, 4, 5, or 6). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, tert-butoxy, pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, and the like.
[0159] Unless otherwise specified, the terms "thiaalkyl" and "azaalkyl" refer to groups in which the oxygen in the above "oxaalkyl" is replaced by sulfur or nitrogen.
[0160] Unless otherwise specified, the term "halogen" or "halo" refers to F, Cl, Br, I. The term "haloalkyl" refers to an alkyl group as defined above in which one, two or more hydrogen atoms or all of the hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include CCl3, CF3, CHCl2, CH2Cl, CH2Br, CH2I, CH2CF3, CF2CF3, and the like.
[0161] Unless otherwise specified, the term "heterocyclyl" or "heterocycle" refers to a non-aromatic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members and the remaining ring members are carbon, including monocyclic rings, fused rings, bridged rings and spiro rings, that is, containing monocyclic heterocyclic groups, bridged heterocyclic groups, spiro heterocyclic groups, and fused heterocyclic groups.
[0162] The term "monocyclic heterocyclyl" refers to a monocyclic group wherein at least one ring member is a heteroatom selected from nitrogen, oxygen or optionally oxidized sulfur. The heterocyclic ring may be saturated or partially saturated.
[0163] Exemplary monocyclic 4- to 18-membered heterocyclyl groups include, but are not limited to (as numbered from the attachment position designated priority 1), pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrazolidin-2-yl, pyrazolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 2,5-piperazinyl, pyranyl, morpholinyl, morpholino, morpholin-2-yl, morpholin-3-yl, oxiranyl, aziridin-1-yl, azepine Cyclopropan-2-yl, azetan-1-yl, azetan-2-yl, azetan-3-yl, azetan-4-yl, azetan-5-yl, thiirane, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, oxathianyl, piperazinyl, homopiperazinyl, homopiperidinyl , azepan-1-yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, oxepanyl, thiepanyl, 1,4-oxathienyl, 1,4-dioxepanyl, 1,4-oxathienyl, 1,4-oxathienyl, 1,4-dithienyl, 1,4-thiazepanyl and 1,4-diazepanyl, 1,4-dithienyl, 1,4-azathienyl, oxazepinyl , diazepinyl, thiazepinyl, dihydrothiophenyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolyl, 2H-pyranyl, 4H-pyranyl, 1,4-dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrazolidinyl, imidazolinyl, pyrimidinyl, or 1,1-dioxo-thiomorpholinyl.
[0164] The term "spiro heterocyclic radical " refers to a 5 to 18 yuan polycyclic heterocyclic radical with a ring connected by a shared carbon atom (called spiral atom), comprising one or more heteroatoms selected from nitrogen, oxygen or the optionally oxidized sulphur as ring members, and the remaining ring members are carbon. One or more rings of spiro heterocyclic radical can contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, spiro heterocyclic radical is 6 to 14 yuan, and more preferably 7 to 12 yuan. According to the number of shared spiral atoms, spiro heterocyclic radical is divided into single spiral heterocyclic radical, two spiral heterocyclic radicals or multiple spiral heterocyclic radicals, and preferably refers to single spiral heterocyclic radical or two spiral heterocyclic radicals, and more preferably 4 yuan / 4 yuan, 3 yuan / 5 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral heterocyclic radicals. Representative examples of spiroheterocyclyl groups include, but are not limited to, the following: 2,3-dihydrospiro[indene-1,2'-pyrrolidine] (e.g., 2,3-dihydrospiro[indene-1,2'-pyrrolidine]-1'-yl), 1,3-dihydrospiro[indene-2,2'-pyrrolidine] (e.g., 1,3-dihydrospiro[indene-2,2'-pyrrolidine]-1'-yl), azaspiro[2.4]heptane (e.g., 5-azaspiro[2.4]heptane-5-yl), azaspiro[3.4]octane (e.g., 6-azaspiro[3.4]octane-6-yl), 2-oxa-6 -azaspiro[3.4]octane (e.g., 2-oxa-6-azaspiro[3.4]octan-6-yl), azaspiro[3.4]octane (e.g., 6-azaspiro[3.4]octan-6-yl), azaspiro[3.4]octane (e.g., 6-azaspiro[3.4]octan-6-yl), 1,7-dioxaspiro[4.5]decane, 2-oxa-7-aza-spiro[4.4]nonane (e.g., 2-oxa-7-aza-spiro[4.4]nonan-7-yl), 7-oxa-spiro[3.5]nonyl, and 5-oxa-spiro[2.4]heptyl.
[0165] The term "fused heterocyclic group" refers to a 5 to 18-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms (carbon and carbon atoms or carbon and nitrogen atoms) with another ring, comprising one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members, and the remaining ring members are carbon. One or more rings of the fused heterocyclic group may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, the fused heterocyclic group is 6 to 14 members, preferably 7 to 12 members and more preferably 7 to 10 members. Depending on the number of member rings, the fused heterocyclic group is divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic fused heterocyclic group, and more preferably a 5 yuan / 5 yuan or 5 yuan / 6 yuan or 6 yuan / 7 yuan bicyclic fused heterocyclic group. Representative examples of fused heterocycles include, but are not limited to, the following: octahydrocyclopenta[c]pyrrole (e.g., octahydrocyclopenta[c]pyrrol-2-yl), octahydropyrrolo[3,4-c]pyrrolyl, octahydroisoindolyl, isoindolinyl (e.g., isoindolin-2-yl or isoindolin-5-yl), octahydro-benzo[b][1,4]dioxin, dihydropyridoxazinyl (e.g., 2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazinyl), or dihydrobenzoxazepinyl (e.g., 5-oxo-3,4-dihydrobenzo[f][1,4 ] oxazepinyl), benzazepinyl (e.g., 2,3,4,5-tetrahydro-1-oxo-2-benzoazepin-6-yl), benzoxazepinyl (e.g., 5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl), dihydroisoquinolinyl (e.g., 1-oxo-2-methyl-3,4-dihydroisoquinolin-6-yl), tetrahydroisoquinolinyl (e.g., 2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl), dihydrobenzoxazine (e.g., 3,4-dihydro-2H-1,4-benzoxazin-6-yl).
[0166] The term "bridged heterocyclic group" refers to a 5- to 18-membered polycyclic heterocyclic alkyl group in which each two rings in the system share two non-connected atoms, containing one or more heteroatoms selected from nitrogen, oxygen, or optionally oxidized sulfur as ring members, and the remaining ring members are carbon. One or more rings of the bridged heterocyclic group may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, the bridged heterocyclic group is 6- to 14-membered, and more preferably 7- to 10-membered. Depending on the number of member rings, the bridged heterocyclic group is divided into a bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic group, and preferably refers to a bicyclic, tricyclic, or tetracyclic bridged heterocyclic group, and more preferably a bicyclic or tricyclic bridged heterocyclic group. Representative examples of bridged heterocyclic groups include, but are not limited to, the following groups: 2-azabicyclo[2.2.1]heptyl, azabicyclo[3.1.0]hexyl, 2-azabicyclo[2.2.2]octyl, and 2-azabicyclo[3.3.2]decyl.
[0167] Unless otherwise specified, the term "heterocycloalkyl" refers to a monocyclic, saturated "heterocyclyl" or "heterocycle" as defined above, with the ring atoms as defined above, i.e., containing 3 to 20 ring atoms ("3-20-membered heterocycloalkyl"), with 1, 2, 3 or 4 (1-4), preferably 1, 2 or 3 (1-3), wherein each heteroatom is independently selected from N, O or S. Preferably, the group contains 3 to 12 ring atoms ("3-12-membered heterocycloalkyl"), more preferably 3 to 10 ring atoms ("3-10-membered heterocycloalkyl"), even more preferably 3 to 8 ring atoms ("3-8-membered heterocycloalkyl"), even more preferably 4 to 7 ring atoms ("4-7-membered heterocycloalkyl"), even more preferably 5 to 10 ring atoms ("5-10-membered heterocycloalkyl"), even more preferably 5 to 6 ring atoms ("5-6-membered heterocycloalkyl"). In certain embodiments, each example of heterocycloalkyl is independently optionally substituted, e.g., unsubstituted (an "unsubstituted heterocycloalkyl") or substituted with one or more substituents (a "substituted heterocycloalkyl"). Some exemplary heterocycloalkyls are given above in the "heterocyclyl" or "heterocycle" section, and also include, but are not limited to, oxanyl, thiomorpholinyl, oxathioxanyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, imidazolinyl, and the like.
[0168] Unless otherwise specified, the term "heterocycloalkenyl" refers to a monocyclic, unsaturated "heterocyclyl" or "heterocycle" as defined above, with the same ring atoms as defined above, i.e., containing 4 to 12 ring atoms ("4-12-membered heterocycloalkenyl"), with 1, 2, 3 or 4 (1-4), preferably 1, 2 or 3 (1-3), wherein each heteroatom is independently selected from N, O or S. Preferably, it contains 4 to 10 ring atoms ("4-10-membered heterocycloalkenyl"), further preferably contains 4 to 8 ring atoms ("4-8-membered heterocycloalkenyl"), further preferably contains 4 to 6 ring atoms ("4-6-membered heterocycloalkenyl"), and further preferably contains 5 to 6 ring atoms ("5-6-membered heterocycloalkenyl"). In certain embodiments, each instance of heterocyclenyl is independently optionally substituted, eg, unsubstituted (an "unsubstituted heterocyclenyl") or substituted (a "substituted heterocyclenyl") with one or more substituents.
[0169] Unless otherwise specified, the term "aryl" refers to a monocyclic, bicyclic, or tricyclic aromatic carbocyclic ring system containing 6 to 16 carbon atoms, or 6 to 14 carbon atoms, or 6 to 12 carbon atoms, or 6 to 10 carbon atoms, preferably 6 to 10 carbon atoms. The term "aryl" can be used interchangeably with the term "aromatic ring." Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, or pyrenyl.
[0170] Unless otherwise specified, the term "heteroaryl" refers to an aromatic monocyclic, bicyclic or polycyclic ring system containing a 5-16 membered structure, or a 5-14 membered structure, a 5-12 membered structure, a 5-10 membered structure, a 5-8 membered structure, or a 5-6 membered structure, wherein 1, 2, 3 or more ring atoms are heteroatoms and the remaining atoms are carbon, the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2 or 3. Examples of heteroaryl groups include, but are not limited to, furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolyl, isoquinolyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzothienyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, benzimidazolyl, benzophthalazinyl, pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4] triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, and the like.
[0171] The term "alkylene" refers to a divalent alkyl group as defined above. The term "alkenylene" refers to a divalent alkenyl group as defined above. The term "alkynylene" refers to a divalent alkynyl group as defined above. The term "cycloalkylene" refers to a divalent cycloalkyl group as defined above. The term "heterocyclylene" refers to a divalent heterocyclyl group as defined above. The term "arylene" refers to a divalent aryl group as defined above. The term "heteroarylene" refers to a divalent heteroaryl group as defined above.
[0172] Unless otherwise specified, the term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with mammalian tissues, particularly human tissues, without excessive toxicity, irritation, allergic response, etc., and is commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. For example, pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the present invention, or separately by reacting the free base or free acid with a suitable reagent.
[0173] The compounds of the present invention also include their "isotopic derivatives". Unless otherwise specified, the term "isotopic derivative" means that the compounds of the present invention may exist in an isotopically labeled or enriched form, containing one or more atoms whose atomic mass or mass number is different from the atomic mass or mass number of the largest atom found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes commonly used as isotopic labels are: hydrogen isotopes, 2 H and 3 H; Carbon isotope: 13 C and 14 C; Chlorine isotope: 35 Cl and 37 Cl; Fluorine isotope: 18 F; Iodine isotope: 123 I and 125 I; Nitrogen isotopes: 13 N and 15 N; oxygen isotopes: 15 O, 17 O and 18 O and sulfur isotopes 35 These isotope-labeled compounds can be used to study the distribution of pharmaceutical molecules in tissues. 3 H and 13 C, because they are easy to label and detect, they are more widely used. Some heavy isotopes, such as deuterium ( 2 H) substitution can enhance metabolic stability and prolong half-life, thereby achieving the goal of reducing dosage and providing therapeutic advantages. Isotope-labeled compounds are generally synthesized from labeled starting materials using known synthetic techniques similar to those used for synthesizing non-isotope-labeled compounds.
[0174] The compounds of the present invention also include solvates thereof. Unless otherwise specified, the terms "solvate" and "solvate" mean a physical association of a compound of the present invention with one or more solvent molecules (whether organic or inorganic). This physical association includes hydrogen bonding. In certain circumstances, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be capable of isolation. The solvent molecules in the solvate may exist in a regular and / or disordered arrangement. The solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" encompasses both solution-phase and isolatable solvates. Solvation methods are well known in the art.
[0175] Unless otherwise specified, the term "stereoisomer" refers to compounds that have the same chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, etc. Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric isomers, enantiomers, and diastereomers based on the differences in the physicochemical properties of the components, for example, by chromatography and / or fractional crystallization.
[0176] Unless otherwise specified, the term "tautomer" refers to structural isomers of different energies that are interconvertible through a low energy barrier. If tautomerism is possible (e.g., in solution), a chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include interconversions that occur via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions that occur via reorganization of some of the bonding electrons.
[0177] Unless otherwise specified, the term "optionally substituted" means that the hydrogen at the substitutable position of the group is not replaced, or is replaced by one or more substituents, preferably substituted by 1, 2 or 3 substituents, preferably selected from the group consisting of halogen, hydroxy, mercapto, cyano, nitro, amino, azido, oxo, carboxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkylsulfonyl, 3-10 membered heterocycloalkyl, C 6-14 Aryl or 5-10 membered heteroaromatic ring group, wherein the C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkylsulfonyl, 3-10 membered heterocycloalkyl, C 6-14 The aryl or 5-10 membered heteroaromatic ring group may be optionally selected from halogen, hydroxy, amino, cyano, C 1- 6 alkyl or C 1-6 The alkoxy group is substituted by one or more substituents, and the oxo group means that two H at the same substitution position are replaced by the same O to form a double bond.
[0178] The term "therapeutically effective amount" refers to a non-toxic but sufficient amount of a drug or medicament that can achieve the desired effect. In an embodiment of the present invention, when a patient is treated according to the present invention, the amount of a given drug depends on many factors, such as a specific dosage regimen, a disease or condition type and its severity, the uniqueness (e.g., weight) of the patient or host to be treated, but, according to specific surrounding circumstances, including, for example, the specific drug, route of administration, the condition to be treated, and the patient or host to be treated, the dosage can be determined conventionally by methods known in the art. For the pharmaceutical composition of the present invention, it comprises a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable carrier, wherein a "therapeutically effective amount" refers to a weight based on the weight of the pharmaceutical composition, wherein the weight of the compound of the present invention accounts for 1-99%, such as 20-80%, 30-70% or 45-55%, and the weight of a pharmaceutically acceptable carrier accounts for 99-1%, such as 80-20%, 70-30% or 55-45%. Pharmaceutically acceptable carriers are those well known in the art and will not be described in detail herein.
[0179] The beneficial effects of the present invention are:
[0180] This invention designs a class of novel compounds, offering a new direction for the development of PDE4B inhibitors. In vitro biochemical enzyme activity studies demonstrate that these compounds exhibit potent and selective inhibition of the PDE4B enzyme. In vivo pharmacokinetic studies in mice also demonstrate good bioavailability and exposure, demonstrating excellent metabolic properties. Therefore, these compounds may be promising compounds for the treatment of PDE4B-mediated diseases. DETAILED DESCRIPTION
[0181] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. Experimental methods in the following examples where specific conditions are not specified are generally performed under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to professionals in the field. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention. The preferred embodiments and materials shown herein are for demonstration purposes only.
[0182] The structures of the compounds of the present invention were determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS) and / or liquid chromatography (HPLC). NMR measurements were performed using a Bruker 400 MHz and / or Varian 400 MHz instrument; LC-MS measurements were performed using an Agilent 1260 Infinity II-6120 / 6125MSD; and HPLC measurements were performed using a Waters UPCC (CA-352) instrument.
[0183] The starting materials in the examples of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art.
[0184] The present invention provides a method for preparing the compound. The compound can be prepared by the following steps.
[0185] Preparation Example 1
[0186] Preparation of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0187] Step 1: Preparation of (1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methanol:
[0188] 2,4-Dichloro-6,7-dihydrothieno[3,2-d]pyrimidine (6.3 g), (1-aminocyclobutyl)methanol hydrochloride (4.6 g), and N,N-diisopropylethylamine (DIEA) (15.6 g) were dissolved in acetonitrile (ACN) (30 mL) and reacted at 85°C overnight. Water (100 mL) was then added, and the mixture was extracted with ethyl acetate (100 mL x 2) and washed with water (100 mL x 3). The organic phase was then dried over anhydrous sodium sulfate. Filtered and dried to obtain the crude product. The crude product was purified by flash chromatography (100-200 mesh silica gel, petroleum ether:ethyl acetate = 0-50%) to obtain a white solid. Acetonitrile (20 mL) and water (40 mL) were then added and stirred at room temperature overnight. The solid was filtered and washed with acetonitrile / water (1:2, 20 mL). The filter cake was dried to obtain the target compound (4.2 g). LCMS (ESI) [M+H] + =272.10
[0189] Step 2: Preparation of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0190] (1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methanol (1 g), Ti(O i Pr)4 (52.4 mg) and S-binaphthol ((S)-BINOL) (105.6 mg) were dissolved in dichloromethane (DCM) (5 mL) and water (0.5 mL), and then stirred for half an hour under nitrogen protection. Then, tert-butyl peroxide (t-BuOOH) (522 mg, 70% aqueous solution) was added under ice bath and stirred at room temperature for 1 hour. LCMS monitoring showed that the product was the main peak. The solution was then spin-dried, isopropyl acetate (15 mL) was added, ultrasonicated for 1 minute, then filtered, washed with isopropyl acetate (2 mL), and dried to obtain the target compound (1 g). LCMS (ESI) [M+H] + =288.08
[0191] Preparation Example 2
[0192] Step 1: Preparation of tert-butyl 3-(4-chlorophenyl)-3-(methoxy-d3)azetidine-1-carboxylate:
[0193] tert-Butyl 3-(4-chlorophenyl)-3-hydroxyazetidine-1-carboxylate (0.50 g) was dissolved in DMF (5 mL) and the nitrogen atmosphere was replaced three times. 60% sodium hydride (141 mg) was added under ice-cooling conditions and stirred for 10 minutes. Deuterated iodomethane (0.51 g) was added and stirred for another 30 minutes. Saturated aqueous NH4Cl solution was added to quench the mixture. The mixture was added to water and extracted with methyl tert-butyl ether. The combined organic phases were washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain the title compound (700 mg, crude product).
[0194] Step 2: Preparation of 3-(4-chlorophenyl)-3-(methoxy-d3)azetidine hydrochloride:
[0195] 3-(4-chlorophenyl)-3-(methoxy-d3)azetidine-1-carboxylic acid tert-butyl ester (650 mg) was added to a 4M hydrogen chloride / ethyl acetate solution (5 mL) and stirred at room temperature for 0.5 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product. Petroleum ether was added to the crude product and the target compound (500 mg) was obtained by slurrying. LCMS (ESI) [M+H] + =201.1.
[0196] Preparation Example 3
[0197] Step 1: Preparation of tert-butyl 3-(4-(difluoromethoxy)phenyl)-3-hydroxyazetidine-1-carboxylate:
[0198] Under nitrogen protection, 1-bromo-4-(difluoromethoxy)benzene (5.08g) was dissolved in anhydrous tetrahydrofuran (40mL). At -78°C, 2.5M n-butyllithium / hexane solution (9.8mL) was added dropwise and reacted at -78°C for 0.5 hours to obtain an off-white turbid liquid. 3-Oxoazetidine-1-carboxylic acid tert-butyl ester (3.00g) was dissolved in anhydrous tetrahydrofuran (10mL), slowly added to the solution at -78°C and stirred for 1 hour. The reaction solution was warmed to 0°C, saturated ammonium chloride solution (20mL) was added to quench the reaction, water (200mL) was added, and the mixture was extracted with methyl tert-butyl ether. The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column (PE:EA=3:1) to obtain the target compound (4.10g). LCMS (ESI) [M+H-56] + =260.2.
[0199] Step 2: Preparation of tert-butyl 3-(4-(difluoromethoxy)phenyl)-3-methoxyazetidine-1-carboxylate:
[0200] Tert-butyl 3-(4-(difluoromethoxy)phenyl)-3-hydroxyazetidine-1-carboxylate (4.00 g) was dissolved in DMF (40 mL), and the nitrogen atmosphere was replaced three times. 60% sodium hydride (0.61 g) was added under ice-bath conditions, and the mixture was stirred in an ice-bath for 10 minutes. Methyl iodide (2.70 g) was added, and stirring in an ice-bath continued for 1 hour. Saturated aqueous NH4Cl solution was added to the reaction solution to quench the reaction, and the mixture was added to water (200 mL). The mixture was extracted with methyl tert-butyl ether, and the combined organic phases were washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (4.46 g).
[0201] Step 3: Preparation of 3-(4-(difluoromethoxy)phenyl)-3-methoxyazetidine hydrochloride:
[0202] tert-Butyl 3-(4-(difluoromethoxy)phenyl)-3-methoxyazetidine-1-carboxylate (4.00 g) was added to a 4M hydrogen chloride / ethyl acetate solution (20 mL) and stirred at room temperature for 0.5 hours. LCMS analysis showed that the starting material was completely consumed. The reaction solution was concentrated under reduced pressure to obtain the title compound (3.23 g, crude product). LCMS (ESI) [M+H] + =230.1.
[0203] Preparation Example 4
[0204] Using the same method as Preparation Example 3, 1-bromo-4-(difluoromethoxy)benzene was replaced with 1-bromo-4-(cyclopropylmethoxy)benzene to prepare 3-(4-(cyclopropylmethoxy)phenyl)-3-methoxyazetidine hydrochloride. LCMS (ESI) [M+H] + =234.2.
[0205] Preparation Example 5
[0206] Using the same method as Preparation Example 3, 1-bromo-4-(difluoromethoxy)benzene was replaced with 1-(4-bromophenyl)pyrrolidine to prepare 1-(4-(3-methoxyazetidin-3-yl)phenyl)pyrrolidine hydrochloride. LCMS (ESI) [M+H-MeO] + =201.3.
[0207] Preparation Example 6
[0208] The same method as Preparation Example 3 was used to replace 1-bromo-4-(difluoromethoxy)benzene with 4-bromo-N,N-dimethylaniline to prepare 4-(3-methoxyazetidin-3-yl)-N,N-dimethylaniline hydrochloride.
[0209] Preparation Example 7
[0210] The same method as Preparation Example 3 was used to replace 1-bromo-4-(difluoromethoxy)benzene with 3-bromo-N,N-dimethylaniline to prepare 3-(3-methoxyazetidin-3-yl)-N,N-dimethylaniline hydrochloride.
[0211] Preparation Example 8
[0212] Using the same method as Preparation Example 3, 1-bromo-4-(difluoromethoxy)benzene was replaced with 5-bromobenzo(d)[1,3]dioxolane to prepare 3-(benzo(d)[1,3]dioxolane-5-yl)-3-methoxyazetidine hydrochloride. LCMS (ESI) [M+H] + =208.1.
[0213] Preparation Example 9
[0214] Using the same method as Preparation Example 3, 1-bromo-4-(difluoromethoxy)benzene was replaced with tert-butyl (4-bromophenyl)(methyl)carbamate to prepare 4-(3-methoxyazetidin-3-yl)-N-methylaniline dihydrochloride. LCMS (ESI) [M+H] + =193.1.
[0215] Example 1 (Compound 1)
[0216] Synthesis of (R / S)-2-(3-(4-chlorophenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0217] Step 1: Preparation of tert-butyl 3-(4-chlorophenyl)-3-hydroxyazetidine-1-carboxylate:
[0218] 4-Chloroiodobenzene (2g) was dissolved in anhydrous tetrahydrofuran (THF) (20mL), and n-butyllithium (n-BuLi) (5.25mL, 1.6M n-hexane solution) was added at -78°C under nitrogen protection, and the system was stirred at -78°C for 10 minutes. Then, a solution of tert-butyl 3-oxoazetidine-1-carboxylate (0.95g) in tetrahydrofuran (5mL) was added dropwise to the system, and the reaction was stirred at -78°C for 1 hour. LCMS monitoring showed that the product was the main peak, and then a saturated aqueous solution of ammonium chloride (20mL) was added to quench the reaction and extract with ethyl acetate (30mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The target compound (1.2g) was obtained by flash chromatography (silica gel, petroleum ether:ethyl acetate = 5:1-2:1). LCMS (ESI) [M-55] + =228.14.
[0219] Step 2: Preparation of 3-(4-chlorophenyl)azetidin-3-ol trifluoroacetate:
[0220] Dissolve tert-butyl 3-(4-chlorophenyl)-3-hydroxyazetidine-1-carboxylate (200 mg) in dichloromethane (2 mL), add trifluoroacetic acid (TFA) (1 mL), and stir at room temperature for 1 hour. LCMS showed that the reaction was complete, and the solution was then dried to give the crude title compound. LCMS (ESI) [M+H] + =184.14.
[0221] Step 3: Preparation of (R / S)-2-(3-(4-chlorophenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0222] 3-(4-Chlorophenyl)azetidin-3-ol trifluoroacetate (200 mg, crude product, obtained from the previous step) was dissolved in dioxane (4 mL), and N,N-diisopropylethylamine (1 mL) was added. The system was stirred until uniform, and then (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (70 mg) was added. The system was reacted in a microwave oven at 120°C for 20 minutes. LCMS monitored the reaction completion, and water (20 mL) was added, followed by extraction with ethyl acetate (30 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude target compound. The crude target compound was added to ethyl acetate (15 mL), stirred at 85°C overnight, and the system was cooled and filtered to obtain the target compound (63.3 mg). LCMS (ESI) [M+H] + =435.28;Chiral HPLC:ee%=100%; 1 H NMR (400MHz, DMSO-d6) δ7.54(d,J=8.4Hz,2H),7.44(d,J=8.8Hz,3H),6.48(s,1H),4.85(t,J=5.5Hz,1H),4.19(s,4H),3.70(d,J=5.5Hz,2H),3.5 1-3.36(m,1H),3.26-3.15(m,1H),2.92(ddd,J=20.7,15.4,7.4Hz,2H), 2.41-2.25(m,2H),2.12(t,J=9.4Hz,2H),1.73(dt,J=19.7,10.2Hz,2H).
[0223] Example 2 (Compound 2)
[0224] Synthesis of (R / S)-2-(3-hydroxy-3-(4-methoxyphenyl)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0225] Step 1: tert-Butyl 3-hydroxy-3-(4-methoxyphenyl)azetidine-1-carboxylate:
[0226] Dissolve 1-bromo-4-methoxybenzene (2g) in tetrahydrofuran (40mL) and add n-butyllithium (4.3mL, 2.5M in n-hexane) dropwise at -78°C under nitrogen. Stir at this temperature for 0.5 hour. Dissolve tert-butyl 3-oxoazetidine-1-carboxylate (2.75g) in tetrahydrofuran (10mL) and add the solution dropwise to the lithium reagent solution at -78°C. Stir at this temperature for 0.5 hour. LCMS indicated the production of a new product. Pour the reaction solution into water (100mL) and extract with ethyl acetate (30mL x 3). The organic phase was dried over sodium sulfate and dried to dryness to obtain the crude product. The crude product was purified on a silica gel column (petroleum ether / ethyl acetate = 3 / 1) to obtain the title compound (1.9g). LCMS: (ESI) [M-Boc-OH+H] + =162.1.
[0227] Step 2: Preparation of 3-(4-methoxyphenyl)azetidin-3-ol trifluoroacetate:
[0228] Dissolve tert-butyl 3-hydroxy-3-(4-methoxyphenyl)azetidine-1-carboxylate (145 mg) in dichloromethane (2 mL), add trifluoroacetic acid (1 mL) at room temperature, and stir at room temperature for 1 hour. LCMS shows the disappearance of the starting material, and the reaction solution is dried to give the title compound (150 mg).
[0229] Step 3: Preparation of (R / S)-2-(3-hydroxy-3-(4-methoxyphenyl)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0230] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-(4-methoxyphenyl)azetidin-3-ol trifluoroacetate (153.95 mg), and N,N-diisopropylethylamine (226.17 mg) were dissolved in dioxane (2 mL) and reacted at 120°C under microwave conditions for 1.5 hours. LCMS indicated complete reaction. The reaction solution was directly separated and purified by Prep-HPLC (C18, 10 mmol / L, aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (40.3 mg). LCMS: (ESI)[M+H]+=431.33; 1H NMR(400MHz, DMSO-d6+D2O)δ7.38(d,J=8.4Hz,2H),6.92(d,J=8.5Hz,2H),4.30-4.05(m,4H),3.75-3.63(m,5H),3 .47-3.35(m,1H),3.30-3.19(m,1H),3.01-2.85(m,2H),2.34-2.19(m,2H),2.17-2.00(m,2H),1.84-1.64(m,2H).
[0231] Example 3 (Compound 3)
[0232] Synthesis of (R / S)-2-(3-(4-chloro-3-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0233] Step 1: tert-Butyl 3-hydroxy-3-(4-chloro-3-methoxyphenyl)azetidine-1-carboxylate:
[0234] 4-Bromo-1-chloro-2-methoxybenzene (2 g) was dissolved in tetrahydrofuran (40 mL). Under nitrogen, n-butyllithium (3.6 mL, 2.5 M in n-hexane) was added dropwise at -78°C and stirred for 0.5 hour. tert-Butyl 3-oxoazetidine-1-carboxylate (2.32 g) was dissolved in tetrahydrofuran (15 mL) and added dropwise to the lithium reagent solution at -78°C and stirred for 0.5 hour. LCMS indicated product formation. Water (10 mL) was added dropwise to the reaction mixture at -78°C to quench the reaction. The reaction mixture was poured into water (300 mL) and extracted with ethyl acetate (100 mL x 3). The organic phase was washed with water (200 mL x 3), dried over anhydrous sodium sulfate, and spin-dried to obtain the crude product. The crude product was purified on a silica gel column (petroleum ether / ethyl acetate = 3 / 1) to obtain the title compound (1.3 g). LCMS:(ESI)[M-OH+H]+ =196.17.
[0235] Step 2: Preparation of 3-(4-chloro-3-methoxyphenyl)azetidin-3-ol trifluoroacetate:
[0236] Dissolve tert-butyl 3-hydroxy-3-(4-chloro-3-methoxyphenyl)azetidine-1-carboxylate (145 mg) in dichloromethane (2 mL), add trifluoroacetic acid (1 mL) at room temperature, and stir at room temperature for 1 hour. LCMS shows the disappearance of the starting material, and the reaction solution is dried to give the title compound (160 mg).
[0237] Step 3: Preparation of (R / S)-2-(3-(4-chloro-3-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0238] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-(4-chloro-3-methoxyphenyl)azetidin-3-ol trifluoroacetate (153.95 mg), and N,N-diisopropylethylamine (DIEA) (226.17 mg) were dissolved in dioxane (2 mL) and reacted at 120°C under microwave for 1.5 hours. LCMS showed the disappearance of the starting material, and the product was isolated and purified (31.9 mg). LCMS: (ESI) [M+H] + =465.2; 1 H NMR (400MHz, DMSO-d6) δ7.52-7.37(m,2H),7.25(d,J=1.9Hz,1H),7.08(d,J=8.3Hz,1H),6.50(s,1H),4.85(t,J=5.6Hz,1H),4.40-4.15(m,4H),3.8 6(s,3H),3.70(d,J=5.8Hz,2H),3.48-3.37(m,1H),3.25-3.15(m,1H),3. 10-2.85(m,2H),2.43-2.26(m,2H),2.20-2.15(m,2H),1.85-1.65(m,2H).
[0239] Example 4 (Compound 4)
[0240] Synthesis of (R / S)-2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0241] Step 1: Preparation of tert-butyl 3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidine-1-carboxylate:
[0242] 4-Bromo-2-chloro-1-methoxybenzene (2.5 g) was dissolved in anhydrous tetrahydrofuran (20 mL). The temperature of the system was lowered to -78°C under nitrogen protection, and then n-butyl lithium (7 mL, 1.6 M in n-hexane) was added. The system was reacted at -78°C for 0.5 hours. A solution of tert-butyl 3-oxoazetidine-1-carboxylate (1.28 g) in tetrahydrofuran (2 mL) was then slowly added dropwise to the solution, and the reaction was stirred at -78°C for 1 hour. LCMS analysis showed the product as the main peak, and aqueous ammonium chloride (10 mL) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phases were dried over anhydrous sodium sulfate and spun down to dryness. The crude product was separated and purified by flash chromatography (Silica gel, petroleum ether:ethyl acetate = 3:1-2:1) to obtain the target compound (1.57 g). LCMS (ESI) [M+H] + =258.12.
[0243] Step 2: Preparation of 3-(3-chloro-4-methoxyphenyl)azetidin-3-ol trifluoroacetate:
[0244] Dissolve tert-butyl 3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidine-1-carboxylate (120 mg) in dichloromethane (2 mL), add trifluoroacetic acid (1 mL), and stir at room temperature for 1 hour. LCMS analysis revealed the product as the main peak. The solvent was then dried to give the crude target compound, which was used directly in the next step without further purification. LCMS (ESI) [M+H] + =214.17.
[0245] Step 3: Preparation of (R / S)-2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0246] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (60 mg), 3-(3-chloro-4-methoxyphenyl)azetidin-3-ol trifluoroacetate (80 mg, crude product), and N,N-diisopropylethylamine (0.5 mL) were dissolved in dioxane (3 mL) and reacted at 120°C for 1 hour. LCMS analysis revealed the product as the main peak, and the solvent was then dried to give the crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to give the title compound (62.66 mg). LCMS (ESI) [M+H] + =465.34; 1 H NMR(400MHz, DMSO-d6)δ7.52(d,J=2.0Hz,1H),7.43(dd,J=7.5,3.2Hz,2H),7. 16(d,J=8.7Hz,1H),6.42(s,1H),4.85(t,J=5.7Hz,1H),4.16(s,4H),3.85(s, 3H),3.70(d,J=5.8Hz,2H),3.49-3.36(m,1H),3.26-3.16(m,1H),3.04-2.80( m, 2H), 2.34 (td, J = 21.4, 9.7Hz, 2H), 2.12 (t, J = 9.4Hz, 2H), 1.85-1.62 (m, 2H).
[0247] Example 5 (Compound 5)
[0248] Synthesis of (R / S)-2-(3-hydroxy-3-(3-methoxyphenyl)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0249] Step 1: Preparation of tert-butyl 3-hydroxy-3-(3-methoxyphenyl)azetidine-1-carboxylate;
[0250] Under nitrogen protection, m-bromoanisole (1.87 g) was dissolved in anhydrous tetrahydrofuran (30 mL) and cooled in an external dry ice ethanol bath. While maintaining the internal temperature at no more than -65 ° C, n-butyl lithium (1.6 M n-hexane solution, 6.6 mL) was added dropwise with stirring. After the addition was complete, the reaction was incubated for 30 minutes. 3-Oxoazetidine-1-carboxylic acid tert-butyl ester (1.88 g) was dissolved in tetrahydrofuran (8 mL) and added to the reaction solution while maintaining the internal temperature at no more than -60 ° C. After 30 minutes of reaction, LCMS monitoring showed that the raw material was consumed. The cooling bath was removed, water (50 mL) was added, and the mixture was naturally warmed to room temperature. Extraction with ethyl acetate (100 ml × 3) was performed. The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash silica gel chromatography (silica gel, petroleum ether:tetrahydrofuran = 100:0 to 50:50 gradient elution) to give the title compound (1.20 g). LCMS (ESI) [2M+H] + =559.4;
[0251] Step 2: Preparation of 3-(3-methoxyphenyl)azetidin-3-ol hydrochloride;
[0252] Under nitrogen protection, tert-butyl 3-hydroxy-3-(3-methoxyphenyl)azetidine-1-carboxylate (1.20 g) was dissolved in dichloromethane (20 mL) and stirred in an ice-water bath for 10 minutes. A 4M solution of hydrogen chloride in ethyl acetate (EA) (3.23 ml) was added to the reaction solution at 0°C. The ice-water bath was removed, and the temperature was raised to room temperature and the reaction was allowed to react for 1 hour. LCMS showed that the starting material was consumed and converted to the product. Filter, wash the filter cake with dichloromethane (5 mL), and concentrate to dryness to obtain the title compound (0.83 g). LCMS (ESI) [M+H] + =216.1.
[0253] Step 3: Preparation of (R / S)-2-(3-hydroxy-3-(3-methoxyphenyl)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0254] Under nitrogen protection, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg) and 3-(3-methoxyphenyl)azetidin-3-ol hydrochloride (90 mg) were added to dioxane (5 mL), followed by N,N-diisopropylethylamine (114 mg). After nitrogen replacement three times, the reaction solution was heated to 110°C and reacted for 1 hour. LCMS showed that the starting material was consumed and converted to product. The heating was turned off, the reaction solution was concentrated to dryness, and the residue was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (118.5 mg). LCMS (ESI) [M+H] + =431; 1 H NMR (400MHz, DMSO-d6) δ7.43(s,1H),7.31(t,J=7.9Hz,1H),7.07(t,J=5.1Hz,2H) ,6.89-6.82(m,1H),6.37(s,1H),4.86(t,J=5.7Hz,1H),4.17(s,4H),3.76(s,3H) ,3.70(d,J=5.7Hz,2H),3.48-3.36(m,1H),3.23(dt,J=13.5,8.3Hz,1H),3.02-2. 83(m,2H),2.34(td,J=21.4,9.7Hz,2H),2.12(t,J=9.3Hz,2H),1.87-1.63(m,2H).
[0255] Example 6 (Compound 11)
[0256] Synthesis of (R / S)-2-(3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0257] Step 1: Preparation of tert-butyl 3-(4-chlorophenyl)-3-hydroxypyrrolidine-1-carboxylate;
[0258] Under nitrogen, p-chloroiodobenzene (2.38 g) was dissolved in anhydrous tetrahydrofuran (30 mL) and cooled in an external dry ice-ethanol bath. While maintaining the internal temperature at -65°C, n-butyllithium (1.6 M in n-hexane, 6.6 mL) was added dropwise with stirring. After the addition was complete, the reaction was incubated for 30 minutes. Tert-butyl 3-oxopyrrolidine-1-carboxylate (2.03 g) was dissolved in tetrahydrofuran (8 mL) and added to the reaction solution while maintaining the internal temperature at -60°C. After 30 minutes of reaction, LCMS monitoring indicated that the starting material was consumed. The cooling bath was removed, 50 mL of water was added, and the mixture was allowed to warm to room temperature. Extraction was then performed with ethyl acetate (100 mL x 3). The organic phases were separated, combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield the crude product. The crude product was purified by flash silica gel chromatography (silica gel, petroleum ether:tetrahydrofuran = 100:0 to 50:50 gradient elution) to give the title compound (1.34 g). LCMS (ESI) [2M + Na + ] + =617.3;
[0259] Step 2: Preparation of 3-(4-chlorophenyl)pyrrolidin-3-ol hydrochloride;
[0260] Under nitrogen, tert-butyl 3-(4-chlorophenyl)-3-hydroxypyrrolidine-1-carboxylate (1.34 g) was dissolved in dichloromethane (20 mL) and stirred in an ice-water bath for 10 minutes. A 4M solution of hydrogen chloride in ethyl acetate (3.38 mL) was added to the reaction solution at 0°C. The ice-water bath was removed, and the temperature was raised to 20°C and the reaction was allowed to proceed for 1 hour. LCMS showed that the starting material was consumed and converted to the product, precipitating a white solid. The filter cake was filtered, washed with dichloromethane (5 mL), and concentrated to dryness to obtain the desired product (0.90 g). LCMS (ESI) [M+H] + =198.1;
[0261] Step 3: Preparation of (5R / S)-2-(3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide;
[0262] Under nitrogen protection, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg) and 3-(4-chlorophenyl)pyrrolidin-3-ol hydrochloride (98 mg) were added to dioxane (5 mL), followed by N,N-diisopropylethylamine (114 mg). After nitrogen replacement three times, the reaction solution was heated to 110°C and reacted for 1 hour. LCMS showed that the starting material was consumed and converted to product. The heat was turned off, the reaction solution was concentrated to dryness, and the residue was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (83 mg). LCMS (ESI) [M+H] + =449 / 451; 1 H NMR (400MHz, DMSO-d6) δ7.56(d,J=8.5Hz,2H),7.46-7.37(m,2H),7.32-7.20(m,1H),5.55(dd,J=19.9,11.6Hz,1H),4.86(dt,J=18.9,5.6Hz,1H),3.9 1-3.70(m,3H),3.70-3.55(m,3H),3.49-3.35(m,1H),3.28-3.15(m,1H),3 .01-2.80(m,2H),2.47-2.25(m,3H),2.23-2.02(m,3H),1.87-1.61(m,2H).
[0263] Example 7 (Compound 12)
[0264] Synthesis of (5R / S)-2-(3-(5-chloropyrimidin-2-yl)pyrrolidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0265] Step 1: Preparation of pyrrolidine-3-carbonitrile hydrochloride:
[0266] Dissolve tert-butyl 3-cyanopyrrolidine-1-carboxylate (5 g) in dioxane (20 mL), add 4 M hydrochloric acid / dioxane (50 mL) at room temperature, stir at room temperature for 2 hours, and spin dry the reaction mixture to obtain the title compound (3.38 g).
[0267] Step 2: Preparation of pyrrolidine-3-carboxamidine hydrochloride:
[0268] Dissolve pyrrolidine-3-carbonitrile hydrochloride (2.4 g) in hydrochloric acid / dioxane (10 mL). Add methanol (MeOH) (1.74 g) under an ice-water bath, maintaining the temperature below 10°C. Stir the mixture at room temperature for 1 hour. Dissolve sodium methoxide (NaOMe) (1.96 g) in anhydrous methanol (8 mL) to prepare a sodium methoxide solution. Slowly add the sodium methoxide solution to the above solution, maintaining the temperature below 15°C, and stir for 1 hour. Finally, add 7M ammonia / methanol solution (8 mL) to the above solution and stir at room temperature overnight. Concentrate the reaction mixture under reduced pressure to obtain the crude target compound, which is directly used in the next reaction without further purification.
[0269] Step 3: Preparation of 5-chloro-2-(pyrrolidin-3-yl)pyrimidine 4-methylbenzenesulfonate:
[0270] To the dioxane solution of pyrrolidine-3-carboximidamide hydrochloride obtained in the previous step, add a solution of sodium methoxide (2.39 g) in anhydrous methanol (40 mL) and stir at room temperature for 30 minutes. Add (Z)-N-[2-chloro-3-(dimethylamino)allyl]-N-methylmethanium hexafluorophosphate (4.34 g) and continue stirring at room temperature for 3.5 hours. The mixture is concentrated under reduced pressure to approximately 60 mL. 2-Methyltetrahydrofuran (80 mL) is added and the mixture is concentrated to approximately 100 mL. 2-Methyltetrahydrofuran (80 mL) is added and the mixture is cooled to 20°C. Water (150 mL) is added and the mixture is stirred for 5 minutes. The organic layer is collected and washed with 30% aqueous sodium hydroxide (120 mL). The organic layer is concentrated to 50 mL and n-propanol (20 mL) is added. At 65°C, slowly add a solution of 4-methylbenzenesulfonic acid (TsOH) (2.43 g) in n-butanol (20 mL) dropwise over 10 minutes. The reaction mixture is concentrated under reduced pressure to 50 mL. Cool to room temperature and filter to obtain the crude target compound (6.6 g). LCMS: (ESI) [M+H] + =184.17.
[0271] Step 4: Preparation of (R / S)-2-(3-(5-chloropyrimidin-2-yl)pyrrolidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0272] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg), 5-chloro-2-(pyrrolidin-3-yl)pyrimidine 4-methylbenzenesulfonate (74.19 mg), and N,N-diisopropylethylamine (65.91 mg) were dissolved in dioxane (2 mL) and heated in a microwave (MW) at 120°C for 2 hours. LCMS showed the disappearance of the starting material. The reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (30 mL x 3). The organic phase was dried over sodium sulfate and dried to dryness to obtain the crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L, NH4HCO3 / water, MeCN) to obtain the title compound (4.15 mg). LCMS: (ESI) [M+H] + =435.29; 1 HNMR(400MHz,DMSO-d6)δ8.90(s,2H),7.23(s,1H),4.84(s,1H),4.00-3.55(m,7H),3.46- 3.35(m,1H),3.25-3.15(m,1H),3.00-2.80(m,2H),2.42-2.10(m,6H),1.88-1.64(m,2H).
[0273] Example 8 (Compound 13 and Compound 14)
[0274] Synthesis of (R / S)-2-(3-(4-(difluoromethoxy)phenyl)-3-hydroxypyrrolidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (Compound 13) and (R / S)-2-(3-(4-(difluoromethoxy)phenyl)-2,5-dihydro-1H-pyrrol-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (Compound 14):
[0275] Step 1: Preparation of tert-butyl 3-(4-(difluoromethoxy)phenyl)-3-hydroxypyrrolidine-1-carboxylate;
[0276] Under nitrogen, 1-(difluoromethoxy)-4-iodobenzene (2.7 g) was dissolved in anhydrous tetrahydrofuran (30 mL) and cooled in a dry ice-ethanol bath. Isopropylmagnesium chloride-lithium chloride (1.3 M, 8 mL) was added dropwise with stirring, maintaining the internal temperature at -65°C. After the addition was complete, the mixture was kept at approximately -65°C for 30 minutes. Tert-butyl 3-oxopyrrolidine-1-carboxylate (2.03 g) was dissolved in tetrahydrofuran (8 mL) and added to the reaction solution, maintaining the internal temperature at -60°C. After 30 minutes of reaction, LCMS monitoring indicated that the starting material was consumed. The cooling bath was removed, 100 mL of water was added, and the mixture was allowed to warm to room temperature. Extraction was then performed with ethyl acetate (100 mL x 3). The organic phases were separated, combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield the crude product. The crude product was purified by flash silica gel chromatography (silica gel, petroleum ether:tetrahydrofuran = 100:0 to 50:50 gradient elution) to give the title compound (0.8 g). LCMS (ESI) [2M+Na] + =681.5;
[0277] Step 2: Preparation of 3-(4-(difluoromethoxy)phenyl)pyrrolidin-3-ol hydrochloride and 3-(4-(difluoromethoxy)phenyl)-2,5-dihydro-1H-pyrrole hydrochloride;
[0278] Under nitrogen protection, tert-butyl 3-(4-(difluoromethoxy)phenyl)-3-hydroxypyrrolidine-1-carboxylate (0.8 g) was dissolved in dichloromethane (20 mL) and stirred in an ice-water bath for 10 minutes. A 4M solution of hydrogen chloride in ethyl acetate (3 mL) was added to the reaction solution at 0°C. The ice-water bath was removed, and the temperature was raised to room temperature and the reaction was allowed to proceed for 1 hour. LCMS showed that the starting material was consumed and converted into the product and dehydration byproducts. The reaction solution was concentrated to dryness to obtain the crude target compound (400 mg). LCMS (ESI) [M+H] + =230;
[0279] Step 3: Preparation of (R / S)-2-(3-(4-(difluoromethoxy)phenyl)-3-hydroxypyrrolidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (Compound 13) and (R / S)-2-(3-(4-(difluoromethoxy)phenyl)-2,5-dihydro-1H-pyrrol-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (Compound 14);
[0280] Under nitrogen protection, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-(4-(difluoromethoxy)phenyl)pyrrolidin-3-ol hydrochloride, and 3-(4-(difluoromethoxy)phenyl)-2,5-dihydro-1H-pyrrole hydrochloride (148 mg, crude mixture, obtained from the previous reaction) were added to dioxane (5 mL), and N,N-diisopropylethylamine (137 mg) was added. After nitrogen replacement three times, the reaction solution was heated to 110°C and reacted for 1 hour. LCMS showed that the starting material was consumed and converted into the target compound. The reaction solution was concentrated to dryness, and the residue was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the target compound (5R / S)-2-(3-(4-(difluoromethoxy)phenyl)-3-hydroxypyrrolidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (Compound 13) (47 mg). LCMS (ESI) [M+H] + =481; 1 H NMR(400MHz,DMSO-d6)δ7.63-7.55(m,2H),7.41-7.04(td,J=72Hz,1H),7.26-7.24(m,1H) ,7.19-7.15(m,2H),7.04(d,J=2.2Hz,1H),5.51(dd,J=21.0,11.8Hz,1H),4.86(dt,J=18.8 ,5.5Hz,1H),3.94-3.56(m,6H),3.48-3.36(m,1H),3.22(dd,J=8.4,5.2Hz,1H),3.01-2.8 0(m,2H),2.35(tt,J=20.3,10.0Hz,3H),2.23-2.02(m,3H),1.75(pd,J=20.0,10.6Hz,2H);
[0281] The target compound (R / S)-2-(3-(4-(difluoromethoxy)phenyl)-2,5-dihydro-1H-pyrrol-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (Compound 14) (45 mg). LCMS (ESI) [M+H] + =463; 1H NMR (400MHz, DMSO-d6) δ7.61(d,J=8.7Hz,1H),7.56(d,J=8.6Hz,1H),7.46-7.06(td,J=72Hz,1H),7.35(d,J=5.9Hz ,1H),7.21(dd,J=15.7,8.6Hz,2H),7.09(d,J=4.0Hz,1H),6.49(s,1H),4.88(dt,J=11.5,5.6Hz,1H),4.61(d,J=11 .0Hz,2H),4.42(s,2H),3.77(dd,J=9.0,5.8Hz,2H),3.45(dq,J=14.2,7.2Hz,1H),3.29-3.18(m,1H),2.98(dt,J=1 6.4,8.2Hz,1H),2.88(dd,J=13.4,7.5Hz,1H),2.47-2.31(m,2H),2.20(dd,J=23.1,10.3Hz,2H),1.89-1.69(m,2H).
[0282] Example 9 (Compound 15)
[0283] Synthesis of (R / S)-2-(3-(5-chloropyrimidin-2-yl)-2,5-dihydro-1H-pyrrol-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0284] Step 1: Preparation of tert-butyl 3-(5-chloropyrimidin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate:
[0285] Tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (500 mg), 5-chloro-2-iodopyrimidine (447 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (Pd(dppf)Cl2) (247 mg), and potassium carbonate (700 mg) were dissolved in dioxane (5 mL) and water (0.5 mL). The system was reacted at 110°C under nitrogen for 16 hours. LCMS analysis revealed the product as the main peak, and the system was then cooled to room temperature. The solid was filtered, the filtrate was dried, and the title compound (550 mg, crude product) was obtained by flash chromatography (silica gel, petroleum ether:ethyl acetate = 3:1-2:1). LCMS (ESI) [M-55] + =226.12.
[0286] Step 2: Preparation of 5-chloro-2-(2,5-dihydro-1H-pyrrol-3-yl)pyrimidine:
[0287] Dissolve tert-butyl 3-(5-chloropyrimidin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (200 mg) in dichloromethane (2 mL), add trifluoroacetic acid (1 mL), and stir at room temperature for 2 hours. TLC shows that the starting material has reacted completely. The crude target compound is then dried to give a crude product, which is used directly in the next step. LCMS (ESI) [M+H] + =182.13.
[0288] Step 3: Preparation of (R / S)-2-(3-(5-chloropyrimidin-2-yl)-2,5-dihydro-1H-pyrrol-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0289] 5-Chloro-2-(2,5-dihydro-1H-pyrrol-3-yl)pyrimidine (200 mg, crude product, obtained from the previous step) was dissolved in dioxane (4 mL), and then N,N-diisopropylethylamine (2 mL) was added. After stirring evenly, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (70 mg) was added, and the system was reacted at 110°C in a microwave for 20 minutes. LCMS monitored the reaction to be complete. The system was cooled to room temperature and stirred overnight, filtered, and the filter cake was rinsed with ethyl acetate. The filter cake was then concentrated to dryness to obtain the target compound (50.63 mg). LCMS (ESI) [M+H] + =433.27; 1 H NMR(400MHz,DMSO-d6)δ8.96(d,J=8.4Hz,2H),7.36(s,1H),7.06(s,1H),4.87 (dt,J=11.4,5.6Hz,1H),4.65(s,2H),4.51(s,2H),3.77(t,J=5.6Hz,2H),3.5 2-3.39(m,1H),3.23(dd,J=14.7,7.0Hz,1H),2.93(ddd,J=20.5,14.3,6.8Hz, 2H), 2.38 (dd, J=33.3, 12.6Hz, 2H), 2.19 (t, J=9.3Hz, 2H), 1.88-1.71 (m, 2H).
[0290] Example 10 (Compound 16)
[0291] Synthesis of (R / S)-2-(1-(5-chloropyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0292] Step 1: Preparation of tert-butyl (R / S)-4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate;
[0293] Under nitrogen protection, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (130 mg) were added to dioxane (5 mL), 2 mL of water was added to the reaction solution, and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (25 mg) and potassium carbonate (121 mg) were added with stirring. After nitrogen replacement three times, the reaction solution was heated to 90°C and reacted for 1 hour. LCMS showed that the starting material was consumed and converted into the product. After the reaction solution was cooled to room temperature, 20 mL each of water and ethyl acetate were added to the reaction solution and extracted and separated to obtain an organic phase. The organic phase was concentrated to dryness, and the residue was separated by column chromatography (petroleum ether / ethyl acetate = 5:1 to 3:1) to obtain the title compound (90 mg). LCMS: (ESI) [M+H] + =435.2.
[0294] Step 2: Preparation of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(1,2,3,6-tetrahydropyridin-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide hydrochloride;
[0295] Under nitrogen protection, tert-butyl (R / S)-4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (90 mg) was dissolved in 4 mL of dichloromethane and stirred in an ice-water bath for approximately 10 minutes. A 4M solution of hydrogen chloride in dioxane (1 mL) was added to the reaction solution at 0°C. The ice-water bath was removed, and the mixture was heated to room temperature and stirred for 1 hour. LCMS showed that the starting material was consumed and converted to the product. The reaction solution was concentrated to obtain the crude target compound (97 mg). LCMS: (ESI) [M+H] + =335.2.
[0296] Step 3: Preparation of (R / S)-2-(1-(5-chloropyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide;
[0297] Under nitrogen protection, (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(1,2,3,6-tetrahydropyridin-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide hydrochloride (37 mg, crude product, obtained from the previous step) was dissolved in 2 mL of dimethyl sulfoxide, 5-chloro-2-iodopyrimidine (36 mg) and N,N-diisopropylethylamine (39 mg) were weighed, and the temperature was raised to 120°C and stirred for 1 hour. LCMS showed that the starting material was consumed and converted to the product. The reaction solution was directly prepared by high-performance liquid chromatography (0.5% ammonium bicarbonate / / water / acetonitrile) to obtain the target compound (9 mg). LCMS: (ESI) [M+H] + =447.1; 1 H NMR (400MHz, DMSO-d6) δ8.46(s,2H),7.88(s,1H),7.23(s,1H),4.86(t,J=5.7Hz,1H),4.39(d,J=2.8Hz,2H),3.95(t,J=5.8Hz,2H),3.83-3.68(m, 2H),3.62-3.49(m,1H),3.29(d,J=8.1Hz,1H),3.18-3.07(m,1H),3.05-2 .94(m,1H),2.61(s,2H),2.41-2.19(m,4H),1.78(dt,J=19.9,9.8Hz,2H).
[0298] Example 11 (Compound 17)
[0299] Synthesis of (R / S)-2-(4-(5-chloropyrimidin-2-yl)phenyl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0300] Step 1: Synthesis of 4-(5-chloropyrimidin-2-yl)phenol:
[0301] Under nitrogen protection, tetrakis(triphenylphosphine)palladium (Pd(Ph3P)4) (2.52g) was added to a mixture of (4-hydroxyphenyl)boric acid (3.00g), 2,5-dichloropyrimidine (3.24g) and potassium carbonate (9.02g) in dioxane (90mL) and water (15mL), and the mixture was heated to 100°C for 14 hours. After the reaction was completed, LCMS detection was performed, and the reaction solution was added with water (100mL) and extracted with ethyl acetate (300mL). The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by flash chromatography (silica gel, ethyl acetate: petroleum ether = 1:5) to obtain the title compound (2.50g). LCMS (ESI) [M+H] + =207.1.
[0302] Step 2: Synthesis of 4-(5-chloropyrimidin-2-yl)phenyl trifluoromethanesulfonate:
[0303] Under ice-water bath conditions, trifluoromethanesulfonic anhydride (Tf2O) (2.05 g) was added to a solution of 4-(5-chloropyrimidin-2-yl)phenol (1.00 g) in dichloromethane (20 mL), followed by the dropwise addition of triethylamine (TEA) (1.47 g). Stirring was continued under ice-water bath conditions for 2 hours, followed by 12 hours at room temperature. After completion of the reaction, as determined by TLC, saturated sodium bicarbonate solution (20 mL) was added, and the mixture was extracted with dichloromethane (50 mL x 3). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification by flash chromatography (silica gel, ethyl acetate:petroleum ether = 1:10) afforded the title compound (1.00 g). LCMS (ESI) [M+H] + =339.0.
[0304] Step 3: Synthesis of 5-chloro-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)phenyl]pyrimidine:
[0305] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (108 mg) was added to a solution of 4-(5-chloropyrimidin-2-yl)phenyl trifluoromethanesulfonate (500 mg), bis(pinacolato) borate ((Bpin)2) (562 mg), and potassium acetate (435 mg) in dioxane (3 mL). The mixture was heated to 100°C and allowed to react for 4 hours. After completion of the reaction, the reaction solution was diluted with water (100 mL) and ethyl acetate (300 mL). The layers were separated, and the organic phase was washed three times with saturated brine (100 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. It was then purified by flash chromatography (silica gel, ethyl acetate:petroleum ether = 1:20) to obtain the title compound (300 mg). LCMS (ESI) [M+H] + =317.1.
[0306] Step 4: Synthesis of (R / S)-2-(4-(5-chloropyrimidin-2-yl)phenyl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0307] Under nitrogen protection, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (13 mg) was added to a mixed solution of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg), 5-chloro-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidine (55 mg) and potassium carbonate (60 mg) in dioxane (2 mL) and water (0.5 mL), and the mixture was heated to 100°C for 2 hours. After the reaction was complete, the reaction solution was diluted with water (10 mL) and ethyl acetate (50 mL), separated, and the organic phase was washed three times with saturated brine (30 mL × 3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by Prep-HPLC (C18, 10 mmol / L HCOOH / water, MeCN) to obtain the title compound (20 mg). LCMS (ESI) [M+H] + =442.2; 1H NMR (400MHz, DMSO-d6) δ9.07(s,2H),8.48(s,4H),8.11(s,1H),4.94(t,J=5.7Hz,1H),3.85(d,J=4.0Hz,2H),3.74-3.59(m,1H),3.40( dd,J=14.8,6.6Hz,1H),3.27-3.21(m,1H),3.05(dd,J=13.5,6.2Hz,1H),2.47-2.39(m,2H),2.36(d,J=9.7Hz,2H),1.94-1.78(m,2H).
[0308] Example 12 (Compound 22)
[0309] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(isoindolin-2-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0310] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), isoindoline (45.55 mg), and N,N-diisopropylethylamine (134.73 mg) were added to dioxane (2 mL) and reacted at 120°C in a microwave for 20 minutes. LCMS showed that the starting material disappeared. The reaction solution was added to 15 mL of water and stirred for 30 minutes. A large amount of insoluble matter appeared and was filtered. The insoluble matter was added to ethyl acetate (20 mL) and stirred at 65°C for 1 hour. The temperature was lowered to room temperature and the target compound (56.79 mg) was obtained by filtration. LCMS: (ESI) [M+H] + =371.1; 1 H NMR(400MHz,DMSO-d6)δ7.49-7.35(m,3H),7.34-7.27(m,2H),4.90-4.72(m,5H),3.85-3.75(m,2H),3.51-3.40(m,1H ),3.30-3.18(m,1H),3.04-2.94(m,1H),2.93-2.84(m,1H),2.45-2.32(m,2H),2.28-2.15(m,2H),1.85-1.60(m,2H).
[0311] Example 13 (Compound 23)
[0312] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(indolin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0313] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg) and indoline (83.3 mg) were added to ethanol (5 mL), and 2 mL of water was added. 1 M dilute hydrochloric acid (0.3 mL) was added with stirring, and the temperature was raised to 65°C and stirred for 1 hour. LCMS showed that the starting material had basically disappeared and the product was generated. 3 mL of saturated sodium bicarbonate solution was added to the reaction solution to adjust the pH to 8. 20 mL of water and 20 mL of ethyl acetate were added to the reaction solution, and the layers were separated. The organic phase was washed with water and concentrated. The residue was prepared by liquid chromatography with acetonitrile / water (0.5% ammonium bicarbonate system) and lyophilized to obtain the title compound (32 mg). LCMS: (ESI) [M+H] + =371.2;ee%=100%. 1 H NMR(400MHz,DMSO-d6)δ8.35(d,J=8.0Hz,1H),7.56(s,1H),7.27-7.11(m,2H),6.91(td,J =7.4,0.9Hz,1H),4.87(t,J=5.7Hz,1H),4.14(t,J=8.7Hz,2H),3.79(d,J=5.7Hz,2H),3.60 -3.47(m,1H),3.28(dd,J=10.9,5.8Hz,1H),3.17-3.10(m,2H),3.10-3.04(m,1H),2.93(d dd,J=13.4,7.3,1.7Hz,1H),2.39(td,J=22.0,9.7Hz,2H),2.25(s,2H),1.89-1.70(m,2H).
[0314] Example 14 (Compound 24)
[0315] Synthesis of (R / S)-2-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0316] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg), 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine hydrochloride (49.23 mg), and N,N-diisopropylethylamine (87.88 mg) were added to dioxane (1.5 mL) and heated in a microwave at 120°C for 2 hours. LCMS showed the disappearance of the starting material, and the reaction solution was directly subjected to Prep-HPLC separation and purification (C18, 10 mmol / L, NH4HCO3 / water, MeCN) to obtain the title compound (16.88 mg). LCMS (ESI) [M+H] + =372.2; 1 H NMR (400MHz, DMSO-d6) δ8.64(d,J=16.4Hz,1H),8.49(d,J=5.0Hz,1H),7.54-7.37(m,2H),4.95-4.75(m,5H),3.79(d,J=5.2Hz,2H),3 .53-3.40(m,1H),3.28-3.18(m,1H),3.05-2.96(m,1H),2.93-2.82(m,1H),2.45-2.31(m,2H),2.30-2.18(m,2H),1.95-1.71(m,2H).
[0317] Example 15 (Compound 25)
[0318] Synthesis of (R / S)-2-(5-chloroisoindolin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0319] 5-Chloro-2,3-dihydro-1H-isoindoline hydrochloride (66 mg) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg) and N,N-diisopropylethylamine (67 mg) in tetrahydrofuran (5 mL) and water (1 mL). The mixture was heated to 70°C and stirred for 12 hours. After completion of the reaction, the reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (30 mL). The organic phases were separated and combined, concentrated under reduced pressure, and purified by Prep-HPLC (C18, 10 mmol / L HCOOH / water, MeCN) to obtain the title compound (35 mg). LCMS (ESI) [M+H] + =405.1; 1H NMR(400MHz, DMSO-d6)δ7.50(d,J=18.1Hz,1H),7.43(dd,J=16.8,8.5Hz,2H),7.36( dd,J=8.2,1.8Hz,1H),4.86(t,J=5.6Hz,1H),4.77(t,J=8.7Hz,4H),3.83-3.74(m,2H ),3.52-3.40(m,1H),3.24(dt,J=13.4,8.3Hz,1H),3.04-2.94(m,1H),2.93-2.84(m, 1H), 2.38 (dt, J=21.1, 10.6Hz, 2H), 2.23 (dd, J=11.1, 7.4Hz, 2H), 1.90-1.70 (m, 2H).
[0320] Example 16 (Compound 26)
[0321] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(5-methoxyisoindolin-2-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0322] 5-Methoxy-2,3-dihydro-1H-isoindoline hydrochloride (65 mg) was added to a mixed solution of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg) and N,N-diisopropylethylamine (16 mg) in tetrahydrofuran (5 mL) and water (1 mL), heated to 70°C, and stirred for 12 hours. After the reaction was completed as determined by LCMS, the reaction solution was diluted with water (10 mL), extracted with ethyl acetate (50 mL), and the layers were separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by Prep-HPLC (C18, 10 mmol / L HCOOH / water, MeCN) to obtain the title compound (30 mg). LCMS (ESI) [M+H] + =401.2; 1H NMR (400MHz, DMSO-d6) δ7.39(s,1H),7.29(dd,J=17.7,8.4Hz,1H),6.99(d,J=23.6Hz,1 H),6.87(d,J=8.3Hz,1H),4.87(s,1H),4.73(dd,J=17.4,7.7Hz,4H),3.79(s,2H),3.76( s,3H),3.51-3.41(m,1H),3.24(dt,J=13.4,8.4Hz,1H),2.98(dd,J=17.0,8.1Hz,1H),2. 88(dd,J=14.0,6.4Hz,1H),2.47-2.31(m,2H),2.22(d,J=8.9Hz,2H),1.92-1.70(m,2H).
[0323] Example 17 (Compound 27)
[0324] Synthesis of (R / S)-2-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)isoindoline-5-carbonitrile:
[0325] 2,3-Dihydro-1H-isoindoline-5-carbonitrile hydrochloride (63 mg) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg) and N,N-diisopropylethylamine (67 mg) in tetrahydrofuran (5 mL) and water (1 mL). The mixture was heated to 70°C and stirred for 12 hours. After completion of the reaction, the reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (30 mL). The organic phase was separated and dried over anhydrous sodium sulfate, concentrated, and purified by Prep-HPLC (C18, 10 mmol / L HCOOH / water, MeCN) to obtain the title compound (35 mg). LCMS (ESI) [M+H] + =396.2; 1H NMR (400MHz, DMSO-d6) δ7.89(d,J=16.4Hz,1H),7.77(d,J=7.9Hz,1H),7.62(dd,J= 19.2,7.9Hz,1H),7.45(s,1H),4.94-4.72(m,5H),3.86-3.75(m,2H),3.53-3.40(m, 1H),3.24(dt,J=13.5,8.3Hz,1H),2.98(dd,J=17.0,8.1Hz,1H),2.93-2.85(m,1H), 2.39(td,J=20.4,10.0Hz,2H), 2.23(t,J=9.3Hz,2H), 1.80(dt,J=28.2,9.5Hz,2H).
[0326] Example 18 (Compound 28)
[0327] Synthesis of (R / S)-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0328] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine dihydrochloride (100.64 mg), and N,N-diisopropylethylamine (179.64 mg) were added to dioxane (2 mL) and stirred under microwave at 120°C for 2 hours. LCMS showed the disappearance of the starting material. The reaction mixture was directly separated and purified by Prep-HPLC (C18, 10 mmol / L, NH4HCO3 / water, MeCN) to obtain the title compound (53.14 mg). LCMS: (ESI) [M+H] + =372.30; 1 H NMR (400MHz, DMSO-d6) δ8.55-8.42(m,1H),7.83(dd,J=19.4,7.5Hz,1H),7.44(s,1H),7.33(dd,J=7.7,4.9Hz,1H),4.94-4.72(m,5H),3.79(d,J= 5.5Hz,2H),3.52-3.40(m,1H),3.30-3.19(m,1H),3.02-2.88(m,1H),2.9 4-2.85(m,1H),2.49-2.33(m,2H),2.25-2.21(m,2H),1.90-1.70(m,2H).
[0329] Example 19 (Compound 29)
[0330] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(5-(2-hydroxypropan-2-yl)isoindolin-2-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0331] Step 1: Preparation of methyl (R / S)-2-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)isoindoline-5-carboxylate:
[0332] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (120 mg), methyl isoindoline-5-carboxylate hydrochloride (106.8 mg) and N,N-diisopropylethylamine (1 mL) were dissolved in dioxane (3 mL), and the system was reacted at 120°C for 1 hour. LCMS monitoring showed that the product was the main peak, and the solvent was then dried by rotary evaporation. Ethyl acetate (5 mL) was added to the crude product and sonicated for 1 minute. The solid was then filtered and the filter cake was rinsed with ethyl acetate. The filter cake was then concentrated to dryness to obtain the target compound (200 mg). LCMS (ESI) [M+H] + =429.31.
[0333] Step 2: Preparation of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(5-(2-hydroxypropane-2-yl)isoindolin-2-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0334] Methyl (R / S)-2-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)isoindoline-5-carboxylate (150 mg) was dissolved in anhydrous tetrahydrofuran (10 mL). Methylmagnesium bromide (2 mL, 3 M in 2-methyltetrahydrofuran) was added under ice-cooling, and the system was stirred at room temperature for 2 hours. LCMS monitoring showed the product as the main peak, and saturated aqueous ammonium chloride solution (5 mL) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (30 mL × 2), and the combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (41.24 mg). LCMS (ESI) [M+H] + =429.32; 1H NMR (400MHz, DMSO-d6) δ7.50 (s, 1H), 7.45-7.36 (m, 2H), 7.31 (dd, J = 13.9, 8.0Hz ,1H),5.02(d,J=8.7Hz,1H),4.87(t,J=5.5Hz,1H),4.76(d,J=10.1Hz,4H),3.80 (d,J=5.5Hz,2H),3.51-3.41(m,1H),3.24(dt,J=13.3,8.3Hz,1H),3.03-2.85(m ,2H),2.40(dd,J=21.4,9.7Hz,2H),2.23(s,2H),1.90-1.72(m,2H),1.43(s,6H).
[0335] Example 20 (Compound 30)
[0336] Synthesis of (R / S)-2-(Benzo[b]thiophen-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0337] Under nitrogen protection, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg) and benzo[b]thiophen-2-ylboronic acid (75 mg) were added to dioxane (8 mL), water (2 mL) was added to the reaction solution, and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (25 mg) and potassium carbonate (121 mg) were added with stirring. After nitrogen replacement three times, the reaction solution was heated to 85°C and reacted for 1 hour. The raw materials were consumed and converted into products. The heating was turned off, and after cooling to room temperature, water (30 mL) was added to the reaction solution, which was then extracted with ethyl acetate (50 mL x 3). The organic phase was separated and combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (22 mg). LCMS (ESI) [M+H] + =386; 1H NMR (400MHz, DMSO-d6) δ8.24(s,1H),8.20(s,1H),8.05-7.94(m,2H),7.47-7.39(m,2H),4.91(t,J=5.6Hz,1H),3.92-3.81(m,2H),3.72-3.59(m ,1H),3.42-3.34(m,1H),3.22(dd,J=17.1,7.9Hz,1H),3.04(dd,J=13.7,6.2Hz,1H),2.39(dt,J=16.2,9.7Hz,4H),1.84(dd,J=18.1,9.2Hz,2H).
[0338] Example 21 (Compound 31)
[0339] Synthesis of (R / S)-N-(2-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)isoindolin-5-yl)methanesulfonamide:
[0340] Step 1: Preparation of tert-butyl 5-(methylsulfonylamino)isoindoline-2-carboxylate;
[0341] Under nitrogen, tert-butyl 5-bromoisoindoline-2-carboxylate (1.2 g), N,N-dimethylglycine (41.3 mg), methylsulfonamide (457 mg), cuprous iodide (76 mg), and anhydrous potassium phosphate (1.7 g) were added to anhydrous dimethyl sulfoxide (DMSO) (30 mL) and heated to 150°C for 48 hours. LCMS monitoring showed partial conversion to product. After the reaction solution cooled to room temperature, water (100 mL) was added and extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash silica gel chromatography (silica gel, gradient elution of petroleum ether:tetrahydrofuran = 100:0 to 50:50) to obtain the title compound (400 mg). LCMS (ESI) [2M+Na] + =647.3;
[0342] Step 2: Preparation of N-(isoindolin-5-yl)methanesulfonamide hydrochloride;
[0343] Under nitrogen, tert-butyl 5-(methylsulfonamido)isoindoline-2-carboxylate (400 mg) was dissolved in dichloromethane (20 mL) and stirred in an ice-water bath for 10 minutes. A 4M solution of hydrogen chloride in ethyl acetate (0.96 mL) was added to the reaction mixture at 0°C. The ice-water bath was removed, and the mixture was allowed to warm to room temperature and react for 1 hour until the starting material was consumed and converted to the product. The mixture was filtered, and the filter cake was washed with 5 mL of dichloromethane and concentrated to dryness to obtain the title compound (230 mg). LCMS (ESI) [M+H] + =213;
[0344] Step 3: Preparation of (R / S)-N-(2-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)isoindolin-5-yl)methanesulfonamide;
[0345] Under nitrogen protection, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg) and N-(isoindolin-5-yl)methanesulfonamide hydrochloride (104 mg) were added to dioxane (5 mL), followed by N,N-diisopropylethylamine (114 mg). After nitrogen replacement three times, the reaction solution was heated to 110°C and reacted for 1 hour. LCMS showed that the starting material was consumed and converted to product. The heat was turned off, the reaction solution was concentrated to dryness, and the residue was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (25.5 mg). LCMS (ESI) [M+H] + =464.1; 1 H NMR(400MHz,DMSO-d6)δ9.72(s,1H),7.40(s,1H),7.35(dd,J=18.7,8.3Hz,1H),7.24(d,J =13.0Hz,1H),7.14(dd,J=13.8,5.7Hz,1H),4.86(t,J=5.7Hz,1H),4.76(t,J=10.5Hz,4H), 3.79(d,J=5.5Hz,2H),3.46(dt,J=16.3,8.0Hz,1H),3.23(dt,J=13.4,8.3Hz,1H),3.04-2. 93(m,4H),2.92-2.84(m,1H),2.47-2.30(m,2H),2.23(d,J=7.8Hz,2H),1.90-1.70(m,2H).
[0346] Example 22 (Compound 40)
[0347] Synthesis of (1-((2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methanol:
[0348] (1-((2-chloro-6H,7H-thieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methanol (50 mg), 5-chloro-2-(piperidin-4-yl)pyrimidine p-toluenesulfonate (102.07 mg) and potassium carbonate (74.63 mg) were added to N,N-dimethylformamide (DMF) (1 mL) and microwave-treated at 150°C for half an hour. LCMS showed that the starting material was almost consumed and product was generated. The reaction solution was filtered and the filtrate was directly separated and purified by Prep-HPLC (C18, 10 mmol / L, NH4HCO3 / water, MeCN) to obtain the target compound (22.49 mg). LCMS (ESI) [M+H] + =433.30; 1 H NMR (400MHz, DMSO-d6) δ8.85(s,2H),5.97(s,1H),4.80(t,J=5.6Hz,1H),4.65-4.50(m,2H),3.68(d,J=5.6Hz,1H),3.21(t,J= 8.1Hz,2H),3.17-3.07(m,1H),3.00-2.85(m,4H),2.36-2.25(m,2H),2.17-2.05(m,2H),1.85-1.85(m,2H),1.81-1.57(m,4H).
[0349] Example 23 (Compound 7)
[0350] Synthesis of (R / S)-2-(3-hydroxy-3-(4-(trifluoromethyl)phenyl)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0351] Step 1: Preparation of tert-butyl 3-hydroxy-3-(4-(trifluoromethyl)phenyl)azetidine-1-carboxylate:
[0352] Dissolve 1-iodo-4-(trifluoromethyl)benzene (2.00 g, 1.0 eq) in anhydrous tetrahydrofuran (40 mL). Under nitrogen, add n-butyllithium (2.5 M in hexane, 1.0 eq) dropwise at -78°C and stir for 0.5 hour. Dissolve tert-butyl 3-oxoazetidine-1-carboxylate (1.5 eq) in anhydrous tetrahydrofuran (15 mL) and add dropwise to the lithium reagent solution at -78°C. Stir for 0.5 hour. LCMS monitoring reveals the disappearance of the starting material, with the product as the main peak. Quench the reaction mixture by adding water (10 mL) dropwise at -78°C. Pour the reaction mixture into water (300 mL) and extract with ethyl acetate (100 mL x 3). The organic phase is washed with water (200 mL x 3), dried over sodium sulfate, and concentrated under reduced pressure to yield the crude product. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain the target compound (1.30 g). LCMS: (ESI) [M-56] + =262.
[0353] Step 2: Preparation of 3-(4-(trifluoromethyl)phenyl)azetidin-3-ol 2,2,2-trifluoroacetate:
[0354] Dissolve tert-butyl 3-hydroxy-3-(4-(trifluoromethyl)phenyl)azetidine-1-carboxylate (165 mg, 1 eq) in dichloromethane (2 mL). Add trifluoroacetic acid (1 mL) at room temperature and stir at room temperature for 1 hour. LCMS monitoring reveals the disappearance of the starting material, with the product as the main peak. The reaction mixture is spin-dried to give the title compound (170 mg).
[0355] Step 3: Preparation of (R / S)-2-(3-hydroxy-3-(4-(trifluoromethyl)phenyl)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0356] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg, 1 eq), 3-[4-(trifluoromethyl)phenyl]azetidin-3-ol 2,2,2-trifluoroacetate (1.5 eq), and DIEA (5 eq) were dissolved in dioxane (2 mL) and reacted at 120°C under microwave for 1 hour. LCMS monitoring indicated the disappearance of the starting material, with the product being the main peak. The reaction solution was directly subjected to Prep-HPLC separation and purification (C18, 10 mmol / L, aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (42 mg). LCMS: (ESI) [M+H] + =469.2; 1H NMR(400MHz, DMSO-d6+D2O)δ7.80-7.68(m,4H),4.35-4.10(m,4H),3.75-3.71(m,1H),3.69-3.64(m,1H),3.48 -3.34(m,1H),3.31-3.20(m,1H),3.02-2.84(m,2H),2.38-2.20(m,2H),2.15-2.05(m,2H),1.85-1.62(m,2H).
[0357] Example 24 (Compound 8)
[0358] Synthesis of (R / S)-2-(4-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetic acid:
[0359] Step 1: Preparation of ethyl 2-(4-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetate:
[0360] 2,4-Dichloro-6,7-dihydrothieno[3,2-d]pyrimidine (1.5 g, 1.0 eq), ethyl 2-(4-aminophenyl)acetate (1.2 eq), and N,N-diisopropylethylamine (3.0 eq) were dissolved in dimethyl sulfoxide (20 mL) and reacted at 145°C for 16 hours. LCMS analysis revealed the product as the main peak. The reaction mixture was cooled to room temperature, water (50 mL) was added, and the aqueous phase was extracted with ethyl acetate (100 mL x 2). The combined organic phases were washed with water (100 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield the crude product. The crude product was separated and purified by flash chromatography (silica gel, petroleum ether:ethyl acetate = 3:1) to yield the title compound (1.98 g). LCMS (ESI) [M+H] + =350.1.
[0361] Step 2: Preparation of (R / S)-ethyl 2-(4-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetate:
[0362] 2-(4-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetic acid ethyl ester (600 mg, 1.0 eq) and S-(-)binaphthol (0.1 eq) were dissolved in dichloromethane (5 mL) and stirred for 5 minutes under nitrogen protection. Then, tetraisopropyl titanate (Ti(O iPr)4) (0.1 eq) and water (1.0 eq) were added and stirred at room temperature for 1 hour. Tert-butyl peroxide (70% / water, 1.5 eq) was added under ice-cooling and stirred at room temperature for 16 hours. LCMS analysis showed that the product was the main product. The solution was concentrated under reduced pressure to obtain the crude product, which was then separated and purified by flash chromatography (silica gel, dichloromethane:methanol = 20:1) to obtain the title compound (230 mg). LCMS (ESI) [M+H] + =366.2.
[0363] Step 3: Preparation of (R / S)-2-(4-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)ethyl acetate:
[0364] Ethyl (R / S)-2-(4-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetate (230 mg, 1.0 eq), 3-(3-chloro-4-methoxyphenyl)azetidin-3-ol trifluoroacetate (1.3 eq) and N,N-diisopropylethylamine (3.0 eq) were dissolved in 1,4-dioxane (4 mL) and then reacted at 120°C for 2 hours. LCMS monitoring showed that the product was the main peak. The system was cooled to room temperature, water (30 mL) was added, and stirred for 0.5 hours. The solid was filtered and the filter cake was washed with water twice to obtain the target compound (200 mg). LCMS (ESI) [M+H] + =543.4.
[0365] Step 4: Preparation of (R / S)-2-(4-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetic acid:
[0366] Ethyl (R / S)-2-(4-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetate (200 mg, 1.0 eq) and lithium hydroxide monohydrate (10 eq) were dissolved in tetrahydrofuran (3 mL), MeOH (3 mL), and water (1.5 mL), and the system was stirred at 25°C for 2 hours. LCMS monitoring revealed the product as the main peak, and aqueous citric acid was added to adjust the pH to 5-6. The aqueous phase was extracted with ethyl acetate (30 mL x 2), and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous formic acid, acetonitrile) to obtain the title compound (42 mg). LCMS (ESI) [M+H] + =515.2; 1 H NMR (400MHz, DMSO-d6) δ9.55(s,1H),7.73(d,J=8.6Hz,2H),7.55(s,1H),7.46(d,J=8.3Hz,1H),7.17(dd,J=13.7,8.6Hz,3H),6.48(s,1H),4.2 6(t,J=8.9Hz,4H),3.85(s,3H),3.57-3.51(m,1H),3.50(s,1H),3.31-3.23(m,3H),3.07(dd,J=17.1,8.0Hz,1H),2.98(dd,J=14.1,6.6Hz,1H).
[0367] Example 25 (Compound 10)
[0368] Synthesis of (R / S)-2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((3-(2-hydroxypropan-2-yl)phenyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0369] Step 1: Preparation of methyl 3-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)benzoate:
[0370] 2,4-Dichloro-6,7-dihydrothieno[3,2-d]pyrimidine (1.2 g, 1.0 eq), methyl 3-aminobenzoate (1.2 eq), and N,N-diisopropylethylamine (3.0 eq) were dissolved in dimethyl sulfoxide (20 mL) and reacted at 120°C for 16 hours. LCMS analysis revealed the product as the main peak. The system was then cooled and water was added. The aqueous phase was extracted with ethyl acetate (100 mL x 2), and the organic phase was washed with water (100 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield the crude product. The crude product was separated and purified by flash chromatography (silica gel, petroleum ether:ethyl acetate = 3:1) to yield the title compound (550 mg). LCMS (ESI) [M+H] + =322.1.
[0371] Step 2: Preparation of methyl (R / S)-3-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)benzoate:
[0372] Methyl 3-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)benzoate (340 mg, 1.0 eq) and S-(-)-binaphthol (0.1 eq) were dissolved in dichloromethane (3 mL). Water (1.0 eq) and tetraisopropyl titanate (1.0 eq) were added under nitrogen and stirred at room temperature for 1 hour. Tert-butyl peroxide (1.5 eq) was then added and stirred at room temperature overnight. LCMS analysis revealed the product as the main peak, and the product was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by flash chromatography (silica gel, dichloromethane:methanol = 20:1) to obtain the title compound (120 mg). LCMS (ESI) [M+H] + =338.1.
[0373] Step 3: Preparation of methyl (R / S)-3-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)benzoate:
[0374] Methyl (R / S)-3-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)benzoate (120 mg, 1.0 eq), 3-(3-chloro-4-methoxyphenyl)azetidin-3-ol trifluoroacetate (2.0 eq) and N,N-diisopropylethylamine (10 eq) were dissolved in 1,4-dioxane (4 mL) and the system was reacted at 120°C for 2 hours. LCMS showed that the reaction was complete, and the system was then cooled to room temperature, water (30 mL) was added, and stirred overnight. Filtered, the filter cake was washed with water (10 mL × 2) and acetone (5 mL) in that order to obtain the title compound (164 mg). LCMS (ESI) [M+H] + =515.3.
[0375] Step 4: Preparation of (R / S)-2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((3-(2-hydroxypropane-2-yl)phenyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0376] Methyl (R / S)-3-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)benzoate (100 mg, 1.0 eq) was dissolved in anhydrous tetrahydrofuran (5 mL), and methylmagnesium bromide (3 M in ether, 10.0 eq) was added under ice-cooling. The system was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete, and saturated aqueous ammonium chloride (10 mL) was added to quench the reaction. The aqueous solution was extracted with ethyl acetate (30 mL × 2), and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate, acetonitrile) to obtain the title compound (4 mg). LCMS (ESI) [M+H] + =515.2; 1H NMR(400MHz,DMSO-d6)δ9.52(s,1H),8.00(s,1H),7.62-7.51(m,2H),7.45(d,J=8 .4Hz,1H),7.22(t,J=7.9Hz,1H),7.15(t,J=6.2Hz,2H),6.48(s,1H),4.94(s,1H) ,4.25(d,J=8.5Hz,4H),3.85(s,3H),3.51(dd,J=16.8,8.2Hz,1H),3.26(d,J=8.4 Hz, 1H), 3.07 (dd, J = 17.1, 7.8 Hz, 1H), 2.97 (dd, J = 13.7, 6.7 Hz, 1H), 1.41 (s, 6H).
[0377] Example 26 (Compound 18)
[0378] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(4-(2-hydroxypropan-2-yl)phenyl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0379] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), [4-(2-hydroxypropan-2-yl)phenyl]boronic acid (1.5 eq), Pd(dppf)Cl2 (0.1 eq), and potassium carbonate (2.5 eq) were added to dioxane (3 mL) and water (1 mL). The atmosphere was replaced with nitrogen three times and stirred at 110°C for 3 hours under nitrogen. LCMS showed that most of the starting material had disappeared, while the product had formed. The reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (8 mg). LCMS:(ESI)[M+1] + =388.28; 1H NMR (400MHz, DMSO-d6) δ8.25(d,J=8.4Hz,2H),7.97(s,1H),7.58(d,J=8.4Hz,2H),5.09(s,1H),4.92(t,J=5.7Hz,1H),3.87-3.77(m, 2H),3.69-3.57(m,1H),3.42-3.33(m,1H),3.25-3.15(m,1H),3.10-2.95(m,1H),2.49-2.10(m,4H),1.93-1.76(m,2H),1.45(s,6H).
[0380] Example 27 (Compound 19)
[0381] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(4-(trifluoromethyl)phenyl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0382] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), [4-(trifluoromethyl)phenyl]boronic acid (1.5 eq), Pd(dppf)Cl2 (0.1 eq), and potassium carbonate (2.5 eq) were added to dioxane (3 mL) and water (1 mL). The mixture was purged with nitrogen three times and stirred at 110°C for 3 hours under nitrogen. LCMS showed the disappearance of the starting material and the product as the main peak. The reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (1 mg). LCMS: (ESI) [M+1] + =398.1; 1 H NMR (400MHz, DMSO-d6) δ8.50(d,J=8.1Hz,2H),8.20(s,1H),7.88(d,J=8.3Hz,2H),4.93(t,J=5.7Hz,1H),3.90-3.76(m, 2H),3.75-3.60(m,1H),3.44-3.36(m,1H),3.30-3.20(m,1H),3.10-3.00(m,1H),2.44-2.30(m,4H),1.93-1.75(m,2H).
[0383] Example 28 (Compound 20)
[0384] Synthesis of (R / S)-2-(4-chlorophenyl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0385] Under nitrogen protection, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a solution of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), (4-chlorophenyl)boronic acid (1.2 eq) and potassium carbonate (2.5 eq) in dioxane (3 mL) and water (0.6 mL). The resulting mixture was stirred and heated to 110°C for 2 hours. LCMS detection showed that the reaction was complete. The reaction solution was diluted with water (20 mL), extracted with ethyl acetate (50 mL), separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (16 mg). LCMS (ESI) [M+H] + =364.2; 1 H NMR (400MHz, DMSO-d6) δ8.31(d,J=8.7Hz,2H),8.11(s,1H),7.57(d,J=8.6H z,2H),4.92(t,J=5.7Hz,1H),3.90-3.76(m,2H),3.70-3.57(m,1H),3.41-3 .35(m,1H),3.21(ddd,J=17.1,8.1,1.8Hz,1H),3.11-2.97(m,1H),2.40(d, J=12.1Hz, 1H), 2.34 (dd, J=15.4, 6.3Hz, 3H), 1.82 (dd, J=17.9, 9.2Hz, 2H).
[0386] Example 29 (Compound 21)
[0387] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(4-(trifluoromethoxy)phenyl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0388] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), (4-(trifluoromethoxy)phenyl)boronic acid (1.5 eq), Pd(dppf)Cl2 (0.1 eq), and potassium carbonate (2.5 eq) were added to dioxane (3 mL) and water (0.6 mL). After nitrogen substitution, the mixture was heated and stirred at 110°C for 3 hours. LCMS showed that the starting material had disappeared and the product was the main peak. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (3 mg). LCMS: (ESI) [M+H] + =414.2; 1 H NMR (400MHz, DMSO-d6) δ8.42(d,J=8.8Hz,2H),8.12(s,1H),7.49(d,J=8.5Hz,2H),4.91(t,J=5.7Hz,1H),3.87-3.75(m, 2H),3.70-3.58(m,1H),3.44-3.34(m,1H),3.24-3.18(m,1H),3.10-2.98(m,1H),2.50-2.10(m,4H),1.90-1.72(m,2H).
[0389] Example 30 (Compound 35)
[0390] Synthesis of (R / S)-2-(4-chloro-5-methoxyisoindolin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0391] Step 1: Preparation of tert-butyl 5-methoxyisoindoline-2-carboxylate:
[0392] Under nitrogen protection, 5-methoxyisoindoline (300 mg, 1.0 eq) was added to dichloromethane (10 mL), and triethylamine was added to the reaction solution. ( The mixture was reacted with di-tert-butyl dicarbonate (1.5 eq) at room temperature for 16 hours. LCMS showed that the starting material was consumed and converted to the product. Water (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified on a silica gel column (petroleum ether:ethyl acetate = 20:1) to obtain the title compound (300 mg). LCMS (ESI) [M+H] + =250.2.
[0393] Step 2: Preparation of tert-butyl 4-chloro-5-methoxyisoindoline-2-carboxylate:
[0394] Under nitrogen protection, tert-butyl 5-methoxyisoindoline-2-carboxylate (300 mg, 1.0 eq) was added to acetonitrile (5 mL) and tetrahydrofuran (5 mL), and N-chlorosuccinimide was added to the reaction solution. ( 1.5 eq) and reacted at room temperature for 16 hours. LCMS showed that the starting material was consumed and converted to the product. Water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (40 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (60 mg). LCMS (ESI) [M+H] + =284.2.
[0395] Step 3: Preparation of 4-chloro-5-methoxyisoindoline hydrochloride:
[0396] Under nitrogen, tert-butyl 4-chloro-5-methoxyisoindole-2-carboxylate (60 mg, 1.0 eq) was added to 1,4-dioxane (5 mL) and stirred in an ice-water bath for 20 minutes. A 4M hydrogen chloride / 1,4-dioxane solution (19.0 eq) was added to the reaction solution and stirred in an ice-water bath for 10 minutes. The ice-water bath was removed and the reaction was allowed to react at room temperature for 2 hours. LCMS showed that the starting material was consumed and converted to the product. The reaction solution was concentrated to obtain the title compound (46 mg). LCMS (ESI) [M+H] + =184.1.
[0397] Step 4: Preparation of (R / S)-2-(4-chloro-5-methoxyisoindolin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0398] Under nitrogen, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (60 mg, 1.0 eq) and 4-chloro-5-methoxyisoindoline hydrochloride (1.0 eq) were added to 1,4-dioxane (5 mL). N,N-diisopropylethylamine (3 eq) was added to the reaction solution, and the reaction mixture was allowed to react at 100°C for 6 hours. LCMS showed that the starting material was consumed and converted to the product. After cooling to room temperature, water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (42 mg). LCMS (ESI) [M+H] + =435.1; 1 H NMR (400MHz, DMSO-d6) δ7.48(d,J=20.9Hz,2H),7.23(d,J=32.6Hz,1H),4.84(d ,J=29.1Hz,1H),4.75(s,2H),4.71(d,J=7.1Hz,2H),3.86(s,3H),3.79(s,2H),3 .53-3.40(m,1H),3.23(dt,J=13.5,8.3Hz,1H),3.05-2.93(m,1H),2.89(dd,J= 13.5, 6.5Hz, 1H), 2.47-2.31 (m, 2H), 2.19 (d, J = 28.1Hz, 2H), 1.91-1.69 (m, 2H).
[0399] Example 31 (Compound 65)
[0400] Synthesis of (R / S)-1-(3-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)phenyl)ethan-1-one:
[0401] Methyl (R / S)-3-((2-(3-(3-chloro-4-methoxyphenyl)-3-hydroxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)benzoate (100 mg, 1.0 eq) was dissolved in anhydrous tetrahydrofuran (5 mL), and methylmagnesium bromide (3 M in ether, 10.0 eq) was added under ice-cooling. The system was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete, and saturated aqueous ammonium chloride (10 mL) was added to quench the reaction. The aqueous solution was extracted with ethyl acetate (30 mL × 2), and the organic phase was dried over anhydrous sodium sulfate and dried to dryness to obtain a crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate, acetonitrile) to obtain the title compound (2 mg). LCMS (ESI) [M+H] + =499.2; 1 H NMR (400MHz, DMSO-d6) δ9.81 (s, 1H), 8.63 (s, 1H), 8.04 (d, J = 8.5Hz, 1H), 7. 65(d,J=8.1Hz,1H),7.55(s,1H),7.47(t,J=7.8Hz,2H),7.17(s,1H),6.52( d,J=11.7Hz,1H),4.29(d,J=14.5Hz,4H),3.85(s,3H),3.54(d,J=8.8Hz,1H ),3.26(d,J=7.2Hz,1H),3.14-3.07(m,1H),3.05-2.97(m,1H),2.56(s,3H).
[0402] Example 32 (Compound 66)
[0403] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(4-(3-methoxyazetidin-1-yl)phenyl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0404] Step 1: Preparation of 1-(4-bromophenyl)-3-methoxyazetidine:
[0405] Under nitrogen, 1-bromo-4-iodobenzene (565 mg, 1.0 eq) and 3-methoxyazetidine hydrochloride (1.0 eq) were added to 1,4-dioxane (10 mL). Pd2(dba)3 (0.05 eq), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (0.05 eq), and cesium carbonate (2.5 eq) were added to the reaction solution. The reaction solution was heated to 100°C and reacted for 2 hours. LCMS showed that the starting material was consumed and converted to product. Heating was stopped, and the reaction solution was concentrated under reduced pressure. The residue was purified on a silica gel column (petroleum ether:ethyl acetate = 20:1) to obtain the title compound (370 mg). LCMS (ESI) [M+H] + =242.1.
[0406] Step 2: Preparation of 3-methoxy-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidine:
[0407] Under nitrogen protection, 1-(4-bromophenyl)-3-methoxyazetidine (370 mg, 1.0 eq) and bis-pinacol borate (1.2 eq) were added to 1,4-dioxane (15 mL), and Pd(dppf)Cl was added to the reaction solution. 2( The reaction mixture was heated to 90°C for 2 hours. LCMS showed that the starting material was consumed and converted to the product. The reaction mixture was concentrated under reduced pressure, and the residue was purified on a silica gel column (petroleum ether:ethyl acetate = 20:1 to 10:1) to obtain the title compound (350 mg). LCMS (ESI) [M+H] + =290.2.
[0408] Step 3: Preparation of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(4-(3-methoxyazetidin-1-yl)phenyl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0409] Under nitrogen protection, (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg, 1.0 eq) and 3-methoxy-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidine (1.2 eq) were added to 1,4-dioxane (8 mL). Water (2 mL) was added to the reaction solution, and Pd(PPh3)4 (0.1 eq) and sodium carbonate (2.5 eq) were added with stirring. The reaction solution was heated to 80°C and reacted for 2 hours. LCMS showed that the starting material was consumed and converted into the product. The reaction mixture was cooled to room temperature, water (30 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (23 mg). LCMS (ESI) [M+H] + =415.3; 1 H NMR (400MHz, DMSO-d6) δ8.17(d,J=8.7Hz,2H),7.80(s,1H),6.49(d,J=8.8Hz,2H),4.92(t,J=5. 3Hz,1H),4.39-4.30(m,1H),4.18-4.07(m,2H),3.80(d,J=4.9Hz,2H),3.71(dd,J=8.5,4.0Hz,2 H),3.65-3.52(m,1H),3.32-3.28(m,1H),3.26(s,3H),3.14(dd,J=17.0,8.1Hz,1H),2.98(dd,J =13.7,5.7Hz,1H),2.46-2.33(m,2H),2.30(dd,J=8.2,4.7Hz,2H),1.82(dt,J=18.0,9.1Hz,2H).
[0410] Example 33 (Compound 67)
[0411] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(4-(4-methylpiperazin-1-yl)phenyl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0412] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (13 mg, 0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (1 eq), 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine (1 eq), and potassium carbonate (2.5 eq) in dioxane (1 mL) and water (0.2 mL). The mixture was heated to 110°C for 2 hours. The reaction was complete by TLC. The reaction solution was diluted with ethyl acetate (100 mL), activated carbon (0.05 g) was added to the dilution, and the mixture was stirred for 4 hours. The mixture was filtered through a diatomaceous earth (2.00 g) filter cake. The filtrate was concentrated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (30 mg). LCMS (ESI) [M+H] + =428.4; 1 H NMR (400MHz, DMSO-d6) δ8.17(d,J=8.9Hz,2H),7.82(s,1H),7.00(d,J=9.0Hz,2H),4.9 2(t,J=5.6Hz,1H),3.81(d,J=5.4Hz,2H),3.65-3.53(m,1H),3.38-3.34(m,1H),3.30- 3.24(m,4H),3.15(dd,J=17.1,8.2Hz,1H),2.99(dd,J=13.7,5.7Hz,1H),2.47-2.42(m ,4H),2.41-2.33(m,2H),2.33-2.24(m,2H),2.22(s,3H),1.84(dd,J=16.6,8.4Hz,2H).
[0413] Example 34 (Compound 68)
[0414] Synthesis of (R / S)-1-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)pyrrolidin-2-one:
[0415] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (13 mg, 0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (1 eq), 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (1.2 eq), and potassium carbonate (2.5 eq) in dioxane (2 mL) and water (0.5 mL). The mixture was heated to 110°C for 2 hours. The reaction was complete by TLC. The reaction solution was diluted with ethyl acetate (100 mL), activated carbon (0.1 g) was added to the dilution and stirred for 4 hours. The mixture was filtered through a 2 g Celite filter cake. The filtrate was concentrated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (30 mg). LCMS (ESI) [M+H] + =413.1; 1 H NMR (400MHz, DMSO-d6) δ8.32(d,J=8.8Hz,2H),8.00(s,1H),7.81(d,J=8.9Hz,2H),4. 93(t,J=5.6Hz,1H),3.89(t,J=7.0Hz,2H),3.82(d,J=4.7Hz,2H),3.70-3.52(m,1H), 3.37(t,J=6.9Hz,1H),3.20(dd,J=17.1,8.1Hz,1H),3.08-2.97(m,1H),2.54(t,J=8. 1Hz,2H),2.46-2.39(m,1H),2.38-2.25(m,3H),2.15-2.01(m,2H),1.93-1.74(m,2H).
[0416] Example 35 (Compound 69)
[0417] Synthesis of (R / S)-2-(4-(dimethylamino)phenyl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0418] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.5 eq), and potassium carbonate (2.5 eq) in dioxane (2 mL) and water (0.5 mL). The mixture was heated to 110°C for 2 hours. TLC confirmed the reaction was complete. The reaction solution was diluted with water (10 mL) and ethyl acetate (30 mL), separated, and the organic phase was concentrated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (10 mg). LCMS (ESI) [M+H] + =373.1; 1 H NMR (400MHz, DMSO-d6) δ8.17(d,J=9.0Hz,2H),7.74(s,1H),6.77(d,J=9.0Hz,2H),4.91(d,J=5.5Hz,1H),3.81(d,J=5.1Hz,2H),3.63-3.53(m, 1H),3.31-3.28(m,1H),3.14(dd,J=17.5,6.8Hz,1H),3.00(s,6H),2.96 (s,1H),2.39(dd,J=22.3,12.3Hz,2H),2.29(s,2H),1.91-1.75(m,2H).
[0419] Example 36 (Compound 70)
[0420] Synthesis of (R / S)-4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)benzonitrile:
[0421] Under nitrogen protection, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50mg, 1eq), (4-cyanophenyl)boronic acid (1.5eq) and potassium carbonate (2.5eq) in dioxane (2mL) and water (0.5mL), and the mixture was heated to 110°C for 2 hours. LCMS detection showed that the reaction was complete. The reaction solution was diluted with water (10mL), extracted with ethyl acetate (30mL), separated, and the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated and purified by Prep-HPLC (C18, 10mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (50mg). LCMS (ESI) [M+H] + =355.2; 1 H NMR(400MHz, DMSO-d6)δ8.45(d,J=8.5Hz,2H),8.25(s,1H),7.98(d,J=8.5H z,2H),4.94(t,J=5.7Hz,1H),3.82(dd,J=5.7,2.7Hz,2H),3.72-3.60(m,1H) ,3.43-3.34(m,1H),3.24(dd,J=17.3,8.3Hz,1H),3.05(dd,J=13.7,5.6Hz, 1H), 2.45-2.38 (m, 1H), 2.33 (t, J = 8.3Hz, 3H), 1.85 (dd, J = 17.1, 8.7Hz, 2H).
[0422] Example 37 (Compound 71)
[0423] Synthesis of (R / S)-N-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)acetamide:
[0424] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide (1.5 eq), and potassium carbonate (2.5 eq) in dioxane (2 mL) and water (0.5 mL). The mixture was heated to 110°C for 2 hours. LCMS confirmed the reaction was complete. The reaction solution was diluted with water (10 mL) and ethyl acetate (30 mL), the layers separated, and the organic phase was concentrated under reduced pressure. The residue was purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (10 mg). LCMS (ESI) [M+H] + =387.1; 1 H NMR (400MHz, DMSO-d6) δ10.18(s,1H),8.25(d,J=8.8Hz,2H),7.96(s,1H),7.70(d,J =8.8Hz,2H),4.92(t,J=5.7Hz,1H),3.82(d,J=5.7Hz,2H),3.62(dt,J=15.8,7.7Hz, 1H),3.38(d,J=8.2Hz,1H),3.19(dd,J=16.3,7.4Hz,1H),3.01(dd,J=13.6,5.6Hz,1 H), 2.42 (dd, J = 11.9, 9.7Hz, 1H), 2.37-2.27 (m, 3H), 2.08 (s, 3H), 1.88-1.77 (m, 2H).
[0425] Example 38 (Compound 72)
[0426] Synthesis of (R / S)-N-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)methanesulfonamide:
[0427] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide (1.5 eq), and potassium carbonate (2.5 eq) in dioxane (2 mL) and water (0.5 mL). The mixture was heated to 110°C for 2 hours. LCMS confirmed the reaction was complete. The reaction solution was diluted with water (10 mL) and ethyl acetate (30 mL), the layers separated, and the organic phase was concentrated under reduced pressure. The residue was purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (15 mg). LCMS (ESI) [M+H] + =423.1; 1 H NMR (400MHz, DMSO-d6) δ9.93 (s, 1H), 8.27 (d, J = 8.7Hz, 2H), 8.01 (s, 1H), 7.29 (d,J=8.7Hz,2H),4.93(t,J=5.7Hz,1H),3.81(d,J=5.6Hz,2H),3.61(dd,J=16. 7,8.5Hz,1H),3.36(s,1H),3.19(dd,J=16.9,7.9Hz,1H),3.08(s,3H),3.01(d d,J=13.8,5.9Hz,1H),2.40(d,J=12.3Hz,1H),2.33(s,3H),1.89-1.76(m,2H).
[0428] Example 39 (Compound 73)
[0429] Synthesis of (R / S)-2-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-2-methylpropionitrile:
[0430] Under nitrogen protection, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), (4-(2-cyanopropan-2-yl)phenyl)boronic acid (1.5 eq) and potassium carbonate (2.5 eq) in dioxane (2 mL) and water (0.5 mL), and the mixture was heated to 110°C for 2 hours. LCMS detection showed that the reaction was complete. The reaction solution was diluted with water (10 mL) and ethyl acetate (30 mL), the layers were separated, and the organic phase was concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (25 mg). LCMS (ESI) [M+H] + =397.1; 1 H NMR (400MHz, DMSO-d6) δ8.35(d,J=8.5Hz,2H),8.10(s,1H),7.66(d,J=8.6Hz ,2H),4.93(t,J=5.7Hz,1H),3.82(d,J=4.1Hz,2H),3.71-3.59(m,1H),3.41- 3.35(m,1H),3.22(dd,J=17.2,8.2Hz,1H),3.04(dd,J=13.7,5.6Hz,1H),2.3 9(dd,J=17.5,7.9Hz,1H),2.36-2.27(m,3H),1.89-1.78(m,2H),1.73(s,6H).
[0431] Example 40 (Compound 74)
[0432] Synthesis of methyl (R / S)-2-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-2-methylpropanoate:
[0433] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg, 1 eq), methyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1.5 eq), and potassium carbonate (2.5 eq) in dioxane (2 mL) and water (0.5 mL). The mixture was heated to 110°C for 2 hours. LCMS confirmed the reaction was complete. The reaction solution was diluted with ethyl acetate (100 mL), and activated carbon (0.10 g) was added to the dilution and stirred for 4 hours. The mixture was filtered through a diatomaceous earth (3.00 g) filter cake. The filtrate was concentrated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (100 mg). LCMS (ESI) [M+H] + =430.3; 1 H NMR(400MHz, DMSO-d6)δ8.28(d,J=8.5Hz,2H),8.04(s,1H),7.44(d,J=8.5Hz,2H), 4.92(t,J=5.6Hz,1H),3.81(d,J=5.0Hz,2H),3.65(dd,J=15.7,6.5Hz,1H),3.59(s,3H),3.43-3.35(m,1H),3.21(dd,J =16.4,7.5Hz,1H),3.03(dd,J=13.8,5.8Hz,1H),2.46-2.39(m,1H),2.38-2.25(m,3H),1.92-1.77(m,2H),1.54(s,6H).
[0434] Example 41 (Compound 75)
[0435] Synthesis of (R / S)-2-(4-(2-aminopropan-2-yl)phenyl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0436] Step 1: Preparation of tert-butyl (R / S)-(2-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)propan-2-yl)carbamate:
[0437] Under nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a solution of tert-butyl (2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)carbamate (1.2 eq) and (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg, 1 eq) in potassium carbonate (2.5 eq). The mixture was heated to 110°C for 2 hours. The reaction was complete by TLC. The reaction mixture was diluted with ethyl acetate (100 mL), activated carbon (0.50 g) was added, and the mixture was stirred for 6 hours. The mixture was filtered through a celite filter cake (3.00 g). The filtrate was concentrated and purified by silica gel column chromatography (methanol / dichloromethane = 1:20) to obtain the title compound (100 mg). LCMS (ESI) [M+H] + =487.1.
[0438] Step 2: Preparation of (R / S)-2-(4-(2-aminopropyl-2-yl)phenyl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0439] A 4M hydrogen chloride / dioxane solution (20 eq) was added dropwise to a solution of tert-butyl (R / S)-(2-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)propan-2-yl)carbamate (60 mg, 1 eq) in dichloromethane (2 mL) and allowed to react at room temperature for 6 hours. TLC confirmed the completion of the reaction. The reaction solution was quenched with saturated sodium bicarbonate solution and the pH was adjusted to 9-10. The product was extracted with dichloromethane (50 mL), separated, and the organic phase was concentrated under reduced pressure. The product was then separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous sodium bicarbonate solution, acetonitrile) to obtain the title compound (30 mg). LCMS (ESI) [M+H] + =387.1; 1H NMR (400MHz, DMSO-d6) δ8.24(d,J=8.4Hz,2H),7.99(s,1H),7.65(d,J=8.4Hz ,2H),4.93(t,J=5.6Hz,1H),3.82(d,J=4.7Hz,2H),3.69-3.57(m,1H),3.41-3 .35(m,1H),3.21(dd,J=16.4,7.4Hz,1H),3.02(dd,J=13.6,5.8Hz,1H),2.44- 2.37(m,1H),2.36-2.25(m,3H),2.08(s,2H),1.89-1.77(m,2H),1.40(s,6H).
[0440] Example 42 (Compound 76)
[0441] Synthesis of (R / S)-2-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-2-methylpropanoic acid:
[0442] Concentrated hydrochloric acid (0.5 mL, 37 wt % 30 eq) was added to a solution of (R / S)-methyl 2-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-2-methylpropanoate (50 mg, 1 eq) in acetic acid (1 mL) and heated to 75°C for 6 hours. LCMS confirmed the reaction was complete. The reaction solution was quenched with concentrated aqueous ammonia and adjusted to pH 6-7. It was then separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the title compound (10 mg). LCMS (ESI) [M+H] + =416.2; 1 H NMR(400MHz,DMSO-d6)δ12.14(s,1H),8.27(d,J=8.4Hz,2H),8.03(s,1H),7.4 7(d,J=8.4Hz,2H),4.93(s,1H),3.81(s,2H),3.68-3.58(m,1H),3.39(d,J=8. 2Hz,1H),3.21(dd,J=16.7,7.5Hz,1H),3.02(dd,J=13.6,5.8Hz,1H),2.41(d, J=11.7Hz, 1H), 2.34 (dd, J=13.1, 6.2Hz, 3H), 1.90-1.77 (m, 2H), 1.51 (s, 6H).
[0443] Example 43 (Compound 77)
[0444] Synthesis of (R / S)-2-(4-(4-((1-(acetoxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-2-methylpropanoic acid:
[0445] Concentrated hydrochloric acid (0.5 mL, 37 wt%, 30 eq) was added to a solution of (R / S)-methyl 2-(4-(4-((1-(hydroxymethyl)cyclobutyl)amino)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-2-methylpropanoate (50 mg, 1 eq) in acetic acid (1 mL) and heated to 75°C for 6 hours. LCMS confirmed the reaction was complete. The reaction solution was quenched with concentrated aqueous ammonia and adjusted to pH 6-7. The product was then separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to afford the title compound (10 mg). LCMS (ESI) [M+H] + =458.2; 1 H NMR (400MHz, DMSO-d6) δ12.42(s,1H),8.40(s,1H),8.28(d,J=8.4Hz,2H),7. 48(d,J=8.4Hz,2H),4.56(q,J=11.1Hz,2H),3.71-3.58(m,1H),3.42-3.37(m ,1H),3.23(dd,J=16.8,7.8Hz,1H),3.02(dd,J=13.7,6.1Hz,1H),2.46-2.40 (m,1H),2.36(t,J=7.6Hz,3H),2.00(s,3H),1.94-1.82(m,2H),1.51(s,6H).
[0446] Example 44 (Compound 78)
[0447] Synthesis of (R / S,E)-2-(4-chlorostyryl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0448] Under nitrogen protection, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.1 eq) was added to a mixture of (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), (E)-(4-chlorostyryl)boronic acid (1.2 eq) and potassium carbonate (2.5 eq) in dioxane (2 mL) and water (0.4 mL), and the mixture was heated to 110°C for 2 hours. TLC detection showed that the reaction was complete. The reaction solution was diluted with water (20 mL), extracted with ethyl acetate (50 mL), separated, and the organic phase was concentrated and purified by Prep-HPLC (C18, 10 mmol / L formic acid aqueous solution, acetonitrile) to obtain the title compound (30 mg). LCMS (ESI) [M+H] + =390.1; 1 H NMR (400MHz, DMSO-d6) δ7.92 (s, 1H), 7.82 (d, J = 8.7Hz, 1H), 7.78-7.72 (m, 2H), 7.47 (d ,J=8.5Hz,2H),7.06(d,J=16.0Hz,1H),4.90(t,J=5.7Hz,1H),3.79(d,J=5.7Hz,2H),3 .58(dt,J=15.9,7.8Hz,1H),3.37(d,J=8.3Hz,1H),3.15(dd,J=16.3,7.3Hz,1H),3.00 (dd,J=13.9,5.7Hz,1H),2.39(d,J=11.1Hz,1H),2.36-2.23(m,3H),1.90-1.75(m,2H).
[0449] Example 45 (Compound 79)
[0450] Synthesis of (R / S)-2-(3-(4-chloro-3-methoxyphenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0451] Step 1: Preparation of tert-butyl 3-(4-chloro-3-methoxyphenyl)-3-methoxyazetidine-1-carboxylate:
[0452] tert-Butyl 3-(4-chloro-3-methoxyphenyl)-3-hydroxyazetidine-1-carboxylate (500 mg, 1 eq) was dissolved in N,N-dimethylformamide (5 mL). The nitrogen atmosphere was replaced three times, and 60% sodium hydride (2.05 eq) was added in an ice-water bath. The mixture was stirred on ice for 10 minutes. Iodomethane (5 eq) was added and stirring continued on ice for 30 minutes. LCMS confirmed complete consumption of the starting material. The reaction mixture was quenched by the addition of saturated NH4Cl solution. The mixture was added to water (30 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified on a silica gel column (petroleum ether:ethyl acetate = 10:1) to obtain the title compound (417 mg).
[0453] Step 2: Preparation of 3-(4-chloro-3-methoxyphenyl)-3-methoxyazetidine trifluoroacetate:
[0454] Dissolve tert-butyl 3-(4-chloro-3-methoxyphenyl)-3-methoxyazetidine-1-carboxylate (1 eq) in dichloromethane (10 mL). Add trifluoroacetic acid (2 mL) under ice-cooling and stir at room temperature for 0.5 hours. LCMS analysis confirmed complete consumption of the starting material. The reaction mixture was concentrated under reduced pressure to obtain the crude title compound (800 mg, used directly in the next step). LCMS (ESI) [M+H] + =228.1.
[0455] Step 3: Preparation of (R / S)-2-(3-(4-chloro-3-methoxyphenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0456] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (150 mg, crude product from the previous step), 3-(4-chloro-3-methoxyphenyl)-3-methoxyazetidine trifluoroacetate (231 mg), and N,N-diisopropylethylamine (538 mg) were dissolved in dioxane (5 mL) and heated at 100°C with stirring for 1 hour. LCMS analysis showed that the starting material was completely consumed. The reaction solution was added to water (50 mL), filtered, and separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the target compound (110 mg). LCMS (ESI) [M+H] + =479.3; 1H NMR (400MHz, DMSO-d6) δ7.53(s,1H),7.47(d,J=8.2Hz,1H),7.14(d,J=2.0Hz,1H),7 .05(dd,J=8.1,1.9Hz,1H),4.85(t,J=5.6Hz,1H),4.21(s,4H),3.90(s,3H),3.72(d d,J=5.8,2.4Hz,2H),3.42(dt,J=16.9,8.3Hz,4H),3.21(dt,J=13.6,8.4Hz,1H),3. 00-2.83(m,2H),2.37-2.22(m,2H),2.20-2.10(m,2H),1.75(dq,J=19.4,9.9Hz,2H).
[0457] Example 46 (Compound 80)
[0458] Synthesis of (R / S)-2-(3-(4-chloro-3-fluorophenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0459] Step 1: Preparation of 4-chloro-3-fluorophenylmagnesium bromide:
[0460] Under nitrogen protection, magnesium chips (696 mg, 1.2 eq) with the oxide layer removed, elemental iodine (0.01 eq), and 4-bromo-1-chloro-2-fluorobenzene (0.6 eq) were added to anhydrous THF (3 mL) and heated until the brown color disappeared. Then, a solution of 4-bromo-1-chloro-2-fluorobenzene (0.4 eq) in anhydrous THF (17 mL) was slowly added and reacted at room temperature for 2 hours. The magnesium chips were largely consumed to obtain the crude target compound, which was used directly in the next step.
[0461] Step 2: Preparation of tert-butyl 3-(4-chloro-3-fluorophenyl)-3-hydroxyazetidine-1-carboxylate:
[0462] Under nitrogen protection, tert-butyl 3-oxoazetidine-1-carboxylate (3.00 g, 1 eq) was added to anhydrous THF (20 mL). At 0°C, the reaction solution from the previous step (5.32 g) was slowly added and stirred at 0°C for 1 hour. TLC detection revealed the formation of new spots. The reaction solution was quenched by adding saturated ammonium chloride solution, and then water (150 mL) was added. The mixture was extracted with MTBE (100 mL × 2). The organic phases were combined, washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The crude product was purified on a silica gel column (petroleum ether: ethyl acetate = 5:1) to obtain the target compound (4.70 g). LCMS (ESI) [M+H-56] + =246.1.
[0463] Step 3: Preparation of 3-(4-chloro-3-fluorophenyl)-3-hydroxyazetidine trifluoroacetate:
[0464] Dissolve tert-butyl 3-(4-chloro-3-fluorophenyl)-3-hydroxyazetidine-1-carboxylate (200 mg, 1 eq) in dichloromethane (1 mL), add trifluoroacetic acid (1 mL), and stir at room temperature for 30 minutes. LCMS analysis indicated the disappearance of the starting material. The reaction mixture was concentrated under reduced pressure to obtain the title compound (240 mg, the crude product was used directly in the next step). LCMS (ESI) [M+H] + =202.1.
[0465] Step 4: Preparation of (R / S)-2-(3-(4-chloro-3-fluorophenyl)-3-hydroxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0466] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg, 1 eq), 3-(4-chloro-3-fluorophenyl)-3-hydroxyazetidine trifluoroacetate (160 mg, the crude product was used directly in the next step), and N,N-diisopropylethylamine (4 eq) were dissolved in a mixed solution of tetrahydrofuran (2.5 mL) and water (0.5 mL) and heated at 70°C with stirring for 2 hours. LCMS detection showed that the starting material was completely consumed. The reaction solution was added to water (20 mL), filtered, and separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the target compound (100 mg). LCMS (ESI) [M+H] + =453.2; 1H NMR (400MHz, DMSO-d6) δ7.61(t,J=8.1Hz,1H),7.55-7.47(m,2H),7.38(dd,J=8.5,2.1Hz,1H),6.64(s,1H),4.87(t,J=5.7Hz,1H),4.18(s,4H),3 .70(dd,J=5.9,1.5Hz,2H),3.42(d,J=8.7Hz,1H),3.27-3.17(m,1H),3.0 1-2.82(m,2H),2.42-2.24(m,2H),2.20-2.05(m,2H),1.87-1.64(m,2H).
[0467] Example 47 (Compound 81)
[0468] Synthesis of (R / S)-2-(3-(4-chloro-3-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0469] Step 1: Preparation of 2-chloro-N-(tetrahydro-2H-pyran-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine:
[0470] 2,4-Dichloro-6,7-dihydrothieno[3,2-d]pyrimidine (5.00 g, 1 eq), 4-aminotetrahydropyran (1.1 eq), and N,N-diisopropylethylamine (3 eq) were dissolved in acetonitrile (50 mL) and stirred at 85°C for 4 hours. LCMS analysis confirmed complete consumption of the starting material. The reaction mixture was concentrated under reduced pressure to obtain a solid, which was slurried with MTBE (50 mL), filtered, and the filter cake was washed with MTBE (20 mL). The filter cake was dried to obtain the title compound (5.43 g). LCMS (ESI) [M+H] + =272.1.
[0471] Step 2: Preparation of (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0472] 2-Chloro-N-(tetrahydro-2H-pyran-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine (0.50 g, 1 eq), S-(-)binaphthol (0.1 eq), Ti(O iPr)4 (0.05eq) was added to DCM (5mL) and water (0.5mL), the nitrogen was replaced 3 times, and the mixture was stirred at room temperature for 1 hour. 70% tert-butyl hydroperoxide (1.1eq) was added under ice bath and stirred at room temperature for 3 hours. LCMS detected that a small amount of raw material remained. Water (20mL) was added under ice bath to quench the reaction, and the mixture was extracted with DCM (20mL×2). After combining the organic phases, the mixture was washed with water (10mL) and saturated brine (10mL) in sequence, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column (petroleum ether: ethyl acetate = 3:1) to obtain the target compound (187mg). LCMS (ESI) [M+H] + =288.1;
[0473] Step 3: Preparation of (R / S)-2-(3-(4-chloro-3-methoxyphenyl)-3-hydroxyazetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0474] (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (50 mg, 1 eq), 3-(4-chloro-3-methoxyphenyl)-3-hydroxyazetidine hydrochloride (1.3 eq), and N,N-diisopropylethylamine (5 eq) were dissolved in a mixture of THF (1.5 mL) and water (0.3 mL) and stirred at 70°C for 1 hour. LCMS confirmed complete consumption of the starting material. The reaction mixture was added to water (20 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with water (10 mL) and saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield the crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate, acetonitrile) to yield the title compound (55 mg). LCMS (ESI) [M+H] + =465.2; 1 H NMR (400MHz, DMSO-d6) δ7.68(d,J=7.5Hz,1H),7.43(d,J=8.3Hz,1H),7.25(d,J=2.0Hz,1H),7.09(d,J=8.2Hz,1H),6.50(s,1H),4.22(t,J =13.5Hz,5H),3.87(s,4H),3.43(dd,J=17.1,8.5Hz,1H),3.30-3.11(m,4H),2.94(ddd,J=26.1,15.5,7.6Hz,2H),1.69(d,J=60.2Hz,4H).
[0475] Example 48 (Compound 82)
[0476] Synthesis of (R / S)-2-(3-(4-chloro-3-fluorophenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0477] Step 1: Preparation of tert-butyl 3-(4-chloro-3-fluorophenyl)-3-methoxyazetidine-1-carboxylate:
[0478] tert-Butyl 3-(4-chloro-3-fluorophenyl)-3-hydroxyazetidine-1-carboxylate (300 mg, 1 eq) was dissolved in DMF (3 mL) and the atmosphere was replaced with nitrogen three times. 60 wt% sodium hydride (2 eq) was added under ice-cooling and stirred for 5 minutes. Methyl iodide (2 eq) was added and stirring continued for 4 hours. LCMS confirmed complete consumption of the starting material. Under ice-cooling, the reaction mixture was quenched with saturated aqueous ammonium chloride and added to water (30 mL). The mixture was extracted with MTBE (20 mL x 2). The combined organic phases were washed with water (10 mL) and saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified on a silica gel column (petroleum ether:ethyl acetate = 10:1) to obtain the title compound (260 mg).
[0479] Step 2: Preparation of 3-(4-chloro-3-fluorophenyl)-3-methoxyazetidine trifluoroacetate:
[0480] tert-Butyl 3-(4-chloro-3-fluorophenyl)-3-methoxyazetidine-1-carboxylate (260 mg, 1 eq) was added to a mixture of TFA (2 mL) and DCM (3 mL) and stirred at room temperature for 0.5 hours. LCMS analysis showed that the starting material was completely consumed. The reaction solution was concentrated under reduced pressure to obtain 3-(4-chloro-3-fluorophenyl)-3-methoxyazetidine trifluoroacetate (350 mg, the crude product was used directly in the next step). LCMS (ESI) [M+H] + =216.1.
[0481] Step 4: Preparation of (R / S)-2-(3-(4-chloro-3-fluorophenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0482] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (200 mg, 1 eq), 3-(4-chloro-3-fluorophenyl)-3-methoxyazetidine trifluoroacetate (343 mg, crude product from the previous step), and N,N-diisopropylethylamine (5 eq) were added to a mixed solution of water (1 mL) and THF (5 mL) and stirred at 70°C for 2 hours. LCMS analysis showed that the starting material was completely consumed. The reaction solution was added to water (20 mL), filtered, and separated and purified by Prep-HPLC (C18, 0.1% formic acid aqueous solution, acetonitrile) to obtain the target compound (209 mg, yield 64%). LCMS (ESI) [M+H] + =467.3; 1 H NMR (400MHz, DMSO-d6) δ7.66 (t, J = 8.0 Hz, 1H), 7.58-7.48 (m, 2H), 7.35 (dd, J = 8. 3,2.1Hz,1H),4.84(t,J=5.6Hz,1H),4.20(d,J=8.9Hz,4H),3.76-3.64(m,2H),3 .43(dd,J=17.0,8.3Hz,1H),3.22(dt,J=13.5,8.3Hz,1H),3.06(s,3H),2.98-2. 84(m,2H),2.30(dt,J=21.0,10.3Hz,2H),2.19-2.10(m,2H),1.85-1.65(m,2H).
[0483] Example 49 (Compound 83)
[0484] Synthesis of (R / S)-2-(3-(4-chlorophenyl)-3-methoxyazetidin-1-yl)-4-((1-hydroxymethylcyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0485] Step 1: Preparation of (4-chlorophenyl)lithium:
[0486] Under nitrogen, 1-chloro-4-iodobenzene (4.18 g, 1 eq) was dissolved in anhydrous THF (50 mL) and stirred until clear. A 2.5 M solution of n-butyllithium in hexane (1 eq) was added dropwise at -78°C. The reaction was stirred at -78°C for 0.5 h to obtain the crude title compound. This was used directly in the next step.
[0487] Step 2: Preparation of tert-butyl 3-(4-chlorophenyl)-3-hydroxyazetidine-1-carboxylate:
[0488] Under nitrogen protection, tert-butyl 3-oxoazetidine-1-carboxylate (2g, 1eq) was dissolved in anhydrous THF (10mL) and slowly added to the reaction solution of the previous step at -78°C. Stir at -78°C for 1 hour and detect by TLC. At 0°C, saturated ammonium chloride solution (10mL) was added to the reaction solution to quench the reaction and purify to obtain a crude product. The crude product was added to petroleum ether (30mL) and stirred at room temperature for 1 hour. It was filtered and the filter cake was washed with petroleum ether (20mL) to obtain the target compound (2.56g). LCMS (ESI) [M+H-56] + =228.1.
[0489] Step 3: Preparation of tert-butyl 3-(4-chlorophenyl)-3-methoxyazetidine-1-carboxylate:
[0490] Under nitrogen, tert-butyl 3-(4-chlorophenyl)-3-hydroxyazetidine-1-carboxylate (500 mg, 1 eq) was dissolved in anhydrous DMF (5 mL). 60 wt% sodium hydride (2.05 eq) was added in an ice-water bath and stirred for 10 minutes. Iodomethane (5 eq) was then added and stirring continued for 30 minutes. LCMS confirmed complete consumption of the starting material. The reaction mixture was quenched by the addition of saturated aqueous NH4Cl. The mixture was added to water (30 mL) and extracted with methyl tert-butyl ether (20 mL x 2). The combined organic phases were washed sequentially with water (20 mL) and saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford the crude title compound (585 mg, used directly in the next step).
[0491] Step 4: Preparation of 3-(4-chlorophenyl)-3-methoxyazetidine hydrochloride:
[0492] 3-(4-chlorophenyl)-3-methoxyazetidine-1-carboxylic acid tert-butyl ester (585 mg, crude product from the previous step) was added to a 4M solution of hydrogen chloride in ethyl acetate (5 mL) and stirred at room temperature for 0.5 hours. LCMS detected that the starting material was completely consumed. The reaction solution was concentrated under reduced pressure, and methyl tert-butyl ether (20 mL) was added to the residue, stirred at room temperature for 30 minutes, filtered, and the filter cake was washed with methyl tert-butyl ether (10 mL) to obtain the target compound (380 mg). LCMS (ESI) [M+H] + =198.1.
[0493] Step 5: Preparation of (R / S)-2-(3-(4-chlorophenyl)-3-methoxyazetidin-1-yl)-4-((1-hydroxymethylcyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0494] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg, 1 eq), 3-(4-chlorophenyl)-3-methoxyazetidine hydrochloride (1.22 eq), and N,N-diisopropylethylamine (3.98 eq) were added to a mixed solution of water (0.5 mL) and THF (2.5 mL) and stirred at 70°C for 2 hours. LCMS showed that the starting material was completely consumed. The reaction solution was added to water (20 mL), filtered, and separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to obtain the target compound (82 mg, yield 52%). LCMS (ESI) [M+H] + =449.3; 1 H NMR (400MHz, DMSO-d6) δ7.49 (s, 5H), 4.84 (t, J = 5.7Hz, 1H), 4.22 (s, 3H), 3.77-3.65 (m, 2H), 3.41 (dt, J = 16.6, 8.0Hz, 2H), 3.27-3.1 5(m,2H),2.99-2.82(m,3H),2.34(d,J=10.5Hz,2H),2.26(d,J=10.0Hz,1H),2.14(t,J=10.2Hz,2H),1.74(dq,J=19.6,10.3Hz,2H).
[0495] Example 50 (Compound 84)
[0496] Synthesis of (R / S)-2-(5-(2-hydroxypropan-2-yl)isoindolin-2-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0497] Step 1: Preparation of methyl (R / S)-2-(5-oxido-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)isoindoline-5-carboxylate:
[0498] (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (130 mg, 1 eq), methyl isoindoline-5-carboxylate hydrochloride (1.2 eq), and N,N-diisopropylethylamine (5 eq) were dissolved in water (0.3 mL) and THF (1.5 mL) and heated at 70°C with stirring for 1 hour. LCMS analysis showed that the starting material was completely consumed. The reaction mixture was added to water (20 mL), filtered, and the filter cake was washed with water (20 mL). The filter cake was collected and ethyl acetate (30 mL) was added, and the mixture was concentrated under reduced pressure to obtain the target compound (170 mg). LCMS (ESI) [M+H] + =429.3.
[0499] Step 2: Preparation of (R / S)-2-(5-(2-hydroxypropyl-2-yl)isoindolin-2-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0500] Under nitrogen, methyl (R / S)-2-(5-oxido-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)isoindoline-5-carboxylate (120 mg, 1 eq) was dissolved in THF (2 mL) and stirred on ice for 10 minutes. A 3M methylmagnesium bromide / 2-methyltetrahydrofuran solution (10.7 eq) was added dropwise, and stirring continued for 1 hour. LCMS confirmed the reaction was complete. Saturated aqueous ammonium chloride was added to the reaction mixture on ice to quench the reaction. The mixture was added to water (30 mL) and extracted with MTBE (20 mL x 2). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield the crude product. The crude product was separated and purified by Pre-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate, acetonitrile) to afford the title compound (27 mg). LCMS (ESI) [M+H] + =429.3; 1H NMR (400MHz, DMSO-d6) δ7.61(t,J=6.3Hz,1H),7.50(s,1H),7.40(t,J=8.3Hz,1H),7.31( dd,J=12.9,8.0Hz,1H),5.04(d,J=5.1Hz,1H),4.81(d,J=8.2Hz,3H),4.30(s,1H),3.92(s ,2H),3.44(q,J=14.4Hz,3H),3.23(dt,J=13.4,8.5Hz,2H),3.03(d,J=7.2Hz,1H),2.90(d d,J=13.6,7.1Hz,1H),1.84(d,J=12.9Hz,2H),1.64(dd,J=17.6,9.3Hz,2H),1.44(s,6H).
[0501] Example 51 (Compound 85)
[0502] Synthesis of (R / S)-2-(5-chloroisoindolin-2-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0503] Step 1: Preparation of (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0504] S-(-)-binaphthol (0.2 eq) was dissolved in DCM (10 mL) and Ti(O i Pr)4 (0.2eq), react at 25°C under nitrogen protection for 1 hour. Water (0.14mL) was added and the reaction continued for 0.5 hours. Then 2-chloro-N-(tetrahydro-2H-pyran-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine (2.00g, 1eq) was added. After reacting for 1 hour, 70wt% tert-butyl hydroperoxide (1.1eq) was added. LCMS monitored the reaction completion. The reaction solution was added to water (30mL) and extracted with DCM:MeOH = 10:1 (20mL×2). The combined organic phases were washed with water (20mL) and saturated brine (20mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the target compound (1.50g). LCMS (ESI) [M+H] + =288.1.
[0505] Step 2: Preparation of (R / S)-2-(5-chloroisoindolin-2-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0506] (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg, 1 eq) and 5-chloroisoindoline hydrochloride (0.91 eq) were added to a mixture of THF (2 mL) and H₂O (0.4 mL). N,N-diisopropylethylamine (4.95 eq) was added, and the mixture was stirred at 70°C for 1 hour. LCMS analysis indicated the formation of the product. The reaction mixture was added to water (30 mL) and extracted with DCM:MeOH = 10:1 (20 mL x 2). The combined organic phases were washed with water (20 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield the crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L aqueous ammonium bicarbonate solution, acetonitrile) to yield the title compound (60 mg). LCMS (ESI) [M+H] + =405.3; 1 H NMR (400MHz, DMSO-d6) δ7.64(d,J=7.6Hz,1H),7.55-7.31(m,3H),4.81(d,J=7.9Hz,4H),4.29(s,1H),3.91(s,2H),3.53-3.35(m,3H) ,3.24(dt,J=13.4,8.5Hz,1H),3.00(dd,J=17.0,8.1Hz,1H),2.91(dd,J=13.4,7.1Hz,1H),1.83(d,J=12.6Hz,2H),1.74-1.57(m,2H).
[0507] Example 52 (Compound 86)
[0508] Synthesis of (R / S)-2-(3-(4-chloro-3-fluorophenyl)-3-methoxyazetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0509] (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (150 mg) and 3-(4-chloro-3-fluorophenyl)-3-methoxyazetidine hydrochloride (150 mg) were added to a mixed solution of tetrahydrofuran (2.5 mL) and H2O (0.5 mL). N,N-diisopropylethylamine (336 mg) was added and stirred at 70°C for 1 hour. The reaction solution was added to water (20 mL) and extracted with DCM:MeOH = 10:1 (10 mL). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (70 mg). LCMS (ESI) [M+H] + =467.3; 1 H NMR(400MHz,DMSO-d6)δ7.71-7.62(m,2H),7.55(dd,J=10.4,2.1Hz,1H),7.35 (dd,J=8.4,2.1Hz,1H),4.26(q,J=10.0Hz,5H),3.89(d,J=8.8Hz,2H),3.42(d q,J=15.1,7.3Hz,2H),3.22(dt,J=13.7,8.4Hz,2H),3.07(s,3H),2.93(ddd,J =21.7,15.4,7.7Hz,2H),1.77(d,J=12.6Hz,2H),1.61(qt,J=11.6,5.8Hz,2H).
[0510] Example 53 (Compound 87)
[0511] Synthesis of (R / S)-2-(5-(difluoromethoxy)isoindolin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0512] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 5-(difluoromethoxy)isoindoline hydrochloride (100 mg), and N,N-diisopropylethylamine (180 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (111 mg). LCMS (ESI) [M+H] + =437.2; 1 H NMR (400MHz, DMSO-d6) δ7.52-7.38(m,2H),7.33-6.99(m,3H),4.91-4.71(m,5H),3.79(d,J=5.8Hz,2H),3.46(dt,J=16.4,7.9Hz,1H),3.24(d t,J=13.3,8.2Hz,1H),2.94(ddd,J=35.6,15.3,7.6Hz,2H),2.38(dt,J=20.2,10.0Hz,2H),2.28-2.17(m,2H),1.80(dd,J=19.0,10.5Hz,2H).
[0513] Example 54 (Compound 88)
[0514] Synthesis of (R / S)-2-(3-(4-chlorophenyl)-3-methoxyazetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0515] (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (200 mg) and 3-(4-chlorophenyl)-3-methoxyazetidine hydrochloride (200 mg) were added to a mixed solution of tetrahydrofuran (4 mL) and H2O (0.8 mL). N,N-diisopropylethylamine (450 mg) was added, and the mixture was stirred at 70°C for 1 hour. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (270 mg). LCMS (ESI) [M+H] + =449.2; 1H NMR (400MHz, DMSO-d6) δ7.67(d,J=7.6Hz,1H),7.50(s,4H),4.26(s,5H),3.88(s,2H),3.41(dd,J=17.2,8.7Hz ,2H),3.22(dt,J=13.7,8.4Hz,2H),3.05(s,3H),3.00-2.84(m,2H),1.75(s,2H),1.62(dt,J=13.6,6.9Hz,2H).
[0516] Example 55 (Compound 89)
[0517] Synthesis of (R / S)-2-(5-fluoroisoindolin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0518] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 5-fluoro-2,3-dihydro-1H-isoindoline hydrochloride (79 mg), and N,N-diisopropylethylamine (180 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (75 mg). LCMS (ESI) [M+H] + =389.0; 1 H NMR (400MHz, DMSO-d6) δ7.49-7.37(m,2H),7.27(dd,J=23.1,9.0Hz,1H),7.18-7.10(m,1H),4.92-4.70(m,5H),3.79(d,J=5.7Hz,2H),3.46(dt,J=16 .4,7.9Hz,1H),3.24(dt,J=13.4,8.3Hz,1H),3.04-2.84(m,2H),2.38(dt, J=20.6,10.4Hz,2H),2.23(t,J=9.8Hz,2H),1.80(dq,J=19.1,9.8Hz,2H).
[0519] Example 56 (Compound 90)
[0520] Synthesis of (R / S)-2-(5,6-difluoroisoindolin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0521] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 5,6-difluoro-2,3-dihydro-1H-isoindoline hydrochloride (87 mg), and N,N-diisopropylethylamine (180 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (119 mg). LCMS (ESI) [M+H] + =407.0; 1 H NMR (400MHz, DMSO-d6) δ7.61-7.42(m,3H),4.90-4.67(m,5H),3.79(d,J=6.0Hz,2H),3.45(dd,J=16.8,8.2Hz,1H),3.23(d t,J=13.4,8.3Hz,1H),3.02-2.85(m,2H),2.38(dd,J=22.1,11.8Hz,2H),2.28-2.14(m,2H),1.79(dq,J=19.3,9.9Hz,2H).
[0522] Example 57 (Compound 91)
[0523] Synthesis of (R / S)-2-(5-(difluoromethyl)isoindolin-2-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0524] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 5-(difluoromethyl)isoindoline hydrochloride (110 mg), and N,N-diisopropylethylamine (180 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 L), and the mixture was stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (93 mg). LCMS (ESI) [M+H]+ =421.3; 1 H NMR(400MHz,DMSO-d6)δ7.69-7.39(m,4H),7.06(td,J=55.9,5.3Hz,1H),4.86(dd ,J=13.2,6.0Hz,5H),3.80(d,J=5.8Hz,2H),3.47(dt,J=16.4,7.8Hz,1H),3.24(dt ,J=13.5,8.3Hz,1H),2.99(dd,J=17.1,8.1Hz,1H),2.89(dd,J=13.5,7.2Hz,1H),2 .39(dt,J=21.6,10.6Hz,2H), 2.24(t,J=9.9Hz,2H), 1.80(dd,J=19.0,9.7Hz,2H).
[0525] Example 58 (Compound 92)
[0526] Synthesis of (R / S)-2-(3-(4-chlorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0527] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-(4-chlorophenyl)-3-(methoxy-d3)azetidine hydrochloride (123 mg), and N,N-diisopropylethylamine (180 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (90 mg). LCMS (ESI) [M+H] + =452.3; 1 H NMR (400MHz, DMSO-d6) δ7.49 (s, 4H), 4.84 (t, J = 5.6Hz, 1H), 4.22 (s, 4H), 3.71 (s, 2H), 3.46-3.37 (m, 2H), 3.22 (dt ,J=15.4,8.5Hz,1H),3.01-2.83(m,2H),2.39-2.23(m,2H),2.16(d,J=10.2Hz,2H),1.74(dq,J=18.9,9.3Hz,2H).
[0528] Example 59 (Compound 94)
[0529] Synthesis of (R / S)-2-(3-(4-chlorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0530] (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-(4-chlorophenyl)-3-(methoxy-d3)azetidine hydrochloride (123 mg), and N,N-diisopropylethylamine (180 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (51 mg). LCMS (ESI) [M+H] + =452.3; 1 H NMR (400MHz, DMSO-d6) δ7.66 (d, J=7.6Hz, 1H), 7.50 (s, 4H), 4.25 (s, 5H), 3.88 (s, 2H), 3.43 (dt, J= 17.0,8.1Hz,3H),3.22(dt,J=13.6,8.5Hz,1H),3.02-2.85(m,2H),1.76(s,2H),1.69-1.53(m,2H).
[0531] Examples 60 & 61 (Compounds 95 & 96)
[0532] Synthesis of (R / S)-2-(3-(2-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide & (R / S)-2-(3-(4-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0533] Step 1: Preparation of tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate:
[0534] Under nitrogen protection, 1-bromo-4-fluorobenzene (5.00g) was dissolved in anhydrous tetrahydrofuran (50mL), and 2.5M n-butyl lithium / hexane solution (13.7mL) was added dropwise at -78°C, and the reaction was continued at -78°C for 0.5 hours. 3-Oxoazetidine-1-carboxylic acid tert-butyl ester (4.50g) was dissolved in anhydrous tetrahydrofuran (20mL), slowly added to the reaction solution at -78°C, and stirred at -78°C for 1 hour. The reaction solution was warmed to 0°C and saturated ammonium chloride solution (10mL) was added to quench the reaction. Water (100mL) was added, and the mixture was extracted twice with methyl tert-butyl ether (100mL). After the organic phases were combined, they were washed once with saturated sodium chloride solution (100mL), dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain a crude product. The crude product was purified by silica gel column (PE:EA=5:1) to obtain the target compound (6.37 g). LCMS (ESI) [M+H-56] + =212.1.
[0535] Step 2: Preparation of tert-butyl 3-(4-fluorophenyl)-3-(methoxy-d3)azetidine-1-carboxylate:
[0536] The mixture (2g) of the first step reaction obtained compound is dissolved with DMF (5mL), replaced nitrogen 3 times, under ice bath condition, added sodium hydride (0.57g), ice bath stirred 10 minutes, continued ice bath stirred 30 minutes after adding deuterated iodomethane (2.17g).LCMS detection raw material consumption is complete.In reaction solution, add saturated NH The Cl aqueous solution is quenched and the reaction is added, mixed solution is joined in water (100mL), extracted 2 times with methyl tert-butyl ether (80mL), washed 1 time with water (50mL) after merging organic phase, saturated aqueous common salt (50mL) washed 2 times, anhydrous sodium sulfate drying, filtered and obtained target compound (2.13g) after being spin-dried for.This crude product is directly used in next step.
[0537] Step 3: Preparation of 3-(4-fluorophenyl)-3-(methoxy-d3)azetidine hydrochloride:
[0538] The mixture of the compounds obtained in the second step (2.10 g) was added to a 4M hydrogen chloride / ethyl acetate solution (15 mL) and stirred at room temperature for 0.5 hours. LCMS analysis showed that the starting material was completely consumed. The reaction solution was directly concentrated under reduced pressure to obtain a crude product of the target compound (1.94 g). The crude product was used directly in the next step. LCMS (ESI) [M+H] + =185.1.
[0539] Step 4: Preparation of (R / S)-2-(3-(2-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide & (R / S)-2-(3-(4-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0540] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), a mixture of the compound obtained in the third step (115 mg), and N,N-diisopropylethylamine (180.49 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL), and the reaction was stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain (R / S)-2-(3-(2-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (7.4 mg, P1) and (R / S)-2-(3-(4-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (61 mg, P2).
[0541] P1:LCMS(ESI)[M+H] + =436.2; 1 H NMR (400MHz, DMSO-d6) δ7.59-7.40(m,3H),7.31-7.21(m,2H),4.85(t,J=5.7Hz,1H),4.37(s,2H),4.26(d,J=10.1Hz,2H),3.72(dd,J=5.8,3.1Hz,2H ),3.46-3.36(m,1H),3.21(dt,J=16.4,8.3Hz,1H),2.99-2.82(m,2H),2.3 0(dq,J=21.0,9.2Hz,2H),2.19-2.11(m,2H),1.76(dq,J=19.4,9.9Hz,2H).
[0542] P2:LCMS(ESI)[M+H] + =436.2;1 H NMR (400MHz, DMSO-d6) δ7.61-7.43(m,3H),7.26(t,J=8.9Hz,2H),4.84(t,J=5.6Hz,1H),4.22(s,4H),3.71(dd,J=5.7,2.8Hz,2H),3.41(dt,J=16.3,7 .8Hz,1H),3.26-3.16(m,1H),2.90(ddd,J=21.8,15.3,7.7Hz,2H),2.31(dq ,J=21.0,10.3Hz,2H),2.15(d,J=7.9Hz,2H),1.75(dq,J=18.8,9.8Hz,2H).
[0543] Examples 62 & 63 (Compounds 97 & 98)
[0544] Synthesis of (R / S)-2-(3-(2-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide & (R / S)-2-(3-(4-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0545] To a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL) was added (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (150 mg), a mixture of the compounds obtained in the third step of Examples 60 & 61 (172 mg), and N,N-diisopropylethylamine (267 mg), and the mixture was stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain (R / S)-2-(3-(2-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (8.4 mg, P1) and (R / S)-2-(3-(4-fluorophenyl)-3-(methoxy-d3)azetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (66 mg, P2).
[0546] P1:LCMS(ESI)[M+H]+ =436.2; 1 H NMR(400MHz, DMSO-d6)δ7.75(s,1H),7.49(dt,J=33.9,7.0Hz,2H),7.31-7.22(m,2H),4.43(d,J=10.2Hz,2H),4 .32(d,J=10.3Hz,2H),4.22(s,1H),3.89(s,2H),3.23(d,J=13.2Hz,4H),3.03-2.86(m,2H),1.83-1.55(m,4H).
[0547] P2:LCMS(ESI)[M+H] + =436.2; 1 H NMR (400MHz, DMSO-d6) δ7.67(d,J=7.6Hz,1H),7.57-7.44(m,2H),7.33-7.19(m,2H),4.24(h,J=10.8Hz,5H),3.87(d,J =7.1Hz,2H),3.48-3.37(m,2H),3.22(dt,J=13.6,8.3Hz,2H),2.93(ddd,J=22.0,15.4,7.6Hz,2H),1.84-1.53(m,4H).
[0548] Example 64 (Compound 99)
[0549] Synthesis of (R / S)-4-((1-(aminomethyl)cyclobutyl)amino)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0550] Step 1: Preparation of tert-butyl ((1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl)carbamate:
[0551] 2,4-Dichloro-6,7-dihydrothieno[3,2-d]pyrimidine (1.00 g), tert-butyl ((1-aminocyclobutyl)methyl)carbamate (1.00 g), and N,N-diisopropylethylamine (1.87 g) were added to acetonitrile (50 mL). The mixture was stirred at 85°C for 24 hours. The mixture was concentrated under reduced pressure, dissolved in methyl tert-butyl ether (50 mL), washed twice with water (30 mL), washed once with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and dried to give a crude product. The crude product was purified on a silica gel column (PE:EA=3:1) to give the title compound (0.85 g). LCMS (ESI) [M+H] +=371.3.
[0552] Step 2: Preparation of tert-butyl (R / S)-((1-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl)carbamate:
[0553] S-(-)-binaphthol (78 mg) was dissolved in DCM (10 mL), and tetraisopropyl titanate (77 mg) was added. The mixture was reacted at 25°C under nitrogen for 1 hour. Water (0.14 mL) was added, and the reaction continued for 0.5 hour. Tert-butyl ((1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl)carbamate (500 mg) was then added. After 1 hour of reaction, tert-butyl peroxide (200 mg) was added. The reaction mixture was added to water (30 mL) and extracted twice with DCM:MeOH (10:1) (20 mL). The combined organic phases were washed once with water (20 mL) and twice with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and spun down to obtain the crude product. The crude product was purified on a silica gel column (PE:EA = 0.1:1) to obtain the title compound (340 mg). LCMS (ESI) [M+H] + =387.1.
[0554] Step 3: Preparation of tert-butyl (R / S)-((1-((2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl)carbamate:
[0555] Tert-butyl (R / S)-((1-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl)carbamate (200 mg), 5-chloro-2-(piperidin-4-yl)pyrimidine p-toluenesulfonate (572 mg), and N,N-diisopropylethylamine (267 mg) were added to a mixed solution of H2O (1 mL) and tetrahydrofuran (5 mL), and the mixture was stirred at 70°C for 2 hours. The reaction solution was diluted with water (20 mL) and extracted twice with DCM:MeOH = 10:1 (20 mL). The organic phases were combined, washed twice with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (380 mg). LCMS (ESI) [M+H] + =548.2.
[0556] Step 4: Preparation of (R / S)-4-((1-(aminomethyl)cyclobutyl)amino)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0557] Tert-butyl (R / S)-((1-((2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl)carbamate (370 mg) was added to a mixed solution of TFA (3 mL) and DCM (3 mL) and stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure and separated and purified by Pre-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (107 mg). LCMS (ESI) [M+H] + =448.2; 1 H NMR (400MHz, DMSO-d6) δ8.86(d,J=0.8Hz,2H),7.49(d,J=44.5Hz,1H),4.72(t,J=14.1Hz,2H),3.44-3.38(m,2H),3.29-3.12(m ,4H),3.11-2.82(m,5H),2.32(p,J=9.9Hz,2H),2.11(t,J=10.4Hz,2H),1.97(d,J=13.1Hz,2H),1.70(dd,J=49.0,11.9Hz,4H).
[0558] Example 65 (Compound 100)
[0559] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(3-methoxy-3-(4-methoxyphenyl)azetidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0560] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (200 mg), 3-methoxy-3-(4-methoxyphenyl)azetidine hydrochloride (200 mg), and N,N-diisopropylethylamine (360 mg) were added to a mixed solution of H2O (1 mL) and tetrahydrofuran (5 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (101 mg). LCMS (ESI) [M+H]+ =445.2; 1 H NMR (400MHz, DMSO-d6) δ7.48 (s, 1H), 7.41-7.30 (m, 2H), 7.03-6.92 (m, 2H), 4.85 (t, J = 5.6Hz, 1H), 4.19 (s, 4H), 3.81-3.66 (m, 4H), 3. 46-3.33(m,2H),3.21(dt,J=16.5,8.3Hz,1H),2.98(s,5H),2.31(dq,J=20.9,10.3Hz,2H),2.14(t,J=10.2Hz,2H),1.86-1.64(m,2H).
[0561] Example 66 (Compound 101)
[0562] Synthesis of (R / S)-(1-((2-(3-(4-chlorophenyl)-3-methoxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl(2-(dimethylamino)ethyl)carbonate:
[0563] (R / S)-2-(3-(4-chlorophenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (120 mg) was added to DCM (3 mL), and N,N'-carbonyldiimidazole (48 mg) was added and reacted at room temperature for 1 hour. LCMS analysis showed that the starting material was completely consumed. Cesium carbonate (175 mg) and 2-(dimethylamino)ethan-1-ol (65 mg) were added to the reaction solution and reacted at room temperature for 2 hours. The reaction solution was purified by silica gel column chromatography (DCM:MeOH=20:1) to obtain a crude product. The crude product was separated and purified by Prep-HPLC (C18, 0.1% TFA / water, MeCN) to obtain the target compound (4.1 mg). LCMS (ESI) [M+H] + =564.2; 1H NMR(400MHz,DMSO-d6)δ9.52(s,1H),7.98(s,1H),7.50(s,3H),4.72(s,2H),4.51(d, J=11.1Hz,1H),4.37(d,J=5.6Hz,2H),4.22(s,2H),3.38(d,J=4.9Hz,3H),3.23(d,J= 13.6Hz,2H),3.03(s,2H),2.91(dd,J=14.1,7.2Hz,2H),2.79(d,J=4.6Hz,4H),2.67( d,J=2.1Hz,1H),2.39-2.31(m,2H),2.25(s,2H),1.84(s,2H),1.25(d,J=7.2Hz,2H).
[0564] Example 67 (Compound 102)
[0565] Synthesis of (R / S)-(1-((2-(3-(4-chloro-3-fluorophenyl)-3-methoxyazetidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl(2-(dimethylamino)ethyl)carbonate:
[0566] (R / S)-2-(3-(4-chloro-3-fluorophenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (500 mg) was added to DCM (5 mL), and N,N'-carbonyldiimidazole (262 mg) was added and reacted at room temperature for 1 hour. Cesium carbonate (712 mg) and 2-(dimethylamino)ethan-1-ol (200 mg) were added to the reaction solution and reacted at room temperature for 2 hours. The reaction solution was purified by silica gel column (DCM:MeOH=20:1) to obtain a crude product. The crude product was separated and purified by Prep-HPLC (C18, 0.1% TFA / water, MeCN) to obtain the target compound (21 mg). LCMS (ESI) [M+H] + =582.2; 1H NMR (400MHz, DMSO-d6) δ9.51(s,1H),8.01(s,1H),7.67(t,J=8.0Hz,1H),7.55(d,J=10.4Hz ,1H),7.35(d,J=8.1Hz,1H),4.71(s,2H),4.51(d,J=10.8Hz,1H),4.36(t,J=5.2Hz,2H),4. 22(s,2H),3.38(d,J=5.1Hz,2H),3.27-3.19(m,2H),3.08-2.87(m,6H),2.80(d,J=4.7Hz,4 H), 2.69-2.65 (m, 1H), 2.33 (d, J = 2.6Hz, 2H), 2.22 (d, J = 19.1Hz, 2H), 1.85 (d, J = 8.5Hz, 2H).
[0567] Example 68 (Compound 103)
[0568] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(3-methoxy-3-(3-methoxyphenyl)azetidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0569] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (200 mg), 3-methoxy-3-(3-methoxyphenyl)azetidine hydrochloride (320 mg), and N,N-diisopropylethylamine (360 mg) were added to a mixed solution of H2O (1 mL) and tetrahydrofuran (5 mL), and the mixture was stirred at 70°C for 2 hours. LCMS showed that the starting material was completely consumed. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the target compound (132 mg). LCMS (ESI) [M+H] + =445.3; 1H NMR (400MHz, DMSO-d6) δ7.49 (s, 1H), 7.36 (t, J = 7.9Hz, 1H), 7.08-6.88 (m, 3H), 4.85(t,J=5.7Hz,1H),4.19(d,J=7.9Hz,4H),3.82-3.64(m,5H),3.41(dt,J=16 .4,7.8Hz,1H),3.21(dt,J=13.4,8.3Hz,1H),3.03(s,3H),2.99-2.83(m,2H),2 .31(dq,J=21.1,10.2Hz,2H),2.20-2.07(m,2H),1.76(dt,J=18.8,10.0Hz,2H).
[0570] Example 69 (Compound 104)
[0571] Synthesis of (R / S)-4-((1-(aminomethyl-d2)cyclobutyl)amino)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0572] Step 1: Preparation of 1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutane-1-carboxamide:
[0573] Methyl 1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutane-1-carboxylate (1.00 g) was added to a 7 M ammonia / methanol solution (10 mL) and stirred in a closed container at 60°C for 48 hours. The reaction mixture was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (PE:EA = 0.1:1) to obtain the title compound (477 mg). LCMS (ESI) [M+H] + =285.1.
[0574] Step 2: Preparation of N-(1-(aminomethyl-d2)cyclobutyl)-2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine:
[0575] 1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutane-1-carboxamide (927 mg) was added to tetrahydrofuran (30 mL), the atmosphere was replaced with nitrogen three times, and the mixture was cooled in an ice bath for 5 minutes. Lithium aluminum deuteride (440 mg) was added portionwise under nitrogen, and the mixture was stirred at 70°C for 2 hours. 15% aqueous sodium hydroxide solution (0.5 mL) and water (0.5 mL) were added dropwise to the reaction mixture under ice bath conditions. The mixture was dried over anhydrous sodium sulfate, filtered, and the filter cake was washed with DCM:MeOH = 10:1 (50 mL). The filtrate was collected and concentrated under reduced pressure to obtain the title compound (1.10 g). LCMS (ESI) [M+H] + =273.1.
[0576] Step 3: Preparation of tert-butyl ((1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl-d2)carbamate:
[0577] N-(1-(Aminomethyl-d2)cyclobutyl)-2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine (1.10 g) and di-tert-butyl dicarbonate (0.90 g) were added to MeOH (5 mL) and stirred at room temperature for 2 hours. LCMS detected the formation of the product. Methyl tert-butyl ether (50 mL) was added to the reaction solution and diluted, washed twice with water (20 mL), washed twice with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column (PE:EA=3:1) to obtain the target compound (257 mg). LCMS (ESI) [M+H] + =373.3.
[0578] Step 4: Preparation of tert-butyl (R / S)-((1-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl-d2)carbamate:
[0579] S-(-)-binaphthol (40 mg) was dissolved in DCM (10 mL), and tetraisopropyl titanate (40 mg) was added. The mixture was reacted at 25°C under nitrogen for 1 hour. Water (0.02 mL) was added, and the reaction continued for 0.5 hour. Tert-butyl ((1-((2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl-d2)carbamate (257 mg) was then added. After 1 hour of reaction, tert-butyl peroxide (98 mg) was added. The reaction mixture was added to water (30 mL) and extracted twice with DCM:MeOH (10:1) (20 mL). The combined organic phases were washed once with water (20 mL) and once with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified on a silica gel column (DCM:MeOH = 20:1) to obtain the title compound (135 mg). LCMS (ESI) [M+H] + =389.1.
[0580] Step 5: Preparation of tert-butyl (R / S)-((1-((2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl-d2)carbamate:
[0581] Tert-butyl (R / S)-((1-((2-chloro-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl-d2)carbamate (135 mg), 5-chloro-2-(piperidin-4-yl)pyrimidine p-toluenesulfonate (256 mg), and N,N-diisopropylethylamine (181 mg) were added to a mixed solution of tetrahydrofuran (2 mL) and H2O (0.4 mL) and stirred at 70°C for 1 hour. Water (20 mL) was added to the reaction solution, and the mixture was extracted twice with methyl tert-butyl ether (10 mL). The combined organic phases were washed once with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (330 mg). LCMS (ESI) [M+H] + =550.2.
[0582] Step 6: Preparation of (R / S)-4-((1-(aminomethyl-d2)cyclobutyl)amino)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0583] Tert-butyl (R / S)-((1-((2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)amino)cyclobutyl)methyl-d2)carbamate (330 mg) was added to a mixed solution of DCM (1 mL) and TFA (1 mL) and stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure and separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (49 mg). LCMS (ESI) [M+H] + =450.1; 1 H NMR(400MHz, DMSO-d6)δ8.86(s,2H),7.43(s,1H),4.70(d,J=13.4Hz,2H),3.48-3.38(m,2H),3.26-3.14(m,3H),3.06(t ,J=12.4Hz,2H),2.98-2.82(m,2H),2.39-2.25(m,2H),2.10(t,J=9.8Hz,2H),1.97(d,J=12.9Hz,2H),1.83-1.54(m,4H).
[0584] Example 70 (Compound 105)
[0585] Synthesis of (R / S)-2-(3-(4-(difluoromethoxy)phenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0586] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (200 mg), 3-(4-(difluoromethoxy)phenyl)-3-methoxyazetidine hydrochloride (370 mg), and N,N-diisopropylethylamine (360 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL), and the mixture was stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (128 mg). LCMS (ESI) [M+H] + =481.1; 1H NMR (400MHz, DMSO-d6) δ7.58-7.44(m,3H),7.31-7.07(m,3H),4.84(t,J=5.7Hz, 1H), 4.22 (d, J=8.5Hz, 1H), 3.72 (dd, J=5.7, 2.7Hz, 2H), 3.41 (dd, J=16.9, 8.3Hz, 1H),3.31(s,1H),3.22(dt,J=13.6,8.3Hz,1H),3.03(s,3H),2.99-2.84(m,2H),2 .40-2.25(m,2H),2.20-2.09(m,2H),1.75(dq,J=18.9,10.2Hz,2H),1.24(s,2H).
[0587] Example 71 (Compound 106)
[0588] Synthesis of (R / S)-2-(3-(4-(cyclopropylmethoxy)phenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0589] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (150 mg), 3-(4-(cyclopropylmethoxy)phenyl)-3-methoxyazetidine hydrochloride (240 mg), and N,N-diisopropylethylamine (272 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL), and the mixture was stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (36 mg). LCMS (ESI) [M+H] + =485.2; 1H NMR(400MHz,DMSO-d6)δ7.45(s,1H),7.38-7.30(m,2H),7.00-6.92(m,2H),4.85(t, J=5.6Hz,1H),4.19(s,2H),3.83(d,J=7.0Hz,2H),3.72(dd,J=5.5,2.8Hz,2H),3.47 -3.38(m,1H),3.27-3.16(m,1H),2.99(s,5H),2.39-2.24(m,2H),2.20-2.10(m,2H) ,1.75(dq,J=19.3,10.0Hz,2H),1.24(s,3H),0.61-0.50(m,2H),0.38-0.27(m,2H).
[0590] Example 72 (Compound 107)
[0591] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(3-methoxy-3-(4-(pyrrolidin-1-yl)phenyl)azetidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0592] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (71 mg), 1-(4-(3-methoxyazetidin-3-yl)phenyl)pyrrolidine hydrochloride (80 mg, N,N-diisopropylethylamine (129 mg) were added to a mixed solution of water (0.5 mL) and tetrahydrofuran (2 mL), and the mixture was stirred at 70°C for 2 hours. The reaction solution was added to water (10 mL), and ethyl acetate (10 mL) was added to the system for extraction. The aqueous phase was extracted twice with ethyl acetate (5 mL), and the organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The product was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to give the title compound (27 mg). LCMS (ESI) [M+H] + =484.4; 1H NMR (400MHz, DMSO-d6) δ7.42 (s, 1H), 7.29-7.15 (m, 2H), 6.56 (d, J = 8.6Hz, 2H ),4.84(t,J=5.6Hz,1H),4.15(d,J=8.9Hz,4H),3.80-3.64(m,2H),3.44-3.3 6(m,1H),3.25-3.16(m,5H),2.95(s,3H),2.93-2.81(m,2H),2.28(d,J=11.2 Hz, 2H), 2.15 (s, 2H), 2.00-1.89 (m, 4H), 1.75 (dq, J = 19.6, 10.4, 9.5Hz, 2H).
[0593] Example 73 (Compound 108)
[0594] Synthesis of (R / S)-2-(3-methoxy-3-(4-methoxyphenyl)azetidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0595] (R / S)-2-chloro-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-methoxy-3-(4-methoxyphenyl)azetidine hydrochloride (100 mg), and N,N-diisopropylethylamine (180 mg) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL), and the mixture was stirred at 70°C for 2 hours. LCMS showed that the starting material was completely consumed. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the target compound (20 mg). LCMS (ESI) [M+H] + =445.2; 1 H NMR (400MHz, DMSO-d6) δ7.62(d,J=7.6Hz,1H),7.43-7.31(m,2H),7.04-6.91(m,2H),4.23(t,J=10.0Hz,4H),3.93-3.83(m,2H),3.77 (s,3H),3.47-3.36(m,2H),3.31-3.16(m,3H),3.00(s,3H),2.97-2.85(m,2H),1.77(d,J=12.4Hz,2H),1.61(td,J=11.7,4.4Hz,2H).
[0596] Example 74 (Compound 109)
[0597] Synthesis of (R / S)-2-(3-(4-(dimethylamino)phenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0598] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 4-(3-methoxyazetidin-3-yl)-N,N-dimethylaniline hydrochloride (130 mg), and N,N-diisopropylethylamine (0.18 g) were added to a mixed solution of H2O (0.4 mL) and tetrahydrofuran (2 mL), and the mixture was stirred at 70°C for 1 hour. LCMS analysis showed that the starting material was completely consumed. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the target compound (82 mg). LCMS (ESI) [M+H] + =458.2; 1 H NMR(400 MHz, DMSO-d6)δ7.43(s,1H),7.31-7.15(m,2H),6.81-6.66(m,2H),4.85(t,J =5.6Hz,1H),4.16(d,J=8.7Hz,4H),3.71(dd,J=5.8,2.5Hz,2H),3.40(dt,J= 16.2,7.8Hz,1H),3.21(dt,J=13.5,8.2Hz,1H),2.93(d,J=22.5Hz,11H),2.3 1(dq,J=21.1,10.3Hz,2H),2.20-2.09(m,2H),1.75(dq,J=19.9,10.0Hz,2H).
[0599] Example 75 (Compound 110)
[0600] Synthesis of (R / S)-2-(3-(3-(dimethylamino)phenyl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0601] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-(3-methoxyazetidin-3-yl)-N,N-dimethylaniline hydrochloride (211 mg), and N,N-diisopropylethylamine (0.18 g) were added to a mixed solution of H2O (0.4 mL) and tetrahydrofuran (2 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (87 mg). LCMS (ESI) [M+H] + =458.2; 1 H NMR(400MHz, DMSO-d6)δ7.45(s,1H),7.23(dd,J=8.9,7.4Hz,1H),6.71(qd,J=4.2,1 .6Hz,3H),4.84(t,J=5.6Hz,1H),4.18(d,J=8.7Hz,4H),3.71(dd,J=5.7,2.4Hz,2H) ,3.41(dt,J=16.4,7.8Hz,1H),3.21(dt,J=13.4,8.3Hz,1H),3.02(s,3H),2.91(s,8 H), 2.31 (dq, J=21.6, 10.0Hz, 2H), 2.20-2.11 (m, 2H), 1.75 (dq, J=19.9, 10.4Hz, 2H).
[0602] Example 76 (Compound 111)
[0603] Synthesis of (R / S)-2-(3-(benzo(d)[1,3]dioxolan-5-yl)-3-methoxyazetidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0604] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (100 mg), 3-(benzo(d)[1,3]dioxolan-5-yl)-3-methoxyazetidine hydrochloride (130 mg), and N,N-diisopropylethylamine (0.18 g) were added to a mixed solution of H2O (0.5 mL) and tetrahydrofuran (2.5 mL) and stirred at 70°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the title compound (40 mg). LCMS (ESI) [M+H] + =459.1; 1 H NMR (400MHz, DMSO-d6) δ7.45 (s, 1H), 6.97 (dd, J = 21.6, 1.1Hz, 3H), 6.04 (s, 2H ),4.83(t,J=5.6Hz,1H),4.15(d,J=9.4Hz,4H),3.71(dd,J=5.7,2.5Hz,2H),3. 41(dt,J=16.5,7.9Hz,1H),3.21(dt,J=13.4,8.3Hz,1H),3.03-2.83(m,5H),2. 30(dt,J=20.9,10.4Hz,2H),2.20-2.09(m,2H),1.75(dq,J=29.0,10.2Hz,2H).
[0605] Example 77 (Compound 112)
[0606] Synthesis of (R / S)-4-((1-(hydroxymethyl)cyclobutyl)amino)-2-(3-methoxy-3-(4-(methylamino)phenyl)azetidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide:
[0607] (R / S)-2-chloro-4-((1-(hydroxymethyl)cyclobutyl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (40 mg), 4-(3-methoxyazetidin-3-yl)-N-methylaniline dihydrochloride (80 mg), and N,N-diisopropylethylamine (0.07 g) were added to a mixed solution of H2O (0.2 mL) and tetrahydrofuran (1 mL), and the mixture was stirred at 70°C for 2 hours. LCMS analysis showed that the starting material was completely consumed. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated and purified by Prep-HPLC (C18, 10 mmol / L NH4HCO3 / water, MeCN) to obtain the target compound (35 mg). LCMS (ESI) [M+H]+ =444.2; 1 H NMR (400MHz, DMSO-d6) δ7.44 (s, 1H), 7.24-7.07 (m, 2H), 6.55 (d, J = 8.5Hz, 2H), 5.77 (d ,J=5.1Hz,1H),4.85(d,J=5.6Hz,1H),4.13(d,J=9.3Hz,4H),3.71(dd,J=5.8,2.7Hz,2 H),3.40(dt,J=17.8,8.5Hz,1H),3.21(dt,J=16.2,8.4Hz,1H),2.94(s,5H),2.67(d,J =5.0Hz, 3H), 2.30 (dt, J = 21.1, 10.3Hz, 2H), 2.14 (t, J = 10.2Hz, 2H), 1.91-1.64 (m, 2H).
[0608] The following compounds were synthesized with reference to the above related examples:
[0609] Biological test evaluation
[0610] Experiment 1: In vitro evaluation of the inhibitory activity of compounds against PDE4B2 and PDE4D2 enzymes
[0611] 1. Experimental materials and instruments:
[0612] 2. Experimental steps:
[0613] 2.1 Preparation and handling of compounds
[0614] 2.1.1 Preparation of DMSO stock solution of compound: Dissolve the compound powder in 100% DMSO to a 10 mM stock solution and shake on a shaker to completely dissolve the compound.
[0615] 2.1.2 Storage of DMSO stock solutions of compounds: DMSO stock solutions of compounds were stored in a desiccator at room temperature.
[0616] 2.1.3 Preparation of Working Stock Solutions: a) Dilute the reference compound, roflumilast, to 60 μM in DMSO and make 10 serial 4-fold dilutions. b) Dilute the test compound to 200 μM in DMSO and make 3 serial 3-fold dilutions. c) Prepare a 200X positive control (60 μM roflumilast) and a 200X vehicle control (100% DMSO). d) Centrifuge the assay plate at 1000 rpm for 1 minute.
[0617] 2.2 Compound testing
[0618] 1) Transfer 20 nL of the compound dilution to each well of the assay plate using an Echo 550.
[0619] 2) Seal the assay plate and centrifuge it at 1000 rpm for 1 minute.
[0620] 3) Prepare 2X PDE4B2 / PDE4D2 in cold PDE assay buffer.
[0621] 4) Add 2 μL of 2X PDE4B2 / PDE4D2 to each well of the assay plate (prepared in step b).
[0622] 5) Seal the assay plate and equilibrate it at room temperature for 10 minutes.
[0623] 6) Prepare 2X Cyclic-3',5'-AMP in PDE assay buffer.
[0624] 7) Add 2 μL of 2X Cyclic-3',5'-AMP (prepared in step f) to each well of the assay plate (prepared in step e) to start the reaction. Incubate at room temperature for 60 minutes.
[0625] 8) Add 4 μL of AMP-Glo Reagent I and incubate at room temperature for 60 minutes.
[0626] 9) Add 8 μL of AMP detection solution. Incubate at room temperature for 60 minutes.
[0627] 10) Read the RLU signal on an Envision 2105 plate reader.
[0628] Experimental results:
[0629] Table 1 Test results of PDE4B2 enzyme inhibition activity
[0630] IC 50 value of PDE4B2 enzyme inhibition: A < 2 nM; 2 nM < B < 5 nM; 5 nM < C < 20 nM; 2 nM < D < 50 nM. Among them, the IC50 values of compounds 79, 82, 83, 86, 88, 92, 94, 100, 105, 107, 108, 109 for PDE4B2 enzyme inhibition are less than 1 nM.
[0631] PDE4D2 / PDE4B2 selectivity (=ratio of IC 50 value of PDE4D2 enzyme inhibition / IC 50 value of PDE4B2 enzyme inhibition): 5 < A < 10; 2 < B < 5; C < 2.
[0632] Control 1 is the compound It is disclosed in CN103889970B.
[0633] Table 2: Comparison of PDE4B2 enzyme inhibitory activity of some compounds
[0634] In the above table, the ratios of the PDE4B2 enzyme inhibitory activities of the compounds in the left column to those in the right column are all less than 1.
[0635] Experimental Example 2: Pharmacokinetic Study of Compound Concentrations in Mice Using LC-MS / MS
[0636] Test principle: Use LC-MS / MS to determine the drug concentration of the target drug in plasma at different times and draw the pharmacokinetic curve of the target compound in the body.
[0637] Test method:
[0638] An appropriate amount of the test compound was weighed, 5% DMSO (INNOCHEM, INBZZHCAE) was added, and vortexed to dissolve. 10% Solutol (BASF, 75389809T0) was then added. The mixture was vortexed to mix thoroughly, and 85% Saline (Fengyuan, 220505102) was added. The mixture was vortexed to obtain 0.4 mg / mL and 1.0 mg / mL dosing formulations.
[0639] Mice were C57BL / 6J males (JH Laboratory Animal Co.LTD). Three mice were selected from each group and administered 2 mg / kg IV or 10 mg / kg PO. Blood was collected 5 minutes (IV group only), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours (PO group only) after administration. Approximately 30 μL of blood samples were collected at each time point and placed in anticoagulant tubes containing EDTA-K2 anticoagulant. Plasma was obtained by centrifugation within 30 minutes. Whole blood samples were placed on wet ice before centrifugation. For each test substance, 42 plasma samples were collected. All collected plasma samples were stored on dry ice or in a freezer until analysis. Blood drug concentrations were determined using a Triple-quadrupole MS system (SCIEX). This includes standard curve and quality control preparation and sample preparation.
[0640] Preparation of standard curve and quality control: dilute the working solution with ACN:H2O (1:1) and add 3 μL of the standard curve and quality control working solution to 57 μL of blank plasma.
[0641] Sample preparation: Add 70 μL of internal standard solution (Propranolol, Tolbutamide, Glipizide, Osalmid, each 200 ng / mL in ACN) to 7 μL of plasma sample, mix for 5 minutes, centrifuge at 4000 rpm for 10 minutes, and transfer 50 μL of supernatant to a new plate containing 200 μL for injection and analysis.
[0642] Chromatographic conditions were optimized according to the samples, including mobile phase composition, elution gradient conditions, flow rate, and retention time. The chromatographic column was Waters Acquity UPLC HSS T3 1.8 μm, 2.1×50 mm, and the injection volume was 2 μL.
[0643] The mass spectrometer was operated with an electrospray ion source and the multi-channel reaction monitoring (MRM) mode was selected for secondary mass spectrometry analysis under positive ion detection mode.
[0644] Based on the drug concentration-time data, WinNonlin 8.2 software was used to calculate the pharmacokinetic parameters according to the non-compartmental model, including peak concentration Cmax, peak time Tmax, area under the drug-time curve AUC, elimination half-life tmax, and 4-6 months. 1 / 2 The AUC was calculated using the linear up log down method.
[0645] Table 3 Pharmacokinetic test results of compound concentrations in mice
[0646] The test results show that the compound of the present invention has good in vivo pharmacokinetics and has drug potential.
[0647] Experiment 3: Inhibitory activity test of compounds on LPS-induced TNFα secretion in human PBMC
[0648] Frozen hPBMC cell stock solution was quickly thawed in a 37°C water bath. The cells were transferred to complete culture medium (RPMI 1640 + 10% FBS + 1% P / S). Centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and the cells were resuspended in 1 mL of complete culture medium (RPMI 1640 + 10% FBS + 1% P / S), then gently pipetted to mix and counted with trypan blue. The cells were counted according to 5×10 4 / well cells, 100μL / well complete culture medium was inoculated into a 96-well cell culture plate. The compound to be screened was formulated into a final concentration of 4×. Added to the cells at 50μL / well. Pre-incubated for 30 minutes in advance. At the same time, a control well was set up without adding the compound. The final concentration of LPS stimulation was 10ng / ml, which was diluted into a 4-fold solution and added to the cells at 50μL / well. At the same time, a control well was set up without adding LPS. Continue to incubate the cells, and collect 10% of the supernatant for detection after 24 hours. The collected supernatant was detected according to the Human TNF-α kit of R&D Company (VAL105G). The inhibitory activity of the compounds provided by the present invention on LPS-induced human TNFα secretion was determined according to the above method.
[0649] Table 4 Inhibitory activity test results of test compounds on LPS-induced TNFα secretion in human PBMC
[0650] The experimental results show that the compound of the present invention has excellent inhibitory activity on the secretion of TNFα by human PBMC, can better inhibit the secretion of inflammatory factor TNFα in human PBMC, and has a good anti-inflammatory effect.
Claims
1. A compound represented by the following formula (I), a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound: in, X is selected from S, SO or SO2; Y is NR Y ; R Y is hydrogen or deuterium; Ring Q is: C 3-8 Cycloalkyl, C 4-8 Cycloalkenyl, 3-10 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl; Each R Q is selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH、-L Y -SH、-L Y -C(O)OH、-L Y -NH-C(O)H、-L Y -C(O)NH2、-L Y -NHC(O)OH、-L Y -C(O)H、 C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-6 Alkyl (e.g. halo-C 1-3 Alkyl), -L Y -OC(O)R d , -L Y -OC(O)OR d Preferably, each R Q is selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH、-L Y -SH、-L Y -C(O)OH、-L Y -NH-C(O)H、-L Y -C(O)NH2、-L Y -NHC(O)OH、-L Y -C(O)H、 C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-6 Alkyl (e.g. halo-C 1-3 Alkyl), -L Y -OC(O)R d More preferably, each R Q is selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH、-L Y -SH、-L Y -C(O)OH、-L Y -NH-C(O)H、-L Y -C(O)NH2、-L Y -NHC(O)OH、-L Y -C(O)H、 C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-6 Alkyl (e.g. halo-C 1-3 alkyl); L Y is optionally substituted: C 1-4 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, C 1-4 Alkyleneoxy, wherein optionally substituted refers to one or more selected from halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, halogenated C 1-3 substituted by an alkyl substituent; L is a bond, or optionally substituted: C 1-4 Alkylene, C 2-4 Alkenylene, C 2-4 Alkynylidene, C 1-4 Alkyleneoxy, wherein optionally substituted refers to one or more selected from deuterium, halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, halogenated C 1-6 substituted by an alkyl substituent; Ring W is C 4-16 Cycloalkyl, C 4-16 Cycloalkenyl, saturated or partially unsaturated 4-18 membered heterocyclic group, 5-16 membered heteroaryl, C 6-18 Aryl; Each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, acetylamino, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m 、-NR b R c 、-C(O)OR d , optionally substituted: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, wherein optionally substituted refers to being replaced by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -C(O)OR d , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 Substituted by a cycloalkyl substituent; R b and R c are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl; R d Selected from H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, C 1-6 Alkylamino; preferably, each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamido, ethylsulfonamido, acetylamino, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m , -NR b R c 、-C(O)OR d , optionally substituted: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, wherein optionally substituted refers to being replaced by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -C(O)OR d , C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 Substituted by a cycloalkyl substituent; R b and R c are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl; R d Selected from H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, halogenated C 1-6 More preferably, each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m , optionally substituted: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, wherein optionally substituted refers to being replaced by one or more selected from halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1- 6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 substituted by a cycloalkyl substituent; Z is C 4-16 Cycloalkyl, C 4-16 Cycloalkenyl, saturated or partially unsaturated 4-18 membered heterocyclic group, 5-16 membered heteroaryl, C 6-12 Aryl; R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, saturated or partially unsaturated 4-6 membered heterocyclic group, -OR Z1 、-NR Z2 R Z3 ; R Z1 Selected from C 1- 6 Alkyl, halogenated C 1-6 Alkyl; R Z2 , R Z3 are independently selected from H, C 1-6 Alkyl; preferably, R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy; More preferably, R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy; n is 0, 1, 2, 3, 4 or 5; q is 0, 1, 2, 3, 4, or 5; m is 0, 1, 2, 3, 4 or 5; The conditions are: (1) When L is a bond, Not for (2) When L is a bond, for When R w Unsubstituted phenyl and (3) When X is SO and L is a bond, Not for Preferably, when X is SO and L is a bond, Not for Any of; (4) When X is S or SO2 and L is a bond, ring Q and ring W are not substituted phenyl at the same time; or when X is S and L is a bond, ring Q is phenyl, and ring W is not and (5) When X is S or SO2 and L is a bond, ring Q is not The heteroatoms in the heterocyclic group and heteroaryl group are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2 or 3.
2. The compound of claim 1, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound, wherein the compound is a compound represented by the following formula (IA), (IB), or (IC): in, X, q, R Q , Ring Q, n, R W , ring W is as described in claim 1.
3. The compound according to claim 1, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound, wherein the compound is a compound represented by the following formula (II-A) to (II-E): Where X, n, R W , Ring W, R Q , q is as described in claim 1.
4. The compound according to claim 1, the stereoisomers, tautomers or mixtures thereof of the compound, and the pharmaceutically acceptable salt of the compound, wherein the compound is a compound represented by the following formula (III-A) to (III-H): in, n、R W , Ring W, R Q , q is as described in claim 1, S* is a chiral sulfur atom, preferably, R configuration.
5. The compound of claim 1, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound, wherein the compound is a compound represented by the following formulas (IV-A) to (IV-E): in, n、R W , Ring W is as described in claim 1, S* is a chiral sulfur atom, preferably, R configuration.
6. The compound according to any one of claims 1 to 5, the stereoisomer, tautomer or mixture thereof of the compound, the pharmaceutically acceptable salt of the compound, wherein: R Y is deuterium; or, R Y is hydrogen; and / or Ring Q is: C 4-6 Cycloalkyl, C 4-6 Cycloalkenyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, phenyl; Preferably, ring Q is: C 4-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl; More preferably, ring Q is: cyclobutane, cyclohexenyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, phenyl, tetrahydropyranyl; Most preferably, ring Q is phenyl or tetrahydropyranyl; and / or Each R Q are independently: halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonamide, ethylsulfonamide, phosphate, carboxylic acid, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -L Y -OH、-L Y -C(O)OH、-L Y -C(O)H、 C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-6 Cycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocyclic group, halogenated C 1-3 Alkyl, -L Y -OC(O)R d ; Preferably, each R Q are independently: halogen, oxo, acetyl, -L Y -OH, -L Y -C(O)OH, C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -L Y -OC(O)R d ; More preferably, each R Q are independently: halogen, oxo, acetyl, -L Y -OH, -L Y -C(O)OH, C 1-3 Alkyl, C 3- 6-cycloalkyl, -L Y -OC(O)R d ; Most preferably, each R Q are independently: hydroxymethyl, carboxymethyl, acetyl, Hydroxyisopropyl, Cl, oxo, cyclopropyl, and / or L Y is optionally substituted: C 1-4 Alkylene, wherein optionally substituted refers to one or more selected from halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, halogenated C 1-3 substituted by an alkyl substituent; Preferably, L Y is optionally substituted: C 1-2 Alkylene, wherein optionally substituted means by one or more selected from halogen, -OH, -SH, -NH2, C 1-3 Alkyl, halogenated C 1-3 substituted by an alkyl substituent; More preferably, L Y is optionally substituted: methylene, ethylene, wherein optionally substituted means substituted by one or more substituents selected from halogen, -OH, -SH, methyl, ethyl; and / or L is a bond, or optionally substituted: C 1-3 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, wherein optionally substituted refers to one or more selected from deuterium, halogen, oxo, -CN, -OH, -SH, -NH2, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-8 Cycloalkyl, halogenated C 1-3 substituted by an alkyl substituent; Preferably, L is a bond, or optionally substituted: C 2-4 Alkenylene, C 2-4 Alkyne, wherein optionally substituted refers to one or more selected from deuterium, -CN, -OH, -SH, -NH2, C 1-3 substituted by an alkyl substituent; More preferably, L is a bond, or optionally substituted: vinyl, propenyl, ethynyl, propynyl, wherein optionally substituted refers to one or more selected from deuterium, -CN, -OH, -SH, -NH2, C 1-3 substituted by an alkyl substituent; Most preferably, L is a bond; or, L is ethynyl; or, L is optionally substituted: propynyl, wherein optionally substituted means with one or more selected from deuterium, -CN, -OH, -SH, -NH2, C 1-3 substituted by an alkyl substituent; and / or Ring W is C 4-12 Cycloalkyl, C 4-12 Cycloalkenyl, saturated or partially unsaturated 4-12 membered heterocyclic group, 5-16 membered heteroaryl, C 6-12 Aryl; Preferably, ring W is C 4-5 Monocyclic cycloalkyl, C 5-10 Bicyclic cycloalkyl, C 4-8 Monocyclic cycloalkenyl, C 7-10 Bicyclic cycloalkenyl, saturated or partially unsaturated 4-8 membered monocyclic heterocyclyl, saturated or partially unsaturated 7-12 membered bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 9-16 membered bicyclic heteroaryl, phenyl, naphthyl; More preferably, ring W is 7. The compound according to any one of claims 1 to 6, the stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compound, wherein: for Preferably More preferably 8. The compound according to any one of claims 1 to 7, the stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compound, wherein: Each R w are independently selected from halogen, oxo, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, -CN, -OH, -SH, -NO2, -NH2, -CONH2, -Z-(R Z ) m , optionally substituted: C 1-6 Alkyl, C 1-6 Alkoxy, wherein optionally substituted refers to being replaced by one or more selected from halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated phenyl, -OC 3-6 substituted by a cycloalkyl substituent; Z is C 4-10 Cycloalkyl, C 4-10 Cycloalkenyl, saturated or partially unsaturated 4-12 membered heterocyclic group, 5-12 membered heteroaryl, C 6-12 Aryl; R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy; Preferably, each R w are independently selected from halogen, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methylsulfonylamide, ethylsulfonylamide, -CN, -OH, -SH, -NH2, -Z-(R Z ) m , optionally substituted: C 1-4 Alkyl, C 1-4 Alkoxy, wherein optionally substituted refers to being replaced by one or more selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, 5-6 membered heteroaryl, C 6-12 Aryl, halogenated C 1-3 Alkyl, halogenated C 1-3 Substituted by an alkoxy group or a halogenated phenyl group; Z is pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, or phenyl; R Z are independently selected from halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy.
9. The compound of claim 1, a stereoisomer, a tautomer or a mixture thereof, a pharmaceutically acceptable salt of the compound, wherein the compound is a compound represented by the following formula (IV-A) or (IV-E), preferably, the compound is a compound represented by the following formula (IV-A): in for Each R w are independently selected from methylsulfonyl, methylsulfonylamide, ethylsulfonylamide, F, Cl, -CN, -OH, -SH, -NH2, or optionally substituted: methyl, ethyl, isopropyl, methoxy, ethoxy, methylthio, ethylthio, wherein optionally substituted refers to being replaced by one or more selected from halogen, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 Preferably, each R w are independently selected from methylsulfonyl, methylsulfonylamide, ethylsulfonylamide, F, Cl, -CN, -OH, -SH, -NH2, 10. The compound of claim 1, a stereoisomer, a tautomer or a mixture thereof, a pharmaceutically acceptable salt of the compound, wherein the compound is a compound represented by the following formula (IV-A) or (IV-E), preferably, the compound is a compound represented by the following formula (IV-A): in for Preferably Each R w Independently selected from Preferably, each R w Independently selected from 11. The compound according to any one of claims 1 to 9, the stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts of the compound, wherein: m is 0, 1, 2 or 3; Preferably, m is 1, 2 or 3; More preferably, m is 1 or 2; and / or n is 0, 1, 2 or 3; Preferably, n is 0, 1 or 2; More preferably, n is 1 or 2; and / or q is 0, 1, 2, or 3; Preferably, q is 0, 1 or 2; More preferably, q is 1 or 2.
12. A compound selected from the following, or a stereoisomer, a tautomer or a mixture thereof, a pharmaceutically acceptable salt of the compound:
13. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to any one of claims 1 to 12, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt of the compound.
14. Use of the compound according to any one of claims 1 to 12, the stereoisomers, tautomers or mixtures thereof, the pharmaceutically acceptable salts of the compound, or the pharmaceutical composition according to claim 13 in the preparation of a medicament for treating and / or preventing a disease mediated by PDE4B, preferably the disease comprises respiratory diseases, gastrointestinal diseases, inflammatory diseases, allergic diseases, autoimmune diseases or cancer, for example: The respiratory disease is selected from respiratory or lung diseases accompanied by increased mucus production, respiratory inflammation and / or obstructive diseases; further preferably, the respiratory disease is selected from idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial pneumonia, chronic obstructive pulmonary disease (COPD), alpha-antitrypsin deficiency, chronic sinusitis, asthma or chronic bronchitis; Gastrointestinal disease selected from stage ileitis, ulcerative colitis or Crohn's disease; Inflammatory disease selected from dry eye syndrome or glaucoma; Autoimmune diseases include diffuse connective tissue diseases such as systemic lupus erythematosus, atopic dermatitis, seborrheic dermatitis, psoriasis, urticaria, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis, or Sjögren's disease.
15. The compound according to any one of claims 1 to 12, the stereoisomers, tautomers or mixtures thereof, and the pharmaceutically acceptable salts of the compound for use in treating and / or preventing diseases mediated by PDE4B, preferably the diseases include respiratory diseases, gastrointestinal diseases, inflammatory diseases, allergic diseases, autoimmune diseases or cancer, for example: The respiratory disease is selected from respiratory or lung diseases accompanied by increased mucus production, respiratory inflammation and / or obstructive diseases; further preferably, the respiratory disease is selected from idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial pneumonia, chronic obstructive pulmonary disease (COPD), alpha-antitrypsin deficiency, chronic sinusitis, asthma or chronic bronchitis; Gastrointestinal disease selected from stage ileitis, ulcerative colitis or Crohn's disease; Inflammatory disease selected from dry eye syndrome or glaucoma; Autoimmune diseases include diffuse connective tissue diseases such as systemic lupus erythematosus, atopic dermatitis, seborrheic dermatitis, psoriasis, urticaria, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis, or Sjögren's disease.
16. A method for treating and / or preventing a disease mediated by PDE4B, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 12, a stereoisomer, a tautomer or a mixture thereof, a pharmaceutically acceptable salt of the compound, or a pharmaceutical composition according to claim 13, wherein the disease preferably comprises a respiratory disease, a gastrointestinal disease, an inflammatory disease, an allergic disease, an autoimmune disease or a cancer, for example: The respiratory disease is selected from respiratory or lung diseases accompanied by increased mucus production, respiratory inflammation and / or obstructive diseases; further preferably, the respiratory disease is selected from idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial pneumonia, chronic obstructive pulmonary disease (COPD), alpha-antitrypsin deficiency, chronic sinusitis, asthma or chronic bronchitis; Gastrointestinal disease selected from stage ileitis, ulcerative colitis or Crohn's disease; Inflammatory disease selected from dry eye syndrome or glaucoma; Autoimmune diseases include diffuse connective tissue diseases such as systemic lupus erythematosus, atopic dermatitis, seborrheic dermatitis, psoriasis, urticaria, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis, or Sjögren's disease.
